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Abstract 
Background: Neuroblastoma is the most common extra-cranial tumor in children. Little is 
known about the etiology of neuroblastoma. The early age at onset and the embryonic nature 
suggest a role for perinatal exposures. In this work, we analyzed whether childhood 
neuroblastoma was associated with specific perinatal characteristics and environmental 
exposures around pregnancy. We assessed the following birth-related characteristics: 
gestational age, birth-weight and fetal growth, and the presence of congenital malformations. 
The maternal reproductive history before the index pregnancy and maternal intake of folic 
acid or vitamins/minerals before or during pregnancy was also assessed. With regards to 
environmental exposures related to parental habits, we focused on maternal use of household 
pesticides during pregnancy, parental smoking and maternal alcohol consumption.  
Methods: We conducted a pooled analysis of two French national-based case-control studies. 
The mothers of 357 neuroblastoma case and 1,783 control children younger than 6 years, 
frequency-matched by age and gender, completed a telephone interview that focused on 
sociodemographic and perinatal characteristics, childhood environment and parental lifestyle. 
Unconditional logistic regression was used to estimate pooled odds ratios (OR) and 95% 
confidence intervals (CIs), including matching variables, study of origin and potential 
confounders. A meta-analysis of our findings with those of previous studies was also 
conducted with regards to maternal smoking and alcohol consumption during pregnancy. We 
used random effects, precision-based weighting to calculate the summary OR including our 
results. 
Results: The first part of the thesis focused on perinatal characteristics. We observed that 
being born either small (OR 1.4 [95% CI 1.0-2.0]) or large (OR 1.5 [95% CI 1.1–2.2]) for 
gestational age and, among children younger than 18 months, having congenital 
malformations (OR 3.6 [95% CI 1.3–8.9]), were significantly associated with neuroblastoma. 
Inverse associations were observed with breastfeeding (OR 0.7 [95% CI 0.5–1.0]) and 
maternal use of any supplements containing folic acid, vitamins or minerals (OR 0.5 [95% CI 
0.3–0.9]) during the preconception period.  
The second part of the thesis showed that maternal use of any type of household pesticide 
during pregnancy was associated with neuroblastoma (OR 1.5 [95% CI 1.2–1.9]). The most 
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commonly used type of pesticides were insecticides and there was a positive association with 
their use alone (OR 1.4 [95% CI 1.1–1.9]) or with other pesticides (OR 2.0 [95% CI 1.1–3.4]). 
In the third part, our analyses showed that maternal smoking during pregnancy was slightly 
more often reported for the cases (24.1%) than for the controls (19.7%) (OR 1.3 [95% CI 0.9–
1.7]; Paternal smoking in the year before child’s birth was not associated with neuroblastoma 
as independent exposure (OR 1.1 [95%CI 0.9–1.4] but the association was stronger when both 
parents reported having smoked during pregnancy (OR 1.5 [95% CI 1.1–2.1]. Finally, in a 
meta-analysis of maternal smoking and neuroblastoma the summary OR from meta-analysis 
was 1.1 [95% CI 1.0–1.3]. 
Conclusions: Our findings support the hypothesis of a defective embryogenesis in 
neuroblastoma since fetal growth anomalies and congenital malformations were associated 
with an increased risk of neuroblastoma. This work also adds to the evidence of an association 
between neuroblastoma and some exposures during pregnancy, such as maternal use of 
household pesticides and maternal smoking, which are additional reasons why to advise 
pregnant women to limit these exposures in this period. Further investigations are needed to 
clarify the role of folic acid supplementation and breastfeeding, given their potential 
importance in neuroblastoma prevention. 
 
Key words: neuroblastoma, childhood cancer, perinatal exposures, etiology, risk factors, 
case-control study.   
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Résumé  
Contexte : Le neuroblastome est une tumeur embryonnaire qui se développe à partir du 
système nerveux sympathique. C’est la tumeur maligne solide extra-cérébrale la plus 
fréquente chez les enfants de moins d’un an. La cause du neuroblastome est encore inconnue 
dans la majorité des cas. Cependant, les caractéristiques embryonnaires de la tumeur ainsi que 
sa courte latence de survenue après la naissance suggèrent l’origine périnatale de ce cancer et 
l’importance d’étudier les expositions survenant pendant la grossesse et les premières années 
de vie de l’enfant. Dans ce travail de recherche, nous avons analysé le lien entre certains 
facteurs périnataux et des expositions pendant la grossesse et le risque neuroblastome chez 
l’enfant. 
Matériel et méthodes : Les données sont issues des enquêtes ESCALE (2003-2004) et 
ESTELLE (2010-2011) menées par notre équipe de recherche. Les mères de 357 cas de 
neuroblastome issus du Registre National des Cancers de l’Enfant (RNCE) ainsi que 1753 
témoins recrutés en population générale ont répondu à un entretien qui portait sur les 
caractéristiques périnatales de l’enfant, les expositions maternelles pendant la grossesse, 
antécédents médicaux familiaux et personnels de l’enfant ainsi que sur des variables 
contextuelles et socioéconomiques. La taille de notre échantillon a permis de réaliser des 
analyses stratifiées sur l’âge au diagnostic et le statut du proto-oncogène MYCN. 
Résultats : Une première analyse sur l’association entre les caractéristiques périnatales et le 
risque de neuroblastome chez l’enfant a mis en évidence des associations positives avec la 
présence de malformations congénitales (OR 3.6 [95% CI 1.3–8.9] parmi les enfants de moins 
de 18 mois) et des altérations de la croissance fœtale tels que le retard de croissance intra-
utérine ou la surcroissance fœtale (OR 1.4 [95% CI 1.0-2.0]) et (OR 1.5 [95% CI 1.1–2.2], 
respectivement). Le fait d’être allaité était inversement associé au risque de neuroblastome 
(OR 0.7 [95% CI 0.5–1.0]). Des associations inverses ont été également observées avec la 
supplémentation maternelle préconceptionnelle en acide folique (OR 0.5 [95% CI 0.3–0.9]). 
La difficulté pour concevoir ou l’utilisation d’assistance médicale à la procréation n’ont pas 
été associé au risque de neuroblastome dans notre étude. 
Dans une deuxième partie de ce travail, nous avons analysé les expositions maternelles 
domestiques et professionnelles aux pesticides pendant la grossesse. Nos résultats suggèrent 
que l’utilisation domestique de pesticides pendant la grossesse pourrait augmenter le risque de 
neuroblastome chez l’enfant (OR 1.5 [95% CI 1.2–1.9]). Des associations positives ont été 
observées avec l’utilisation d’insecticides seulement (OR 1.4 [95% CI 1.1–1.9]), ou en 
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combinaison avec d’autres pesticides (OR 2.0 [95% CI 1.1–3.4]). L’exposition 
professionnelle de la mère pendant la grossesse était également associée au risque de 
neuroblastome.  
La troisième partie de ce travail a porté sur l’analyse du tabagisme parental et la 
consommation maternelle d’alcool pendant la grossesse. La consommation maternelle de 
tabac était plus fréquente chez les mères des cas (24.1%) par rapport aux mères des témoins 
(19.7%) ; (OR 1.3 [95%CI 0.9–1.7]; OR à partir d’une méta-analyse 1.1 [95%CI 1.0–1.3]. 
Conclusion : Nos résultats portant sur les associations entre neuroblastome, surcroissance 
fœtale et malformations congénitales supportent l’hypothèse d’un rôle des altérations de 
l’embryogénèse dans la survenue des neuroblastomes de l’enfant. Ce travail contribue à 
l’évidence en faveur des associations entre neuroblastome et certaines expositions pendant la 
grossesse, notamment l’utilisation domestique de pesticides et le tabagisme maternelle. Nos 
résultats soulignent l’importance des recommandations visant à réduire l’exposition aux 
pesticides et le tabagisme maternel pendant la grossesse. Des nouvelles études sont 
nécessaires afin d’éclaircir le rôle de l’allaitement, ainsi que la supplémentation 
préconceptionnelle en acide folique dans la survenue de neuroblastome, vu son rôle potentiel 
dans la prévention de ce cancer.  
 
Mots clés: neuroblastome, facteurs de risque, pesticides, tabac, alcool, facteurs périnataux, 
acide folique, allaitement 
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Preface 
 
This thesis involves the analysis of data collected about childhood neuroblastoma in the 
ESCALE and ESTELLE French studies.  
The general aim was to investigate whether specific birth-related characteristics and 
environmental exposures around pregnancy were associated with neuroblastoma. 
Chapter 1 gives an overview of the descriptive epidemiology of neuroblastoma using data 
from the National Registry of Childhood Cancer (RNCE) and describes the burden of disease 
and overall survival. It also contains what is known about the disease, the hypothesis of a 
prenatal origin and a review of the literature about the suspected risk factors of 
neuroblastoma. The exposures were chosen based on previous research that suggested a 
biologically plausible association with neuroblastoma.  
The majority of the contents of these chapters has been published in three papers that 
explored: 
1. Birth related characteristics, congenital malformations and perinatal exposures 
2. Maternal use of household pesticide during pregnancy 
3. Parental smoking and maternal alcohol consumption during pregnancy 
To avoid repetition and to increase readability, the content of the published papers has now 
been edited for inclusion in relevant sections of the thesis, and the complete papers are 
included as appendices. 
Chapter 2 gives a description of the general study methods including recruitment of the study 
population and data collection methods. 
Chapter 3 describes the main results of this study. 
Chapter 4 contains a detailed discussion of the findings. 
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Introduction and background 
 
4 
 
 
1 Introduction 
Childhood cancers are the second leading causes of death in children aged 1 to 14 years. Each 
year in France, about 1700 children younger than 15 years are diagnosed with cancer. The 
incidence of the disease has been stable since 2000[1]. Neuroblastoma is the most common 
extra-cranial solid tumor in childhood and it is the most frequently diagnosed neoplasm 
during infancy. Compared with other childhood cancers such as leukemia and lymphoma, the 
sporadic occurrence of neuroblastoma has made this disease particularly challenging to study 
so literature is sparse.  
 
1.1 Descriptive epidemiology of neuroblastoma 
In the International Classification of Disease for Oncology (ICD-O-3)[2], neuroblastoma are 
classified into the two morphology codes 95003 (neuroblastoma, the most frequent) and 
94903 (ganglioneuroblastoma, the best differentiated form of neuroblastoma). Both are 
grouped in the category IV (Tumors of the sympathetic nervous system), subgroup IV.a of the 
International Classification for Childhood Cancers (ICCC)[3]. 
In this chapter, the epidemiological features of neuroblastoma are described using the 2000-
2013 data extracted from the French National Registry of Childhood Cancer (RNCE) 
(http://rnce.inserm.fr). The RNCE registers 130 to 150 new cases of neuroblastoma aged less 
than 15 years every year. 
 
1.1.1 Incidence 
According to ICD-O-3 categories, 11% of the French cases are ganglioneuroblastoma and 
89% neuroblastoma. Almost half of the tumors are located in the adrenal glands, 20% in other 
abdominal sites, 16% in mediastinum and the remaining 15% are distributed in pelvis, 
cervical or lumbar chains of the sympathetic nervous system. Almost half of the cases have 
distant metastases at diagnosis. The proportion of infants (under one year) with metastases is 
less but nearly a quarter are stage 4S (stage 4S; S=special). These infants have small primary 
tumors with metastasis in liver or skin, and with less than 10% marrow involvement. 
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Amplification of MYCN oncogene is present in less than 10% of infant neuroblastoma, but in 
more than 20% of neuroblastoma after the age of one year. 
The annual age-standardized incidence rate in France is around 14 cases per million of 
children aged 0-14 years (Table 1). Neuroblastoma is mostly diagnosed before the age of 5 
years (85%) and 40% occur in infancy. It is very uncommon after the age of 10 years. Annual 
incidence rates range from 73 cases per million in infancy to 1 case per million after the age 
of 10 years. One out of ten cases of neuroblastoma are neonates (<28 days). Most of them 
(65%) are diagnosed before birth by routine ultrasonography. 
An increase in incidence has been reported for Europe as a whole over the earlier period 1978 
to 1997 with an average change of 1.5% per year[4]. In the US the incidence rates were stable 
in metropolitan areas over the period 1973-2003, while raising by 2% in non-metropolitan 
areas[5]. 
The incidence rate increase could be partly explained by the changes in registry coverage and 
registration methods over the period. The highest incidence rates have been reported in 
countries with greater medical surveillance such as Western Europe, US, Canada, Japan, and 
Australia which may reflect better diagnostic facilities[6]. Incidence rates reported by low and 
medium resource countries are generally lower[7], [8]. A recent study revealed a statistically 
significant positive association between human development index and neuroblastoma 
incidence rates[9], which may reflect true risk factors as well as differences in diagnosis and 
registration practices. 
Because neuroblastomas frequently produce increased levels of catecholamines, the 
metabolites of which are detectable in the urine, active screening programs have been 
implemented in several countries in the past, including Japan, Germany and Canada. The 
rationale for mass screening around 6 to 12 months of life assumed that high-risk 
neuroblastomas, which are more frequent after 18 months, were low-risk neuroblastomas that 
had then become of worse prognosis. Eventually, screening led to an increase in incidence 
rates among infants, some of whom would have never developed symptomatic disease, but 
did not decrease high-risk neuroblastoma and thus did not improve survival. [10]–[12]  
 Ethnic differences have been suggested in previous periods. Nevertheless, annual incidence 
rate in black children in the USA is now 10.2 per million for 2001-2010, closer to that of 
white children while very low rates are reported in the mostly black population of Sub-
Saharan Africa[8]. 
6 
 
Table 1: Number of cases of neuroblastoma and annual incidence rates in France (2000-
2013), by age groups, by MYCN status and tumor extension (source: RNCE) 
  Age groups (years)   Total 
  < 1  1-4 5-9 10-14   
Incidence rate 
 
     IR  (/million*year) 73.1 22.2 4.0 1.1 
 
12.5 
ASR (/million*year) 
     
14.1 
       Mean annual numbers  55 67 15 4 
 
141 
 
39.0% 47.5% 10.6% 2.8% 
 
100.0% 
       MYCN amplification 
 
     Amplified 7.2% 26.4% 
   
16.6% 
Non amplified 78.1% 59.8% 
   
67.8% 
Unknown 14.7% 13.8% 
   
15.6% 
       Tumoral extension 
 
     Non metastatic 61.7% 44.8% 49.1% 44.3% 
 
51.8% 
Metastatic not 4S 24.4% 54.9% 50.5% 55.7% 
 
42.6% 
Metastatic 4S 13.9% 0.2%       5.6% 
IR: Incidence rate; ASR: age-standardized rate 
 
1.1.2 Survival  
The overall survival rates in France were 92% at 1 year and 75% at 5 years after diagnosis in 
2000-2010 (Table 2). Survival varies strongly with age, with best prognosis in children aged 
under 18 months. An age of 18 months or more, presence of metastases, MYCN amplification 
and some tumoral genomic profiles are factors with poor prognosis (see section1.2 Clinical 
and biological features of neuroblastoma). The particular clinical phenotype of neuroblastoma 
4S occurs in about 5-10% of cases and almost always regress[13].  
Treatment protocols have evolved over the last 40 years to better account for poor prognostic 
factors and to intensify the treatment of high-risk groups[6], [14], [15]. However, recent data 
shows a stagnation and even a significant fall in survival for neuroblastoma in Central 
Europe[16] and USA[17], while survival has increased in France, reaching 78.7% for the 
period 2010-20141. 
There are still survival disparities between countries, even within Europe[16]. A 5-year 
overall survival estimate of 59% was recently reported for Southern and Eastern European 
countries[18] compared to 77% in the USA. Disparities could be attributed, at least partly, to 
                                                 
1
 http://nce.vjf.inserm.fr/index.php/fr/statistiques/survie/variations-temporelles-du-taux-de-survie-a-5-ans-entre-
2000-et-2014-par-groupe-diagnostique 
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differences in detection or registration since more elaborate healthcare systems may capture 
more low-risk cases, including for example, spontaneously regressive cases.  
Finally, relapse and long-term outcomes in survivors also depend on the clinical and 
biological features of neuroblastoma. Nearly 6% of patients die later than 5 years after 
diagnosis, usually from disease recurrence or second malignant neoplasms. Relapse occurs in 
more than 50% of children with high-risk neuroblastoma and 20% of intermediary-risk[19]. 
Cohorts of survivors have shown that children who have had a neuroblastoma were likely to 
have chronic health conditions, particularly after multimodality therapy. In the Childhood 
Cancer Survivor Study cohort in the USA, nearly a third of the survivors developed 
neurological complications and about 8% developed endocrine, sensory, and musculoskeletal 
complications [20].  
 
Table 2: Five-year overall survival by age, by MYCN status and tumoral extension (RNCE, 
France, 2000-2010) 
  5 years survival [95% CI]   Total 
  < 1 year old ≥ 1 year old     
Total 90.3 [88.0-92.2] 66.0 [63.2-68.7]  75.3 [73.3-77.2] 
MYCN      
Amplified 40.0 [27.0-52.7] 44.1 [38.0-50.0]  43.3 [37.8-48.7] 
Non amplified 95.1 [93.1-96.6] 71.9 [68.4-75.2]  82.4 [80.2-84.4] 
Unknown 89.4 [82.1-93.8] 71.7 [64.6-77.6]  78.1 [72.9-82.4] 
Tumor extension     
Non metastatic 96.5 [94.3-97.8] 89.7 [86.6-92.2]  93.0 [91.1-94.4] 
Metastatic not 4S 71.3 [61.4-79.1] 45.2 [41.2-49.2]  48.7 [44.9-52.4] 
Metastatic 4S 84.6 [78.6-89.0] 48.6 [19.2-73.0]   82.5 [76.5-87.1] 
     
 
 
1.2 Clinical and biological features of neuroblastoma 
Neuroblastoma is an embryonic and neuroendocrine tumor that arises in the developing 
sympathetic nervous system. The tumor can develop from any neural crest element, which 
results in tumors at any site in the sympathetic nervous system (adrenal glands and/or 
sympathetic ganglia). Around 80% of cases develop in the abdomen, with more than 50 % of 
tumors occurring in the medulla of the adrenal glands. Other locations include the paraspinal 
sympathetic ganglia of the neck, chest or pelvis. 
The clinical signs and symptoms of neuroblastoma vary greatly depending on size, location, 
and spread of the tumor. The most common presentation of neuroblastoma is a painless 
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abdominal mass and often the diagnosis is made following an incidental finding. When 
present, symptoms can be related to the mass effect from the primary tumor, metastatic 
disease, or paraneoplastic syndromes. Large tumors can cause abdominal pain and distension, 
damage of the cervical ganglions or spinal cord compression. Metastatic disease is present at 
diagnosis for overall 50% of cases and the most frequent locations are regional lymph nodes, 
bone marrow and bone. Finally, in rare cases neuroblastoma can be associated with 
syndromes like opsoclonus-myoclonus syndrome or profuse watery diarrhoea as result of 
hypersecretion of vasoactive intestinal peptide. 
The diversity on neuroblastoma clinical behaviour correlates closely with a number of clinical 
and biologic features. Remarkable efforts have been made in the last decades in developing 
risk-group assignment in order to provide to each child with neuroblastoma the optimal 
treatment regimen[21]. Children with low-risk disease may be observed or undergo surgery. 
Those with intermediate-risk disease may receive chemotherapy and undergo surgical 
resection, while those with high-risk disease receive intensive multimodality therapy (that 
includes chemotherapy, surgery, radiation, and immunotherapy).  
The International Neuroblastoma Risk Group classification [22] considers the following 
factors as the most statistically and clinically relevant factors: 
 Stage of the tumor at diagnosis 
 Age at diagnosis (less than 18 months / 18 months or more) 
 Histologic category and grade of tumor differentiation 
 Status of MYCN oncogene (amplified or not amplified) 
 Other genetic characteristics of the tumor like Chromosome 11q status and DNA 
ploidy 
Besides being relevant as risk stratification and treatment factors, the stage and age at 
diagnosis[23], as well as the status of MYCN oncogene status  [24], [25] have also been used 
in etiological approaches as a proxy for potential modifiers of the associations with risk 
factors. 
To date, several genetic alterations have been described in neuroblastoma, which concern 
gene amplification, polymorphisms and chromosome alterations with loss or gain of 
chromosome material.  
The amplification of the oncogene MYCN, at chromosome 2p24, is the most frequently 
reported tumor genetic alteration. The MYCN gene provides instructions for making a protein 
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that plays an important role in the formation of tissues and organs during the embryonic 
development. Amplification of the MYCN oncogene is observed in 20-25% of all 
neuroblastoma. It is more frequent among children with neuroblastoma diagnosed later and 
harbors a particularly poor prognosis (reviewed in [26]).The MYCN amplification can occur in 
a context of co-activation with other genes. Owing to their similar locations on 2p, ALK and 
MYCN can be co-amplified. Somatic mutations in ALK are reported in approximately 14% of 
high-risk neuroblastoma[27]. 
Segmental chromosomal alterations (SCAs) are characterised by losses of chromosomes (1p, 
3p, 4p and 11p) and/or gains of chromosomes (1q, 2p and/or 17q)(reviewed in[28]). They are 
associated with poor prognosis in most cases. 
Finally, LIN28B polymorphisms have been shown to be associated with high-risk 
neuroblastoma. LIN28B is known to play a crucial role throughout embryonic development, 
controlling cell growth during neural crest cell lineage differentiation. In neuroblastoma cells, 
misexpression of LIN28B leads to high levels of N-MYC, the protein encoded by MYCN [29].  
 
1.3 Natural history: the hypothesis of a perinatal origin 
During the early seventies, Knudson[30] proposed the hypothesis that a “two hit” model may 
explain familial neuroblastoma development, like in retinoblastoma. The first hit being a 
germline mutation and the second hit an acquired somatic mutation. Although the majority of 
neuroblastoma are sporadic cases, the multiple-hit model is still supported by considerable 
evidence suggesting that neuroblastoma is initiated in utero during sympathoadrenal 
development[31] (Figure 1). 
During the early embryonic development (three to five weeks after conception), the neural 
crest develops from the neural tube. The neural crest cells will then migrate towards the dorsal 
aorta and differentiate into sympathoadrenal progenitor cells, from which develop the cells of 
the peripheral nervous system. The migration process requires high expression levels of N-
MYC and bone morphogenetic proteins (BMPs). However, once this process has been 
completed, N-MYC proteins levels should gradually reduce to allow sympathoadrenal 
maturation and differentiation into sympathetic neurones. The prenatal origin hypothesis 
suggests that the earliest origin for neuroblastoma may be a neural crest cell that has not 
received or has not responded to cues that determine cell differentiation. This would represent 
the first hit towards malignant differentiation. During normal embryonic development, these 
aberrant undifferentiated cells are detected and the excess of neural precursors undergoes 
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apoptotic cell death. A second hit would provide to these cells the resistance to apoptotic 
signals and give raise to the postnatal survival of neuroblast precancer cells. A third hit during 
the postnatal period may induce precancer cell transformation, and result in neuroblastoma in 
early childhood[31]. 
Paternal periconceptional exposures may also be involved. It has been shown that some 
exposures like tobacco smoke may have germ-cell mutagen effects[32]. Furthermore, 
epigenetic changes in human sperm may impair normal embryo development, particularly cell 
death and apoptosis[33].  
 
1.4 Etiology of neuroblastoma 
1.4.1 Genetic aspects of neuroblastoma 
The possibility of neuroblastoma genetic predisposition has long been suggested after the 
observation of familial cases. Neuroblastoma has been described in the context of disorders 
related to abnormal development of the neural crest derived tissues like central congenital 
Figure 1: Neural crest development and neuroblastoma. Extracted from Marshall 
et al "The prenatal origins of cancer". 
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hypoventilation syndrome and Hirschsprung disease. In addition, the associations, while rare, 
between neuroblastoma and the familial tumor syndrome neurofibromatosis type 1 (NF1), 
Noonan or Costello syndromes, underlay the potential importance of the RAS-MAPK pathway 
in neuroblastoma development.  
Familial neuroblastoma per se is rare. A family history of the disease is found in about 1-2% 
of newly diagnosed cases.  
The missense mutations of PHOX2B gene on chromosome 4p were the first germ line 
mutations to be identified in neuroblastoma predisposition[34]. The PHOX2B gene provides 
instructions for making a protein, very active in the neural crest, that acts early in 
development to help promote the formation and differentiation of neurons. The germline gain-
of-function in the anaplastic lymphoma kinase gene (ALK) on chromosome 2p23 has been 
identified in more than half of familial cases[27], [35]. The ALK gene provides instructions 
for making a protein called ALK receptor tyrosine kinase, which is thought to act early in 
development to help regulate the proliferation of nerve cells. Taken together, the presence of 
constitutional PHOX2B and ALK mutations constitute key events in neuroblastoma 
oncogenesis in affected individuals. 
As shown by genome-wide association studies (GWAS) (reviewed in [28]), some 
constitutional genomic variants correlate with either high-risk or low-risk neuroblastoma and 
indicate that favorable and unfavorable forms of neuroblastoma may represent distinct entities 
in terms of genetic events that initiate tumorigenesis.  
 
1.4.2 Birth-related characteristics  
The embryonic nature of the tumor cells and the early age at neuroblastoma onset suggest that 
preconceptional and perinatal events may be involved in its etiology.  
1.4.2.1 Birth-weight, gestational age and fetal growth 
Previous studies have shown that in-utero events may influence later susceptibility to certain 
diseases. Fetal growth abnormalities are associated with increased risk of stillbirth, increased 
neonatal morbidity and mortality. Both fetal growth restriction (when the fetus does not 
achieve its growth potential) and macrosomia (or fetal over-growth) have been associated 
with long-term risks to health, such as type 2 diabetes and cardiovascular pathology[36]. In 
addition, fetal growth abnormalities have been associated with increased risk of some cancers 
in childhood. A positive association has been consistently reported between fetal over-growth 
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and childhood acute lymphoblastic leukemia (LLA)[37] and Wilms’ tumor[38], [39], while 
for other childhood cancers, results are still heterogeneous.  
The insulin-like growth factors (IGFs) are thought be involved in the biological mechanisms 
underlying such associations[40]. IGFs are mitogenic and anabolic proteins that are important 
in the regulation of cell proliferation during normal embryogenesis. However, they are also 
believed to play a role in carcinogenesis. 
Two different approaches have been advocated for the study of fetal growth, both adjusting 
birth-weight for gestational age. One is based on the premise that fetal growth is mainly 
influenced by genetics factors and uses growth charts customized for specific phenotypic 
traits like maternal ethnicity, height and weight[41]. The other is based on the theory that 
growth potential is similar within populations and uses optimal fetal growth standards at a 
population level. This second approach has mainly been used in epidemiological studies that 
have used the combined analysis of birth-weight and gestational age as a proxy for fetal 
growth. For each gestational age, birth weight below the 10th and above the 90th percentiles 
of the expected distribution of birth weight in the population are commonly used cut-offs to 
define the fetus at risk that may benefit from higher surveillance of fetal well-being. Some 
other studies have used birth-weight per se for the characterization of the exposure, with low 
birth-weight defined by “less than 2500 g” and high birth-weight defined by “more than 4000 
g”. 
Gestational age has also been analyzed in order to assess its potential association with 
childhood cancer as an independent risk factor.  
With regards to neuroblastoma, several case-control studies have analyzed the relationship 
between gestational age, birth-weight and neuroblastoma, some of them based on maternal 
interview at the time of diagnosis[23], [38], [42], [43] and some using information from birth 
certificates[44]–[49]. They are summarized in Table 3.  
Overall, no association has been shown between neuroblastoma and gestational age. By 
contrast, a slight positive relationship was observed with high birth-weight with a pooled OR 
of 1.2 [95% CI 1.0-1.4] for birth-weight >4000g, compared to those ≤4000 g, in a meta-
analysis[50]. Results were heterogeneous among the five studies[38], [46]–[49] that 
considered birth-weight by gestational age. 
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Table 3: Literature review - association between neuroblastoma and birth related characteristics 
Study Exposure  Prevalence  Reference group OR [95% CI] 
Interview-based case-control studies     
US-Canada,1992-1994 
504cases<19 years[42] 
<32 weeks 2% 37-42 weeks  1.9 [0.7-4.4] 
33-36 weeks 6% 0.5 [0.3-1.0] 
> 42 weeks 1% 0.9 [0.3-3.0] 
<1500 g 1% 2501-4000 g 2.6 [0.7-10.3] 
1500-2500 g 6% 1.1 [0.6-2.0] 
4000-4499 g 11% 1.1 [0.7-1.7] 
≥ 4500 g 1% 1.4 [0.6-3.2] 
Germany, 1988-1994,  
183 cases< 15 years[23]  
<37 weeks 4% 37-42 weeks 2.5 [1.3-4.6] 
< 2500 g 3% 2500-4000 g 2.4 [1.2-4.7] 
> 4000 g 11% 1.3 [0.8-2.2] 
Germany, 1992-1994,  
160 cases <14 years[38] 
SGA 
LGA 
11% 
8% 
AGA 1.2 [0.7-2.1] 
1.6 [0.9-2.7] 
Italy, 1998-2001,  
207 cases < 15 years[43] 
≤37 weeks 15% 38-42 weeks 0.8 [0.5-1.3] 
>42 weeks 5% 0.8 [0.3-2.2] 
< 2500 g 6% 2500-4000 g 0.6 [0.2-1.6] 
> 4000 g 8% 1.1 [0.6-2.0] 
Record linkage studies         
Norway, 1967-2004,  ≤ 18 months  
178 cases < 15 years[44]  
 
 
 > 18 months 
<37 weeks N/S 40-41 weeks 0.6 [0.2-2.0] 
> 42 weeks N/S 1.2 [0.7-2.0] 
< 2500 g N/S 3000-3499 g 1.1 [0.3-3.7] 
≥ 4000g N/S 1.8 [1.0-3.1] 
<37 weeks N/S 40-41 weeks 0.7 [0.2-2.8] 
> 42 weeks N/S 1.6 [0.8-3.0] 
≥ 4000g N/S 3000-3499 g 0.9 [0.4-1.8] 
US New-York state, 1976-1987 
155 cases <6 years[45] 
<37 weeks 11% 37-42 weeks 0.4 [0.1-0.9] 
>42 weeks 12% 0.3 [0.1-0.7] 
< 2500 g 7% 3000-3499 0.9 [0.4-2.2] 
> 4000 g 12% 1.2 [0.6-2.2] 
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US Minnesota state, 1976-2004, 
155 cases <14 years[46]  
<37 weeks 9% ≥37 weeks 1.0 [0.6-1.8] 
< 2500 g 7% 2500-4000 g 1.2 [0.6-2.3] 
> 4000 g 15%   1.1 [0.7-1.7] 
SGA 7% AGA 2.1 [1.1-4.0] 
LGA 24% AGA 1.0 [0.7-1.5] 
US California state,1988-1997, 
508 cases<5 years[47]  
<37 weeks 12% 37-41 weeks 0.8 [0.6-1.2] 
>42 weeks 11% 1.1 [0.8-1.5] 
< 2500 g 5% 2500-3999 g 1.0 [0.6-1.6] 
≥ 4000g 12% 1.2 [0.9-1.7] 
term and < 2500 g 2% Term and /2500-3999 g 1.4 [0.6-3.0] 
Term and ≥ 4000g 10% 1.2 [0.9-1.8] 
US Washington state, 1980-2004, 
240 cases <15 years[48]   
<37 weeks 8% 37-42 weeks 0.6 [0.3-1.1] 
>42 weeks 4% 1.2 [0.9-1.8] 
< 2500 g 5% 2500-3999 g 0.7 [0.4-1.5] 
> 4000 g 13% 1.4 [0.7-2.6] 
SGA 9% AGA 0.9 [0.6-1.5] 
LGA  10% 1.3 [0.8-1.9] 
US New-York state, 1983-2001,  
529 cases <15 years[49]  
<38 weeks 
< 2500 g 
> 4500 g 
SGA 
LGA 
14% 38-40 weeks 
2500-4500 g 
 
AGA 
0.9 [0.7-1.2] 
1.5 [1.0-2.1] 
1.4 [0.7-2.5] 
1.0 [0.5-1.9] 
1.1 [0.8-1.6] 
%E: proportion of exposed; SGA: small for gestational age; LGA: large for gestational age; AGA: appropriate for gestational age; N/S: not specified 
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1.4.2.2 Congenital malformations 
Congenital malformations, also known as birth defects or congenital anomalies, are structural 
or functional anomalies, which may be diagnosed prenatally, at birth or later in life. The term 
encompasses a heterogeneous group of pathologies that can be caused by single gene defects, 
chromosomal disorders, multifactorial inheritance, environmental teratogens and 
micronutrient deficiencies or excesses[51]. 
Congenital malformations have been long described to be associated with different types of 
childhood cancer, especially leukemia and brain tumors[52]–[54]. They may suggest the 
existence of genetic factors or materno-fetal exposures that increase cancer risk. For example, 
the reported association between Wilms' tumor and WAGR syndrome (Wilms’ tumor, 
aniridia, genitourinary malformations and mental retardation) led to the identification of the 
WT1 gene[55], [56]. Evidence about the increased risk of cervical and vaginal clear cell 
adenocarcinoma and reproductive tract abnormalities among women exposed to 
diethylstilbestrol (DES) raised the hypothesis that biological processes, corresponding to non- 
optimal development, might then induce possible carcinogenicity processes.  
Nine studies which investigated the link between congenital malformations and 
neuroblastoma reported positive associations (Table 4). Both congenital malformations and 
neuroblastoma are rare, which has limited the ability to do detailed analyses. The association 
with any malformation has been consistently reported by both interview- [43], [57] and birth 
certificate-based studies[44], [47], [48], [53], [58]–[60]  
1.4.2.3 Maternal folic acid intake  
Folic acid is a synthetic form of folate, which is water soluble B vitamin most commonly 
found in green vegetables. Periconceptional folic acid supplementation has been shown to 
reduce the risk of neural tube defects by almost three-quarters[61]. Neural tube defects occur 
when the neural tube, which originates on the neural crest, fails to close early during the 
embryonic development (after 28 days after conception). This can result in significant 
morbidity and mortality because of damage of the exposed neural tissue. In 1991, the Centers 
for Disease Control and Prevention (CDC) recommended that women with a previous history 
of neural tube defects in offspring should consume 400 µg of folic acid daily starting at the 
time they begin planning a pregnancy. Subsequently, in 1992, the U.S. Public Health Service 
extended this recommendation to all women of childbearing age[62]. Because these 
recommendations may be difficult to achieve for a large part of the general population, 
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mandatory fortification programs have been implemented in many countries. Up to 2010, the 
CDC reported that 53 countries had regulations for mandatory fortification of wheat flour 
with folic acid[63]. However, in France, no such mandatory fortification program has been 
implemented. Health promotion campaigns encouraging prenatal folic acid supplementation 
began in 2004, after the ESCALE study period.  
Because neural tube defects arise from the same embryonic structures as neuroblastoma, it has 
been hypothesized that the risk of neuroblastoma could also be reduced by maternal folic acid 
supplementation before conception and in the first trimester of pregnancy. Biological 
plausibility of this association is supported by evidence suggesting that low folate levels 
during the periconceptional period may be associated with increased DNA methylation, 
thereby modifying the expression of genes, such as TFAP2A, a critical gene for neural crest 
development or STX11, a gene implicated in acute myeloid leukemia[64]. 
Four studies have investigated the association between vitamin/folic acid supplementation 
during pregnancy and neuroblastoma[65]–[68] (Table 5), three of which reported an inverse 
association with supplementation during pregnancy[65]–[67], based on maternal interview. In 
addition, an interventional time series analysis found that the incidence of neuroblastoma 
significantly declined after the implementation of a mandatory food fortification program in 
Canada[65].  
1.4.2.4 Breastfeeding 
Breastfeeding is known to be protective against many childhood diseases because its 
nutritional, immune modulating and growth-promoting benefits. Inverse associations have 
been reported with childhood leukemia[69]. Biological plausibility for this association is 
supported by the fact that breastfeeding provides an influx of growth factors that promote cell 
differentiation[70] influences microbiota composition[71] and strengthens the infant immune 
system[72].   
Studies on neuroblastoma and breastfeeding are summarized in Table 6. Breastfeeding was 
reported to reduce risk of neuroblastoma in a large study performed in US and Canada (OR 
0.6 [95% CI 0.5-0.9])[73], while two other studies[74], [75] based in less than 50 cases did 
not report significant associations. 
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Table 4: Literature review - association between congenital malformations and risk of neuroblastoma 
Study Exposure (Classification System) %E RR [95% CI] 
Interview-based case-control studies       
US and Canada, 1992-94,  
538 cases <19 years [57] 
Any malformation (ICD-10) 5.0% 2.5 [1.6-4.2] 
Major malformation 1.0% 7.5 [2.2-25.5] 
Italy, 1998-2001,  
207 cases <15 years[43] 
N/S 1.3% 4.9 [1.8-13.6] 
Record linkage studies    
England, Scotland and Wales, 1971-1986,  
1208 cases < 15 years[58] 
Spina bifida (ICD-10) N/S 0.7 (ns) 
Cardiac septal defects (ICD-10) N/S 1.1 (ns) 
Tetralogy of Fallot (ICD-10) N/S 8.3 (ns) 
Genitourinary (ICD-10) N/S 1.5 (ns) 
Spine malformations (ICD-10) N/S 1.7 (ns) 
Canada, 1977-1993 
141 cases < 15 years [59] 
Any malformation (ICD-9) 4% 1.9 (p < 0.03) 
    
Norway, 1978-1997,  < 18 months 
178 cases<15 years[44]  
 ≥ 18 months 
Any malformation (N/S) N/S 3.7 [1.7-8.0] 
 N/S 0.7 [0.1-4.7] 
Australia, 1984-1993,  
52 cases < 15 years [53] 
Any malformation (ICD-9, British 
Pediatric Association modification) 
2.5% 7.9 [3.3 – 18.8] 
US, Washington state, 1980-2004,  
240 cases < 20 years[48]  
Any malformation (N/S) 
Major malformations 
4.8% 2.1 [1.3-3.4] 
0.6% 6.9 [2.9-16.1] 
US, California state, 1988-1997 < 1-4 years 
508 cases < 5 years[47]  < 1 year 
US Washington state, 1984-2013 
327 cases <20 years[60]  
Any malformation (N/S) 
 
Non-chromosomal malformations 
(ICD-9) 
N/S 
 
 
5% 
1.0 [0.4-2.7] 
1.6 [0.8-3.3] 
 
1.9 [1.3-2.8] 
 
%E: proportion of exposed; CI: confidence interval; N/S: not specified; RR: relative risk estimate (odds ratio or standardized incidence ratio). 
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Table 5: Literature review - association between neuroblastoma and folic acid/vitamins supplementation in the periconceptional period 
Study Exposure  Exposure period %E RR [95% CI] 
Interview-based case-control studies     
US-Canada, 1992-1994,  
538 cases <15 years[67] 
Vitamins use 12 to 2 months before 
pregnancy 
17% 0.7 [0.4-1.1] 
1 month before pregnancy 19% 0.7 [0.7-1.1] 
1st trimester 52% 0.7 [0.5-1.0] 
2nd trimester 80% 0.6 [0.4-0.9] 
3rd trimester 78% 0.6 [0.4-0.9] 
Vitamin, folic acid ≥ 
0.4 mg  
1st trimester N/S 0.7 [0.5-0.9] 
2nd and 3rd trimester N/S 0.6 [0.5-0.9] 
New York state, 1976-1987 
183 cases < 15 years [66] 
Vitamin use During pregnancy 57% 0.5 [0.3-0.7] 
Incidence studies     
Ontario 1985-2000,  
< 17 years [65] 
Trend before/after population food fortification 
program with folic acid 
 0.4 [0.2-0.6] 
 
Norway, 1999-2010,  
72 cases <15 years [68] 
Vitamins only Before and/or during 
pregnancy 
8% 1.0 [0.3-2.8] 
Folic acid only 17% 1.1 [0.5-2.1] 
Both 19% 1.0 [0.5-2.1] 
%E: proportion of exposed; CI: confidence interval; N/S: not specified; RR: relative risk estimate (odds ratio, Incidence rate, or hazard ratio) 
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Table 6: Literature review - association between neuroblastoma and breastfeeding 
Study Exposure  Reference  %E RR [95% CI] 
Interview-based case-control studies       
Russia,1986-1988,  
42 cases < 14years [74] 
As reported by interviewed mothers 
< 1 months 
> 12 months N/S 7.5 [0.7-97.3] 
 1-2 months  N/S 1.1 [0.2-8.1] 
 3-4 months N/S 2.1 [0.5-9.3] 
 5-6 months N/S 1.9 [0.4-10.9] 
  7-12 months N/S 2.1 [0.5-9.6] 
US-Canada, 1992-1994 
393 cases > 6 months-19 years[73] 
Breast and bottle Never  13% 0.7 [0.5-1.2] 
Breast only   56% 0.6 [0.5-0.9] 
0-3 months  16% 0.7 [0.4-1.0] 
4-6 months  13% 0.7 [0.5-1.2] 
7-9 months  9% 0.6 [0.4-1.1] 
9-12 months  7% 0.6 [0.3-1.1] 
≥ 13 months  10% 0.5 [0.3-0.9] 
        p-trend < 0.01 
Record linkage studies     
Sweden,1988-1991,  
34 cases <14 years[75] 
1-6 months <1 month ns 0.6 [0.1-2.8] 
≥ 6 months ns 0.5 [0.1-2.6] 
%E: proportion of exposed; CI: confidence interval; N/S: not specified; RR: relative risk estimate (odds ratio or standardized incidence rate) 
20 
 
1.4.3 Environmental risk factors 
1.4.3.1 Pesticides 
Pesticides are defined as any substance, molecule or product aimed to eliminate pests[76]. 
The term covers a large, heterogeneous group of chemicals. Pesticides are used in a large 
number of settings including the rural sector, public spaces and around the home. France is 
the second leading European country with regards to agricultural pesticides purchase. This is 
mainly related to its agricultural surface (the biggest in Europe) and the prevalence of high 
pesticide use (grapevine, wheat and canola). 
The general population is exposed to multiple sources of pesticides, which contribution to the 
overall individual exposure is yet to be determined. The main sources of pesticide exposure in 
general population are food, contamination from outdoor and indoor air, soil or indoor dust, 
and the use of pesticides in gardens and on domestic animals.  
As well as playing a role in enhancing food production and contributing to the control of 
diseases like malaria, pesticides have also been associated with adverse health events such as 
childhood leukemia[77]. The International Agency for Research on Cancer (IARC) has 
classified seven pesticides as “probable or possible” human carcinogens and many more as 
carcinogenic to laboratory animals[78][79]. Previous studies have shown that pesticides can 
reach the fetus after maternal exposure and, in many cases, induce genotoxic damage 
(reviewed in[80]). 
Exposures to pesticides have been the most investigated environmental exposures with 
regards to neuroblastoma and the published papers are summarized in Table 7. This thesis 
focused on maternal use of household pesticides and maternal occupational exposure during 
pregnancy. Increased risk of neuroblastoma was associated to self-reported use of household 
pesticides before[25] or after birth[23] in two previous case-control studies.  
Maternal occupational exposures were addressed by five case-control studies[23], [81]–[84] 
and three of them[23], [81], [83] reported increased risk of neuroblastoma with farming or 
pesticides use. Two cohorts[85], [86] and seven case-control studies [23], [25], [81]–[84] 
investigated paternal exposure with inconsistent results, as summarized by a meta-analysis 
showing no association with neuroblastoma[87].  
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1.4.3.2 Tobacco smoking and alcohol 
Tobacco smoke and alcohol consumption are of interest as potential risk factors of 
neuroblastoma. The IARC has classed tobacco smoke and its metabolites as proven 
carcinogens to humans (Group 1)[88]. Tobacco smoke compounds, either directly or after 
metabolism, react with specific sites in DNA to form covalent binding products called 
addition products (or adducts) that can cause mistakes during DNA replication. Several 
adducts have been found in placental and umbilical cord DNA, showing that tobacco smoke 
compounds can cross the placenta leading to fetal exposure and DNA damage [89]. It has also 
been shown that paternal smoking affects both genomic and epigenomic components of the 
sperm and could be related with developmental defects in the offspring[90].  
Teratogen and carcinogenic effects have also been shown with regards to alcohol 
consumption. The underlying biological mechanisms are not clear, but explanatory 
hypotheses highlight the potential of ethanol and its metabolites to generate oxidative stress, 
induction of mitogen-activated protein kinases (MAPK) and folate and DNA methylation, 
among others [91].  
Overall, literature suggests that maternal tobacco smoking during pregnancy is associated 
with a slight increase in risk of neuroblastoma, based on 8 studies[23], [24], [43], [45], [46], 
[48], [92], [93] estimated by a pooled OR of 1.2 [95% CI 1.0-1.4] in a recent meta-
analysis[94]. Fewer studies report data on paternal smoking and no consistent pattern has 
been observed to date. Findings on maternal alcohol drinking during pregnancy are also 
heterogeneous[23], [24], [45], [46], [92]. The literature on tobacco smoking and alcohol are 
described in more detail in the Results section (3.4.2.3 Meta-analysis).  
 
1.4.3.3 Other environmental factors 
Associations with parental occupational exposures to magnetic fields, hydrocarbons or other 
chemicals [82]–[84], [95] or residential exposure to air pollutants [96], [97] have been 
investigated reported and no consistent pattern has emerged to date. 
 
22 
 
Table 7: Literature review - association between parental pesticide exposure and neuroblastoma 
Study Exposure  Parent Period %E 
(controls) 
RR [95% CI] 
Parental occupational exposures - cohorts        
Norway, 1952-1991,  
27 cases [85]  
Field vegetable farming  
 (agricultural census) 
Any parent  Any time  
 
Any time 
N/S 2.5 [1.0;6.1] 
US, 1993-1997,  
3 cases[86]  
Farming Any parent  N/S 1.3 [0.4;3.9] 
Parental occupational exposures – case-control studies        
US Greater Philadelphia area, 
1970-1979, 104 cases[81]  
Farming  Any parent Pregnancy 
Preconception 
N/S 
N/S 
0.7 [0.1;5.8] 
3.5 [0.7-35] 
US and Canada, 1992-1996,  
504 cases[82] 
Farming  Maternal Any time N/S 2.2 [0.6;8.8] 
Paternal Any time N/S 0.9 [0.4;1.8] 
US New-York state, 1976-1987,  
183 cases[83] 
Field vegetable farming 
  
Maternal Pregnancy N/S 0.8 [0.2;3.2] 
Paternal Pregnancy N/S 1.0 [0.2;3.9] 
Insecticides use  Maternal Pregnancy N/S 2.3 [1.4;3.7] 
Paternal Pregnancy N/S 1.7 [1.0;2.7] 
Germany, 1988-1994,  
183 cases[23]  
  
Farming  Maternal After birth 3% 1.2 [0.4;3.7] 
Any occupational use  Maternal Any time 1% 5.1 [1.1;23.4] 
Paternal Any time 4% 1.8 [0.8;3.7] 
Great Britain, 1962-1999, 
2920 cases[84] 
Agriculture  Paternal Pregnancy 2% 0.9 [0.6;1.3] 
Agrochemical industry Paternal Pregnancy 3% 1.0 [0.7;1.4] 
Parental non-occupational exposures - case-control studies    
US and Canada, 1992-1994,  
538 cases[25]  
Household use Both parents Ever 31% 1.6 [1.0;2.3] 
Preconception-pregnancy 18% 1.3 [0.8;3.3] 
After birth 18% 1.4 [0.9-2.2] 
Garden Both parents Ever 22% 1.7 [0.9;2.1] 
Preconception-pregnancy 13% 1.3 [0.8;2.0] 
 After birth 12% 1.8 [1.0-3.1] 
Germany, 1988-1993,  
183 cases[23] 
Household insecticides use After birth 6% 1.8 [0.9;3.4] 
Garden pesticides  After birth 10% 0.9 [0.5;1.6] 
RR [95%CI]: RR estimated (Standardized incidence ratio or odds ratio) and its 95% confidence interval; N/S: not stated 
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1.5 Aims of the work 
The present work aimed at further understanding the perinatal and environmental risk factors 
of childhood neuroblastoma, with the period around pregnancy as a critical window of 
exposure.  
With regards to perinatal factors, we investigated the following factors: 
 Birth-related characteristics (gestational age, birth-weight and fetal growth), with 
the hypothesis that increased fetal growth could be related to neuroblastoma. 
 The presence of congenital malformations, with the hypothesis that developmental 
genes are responsible of both congenital malformations and embryonic tumors, 
particularly neuroblastoma. 
 Maternal intake of folic acid before or during pregnancy, with the hypothesis that 
low folate levels during the periconceptional period may be associated with 
increased risk of neuroblastoma because of abnormal gene expression during 
neural crest development. 
 Breastfeeding, which is suggested to reduce the risk of many childhood cancers. 
 
 With regards to environmental exposures related to parental habits, we focused on the 
following exposures around pregnancy, which are suspected risk factors:  
 Maternal use of household pesticides during pregnancy, and maternal occupational 
exposure to pesticides. 
 Maternal smoking during pregnancy and paternal smoking in the year before 
pregnancy 
 Maternal alcohol consumption during pregnancy 
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2 Population and methods 
 
These analyses used data from the ESCALE and ESTELLE studies, two nationwide case-
controls studies based on the French national registry of childhood cancers. The ESCALE 
study (Etude Sur les Cancers et les Leucémies de l’Enfant) was performed in 2003-2004 and 
included all cases of neuroblastoma, leukemia, lymphoma and malignant brain tumor. The 
ESTELLE study (Etude Sur les Tumeurs Embryonnaires, Leucémies et Lymphomes de 
l’Enfant) was performed in 2010-2011 and included cases of neuroblastoma, leukemia, 
lymphoma, malignant brain tumor, Wilms’ tumor and hepatoblastoma. 
 
2.1 Study population 
2.1.1 Case and control ascertainment 
2.1.1.1 The French National Registry of Childhood cancers (RNCE) 
As a Health Registry, the RNCE is a continuous and exhaustive collection of individual data 
for public health and research purposes, on childhood cancers and some borderline tumors 
diagnosed in France (http://rnce.inserm.fr).  
The RNCE is composed by two entities: 
 The registry of childhood hematological malignancies (RNHE), starting in 1990 
 The registry of childhood solid tumors (RNTSE), starting in 2000 
The RNCE was created with three main goals: 
1. To estimate and monitor childhood cancer incidence and survival rates in France by 
histologic/cytological/molecular subtypes, as well as to detect geographical and temporal 
variations of the rates. 
2. To support etiological research on the potential risk factors of childhood cancers.  
3. To provide assistance for the assessment of health providers and quality of care. 
The RNCE currently includes all children younger than 18 years old and living in mainland 
France or in the overseas at the time of diagnosis. Up to 2011, the RNCE included cases under 
15 years of age and living in France mainland only. 
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Complete information about each patient is collected by active searching in the forty-seven 
Hospital Centres that provide care for children with a cancer or borderline tumor (Figure 2) 
and in additional services where cases are detected using medico-administrative databases. 
Trained clinical research associates transmit the information to the RNCE coordinators, 
responsible for data monitoring and validation, and for diagnoses coding and staging.  
Figure 2: Location of oncology centres in France and overseas 
 
2.1.1.2 Inclusion in the ESCALE and ESTELLE studies 
The parents of the eligible cases were contacted at hospital by the network of the RNCE 
clinical research assistants. The eligible cases were children diagnosed with a neuroblastoma 
during the study period, younger than 15 years old and living in mainland France at the 
moment of diagnosis (Figure 3). Their biological mother had to be eligible for interview, 
which led to exclusion of adopted children, children whose biological mother had died, did 
not speak French, or had a serious psychiatric disorder (n=34). Children who had died and 
those in palliative care (n=22) were not eligible because of ethical reasons. 
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2.1.1.3 Control selection (Figure 4) 
Eligible controls were children from general population that had not been diagnosed with 
cancer. Like the cases, the children who had been adopted, or whose biological mother had 
died or did not speak French were not eligible as controls (Figure 4).   
The procedure for control sampling was slightly different for the two studies. In the ESCALE 
study, a base of 60,000 telephone numbers was randomly extracted from the national 
telephone directory. The set was representative of the population in terms of the 
administrative regions and urbanization. By incrementing each number by 1, a new set of 
60,000 numbers was generated. The new set included unlisted numbers and had geographic 
and demographic distribution similar to those of the initial set (same first six digits, which 
indicate the location of the line). In the ESTELLE study, the population controls were 
children free from cancer selected in France. Forty successive sets of 5,000–25,000 
allocatable telephone numbers were randomly generated and dialed over the 2 years of the 
subject recruitment period.  
In both studies, the telephone numbers were generated by sequential sets so as to refresh the 
base every 3 months. The obtained numbers had to be dialed up to six times at different 
schedules before being abandoned.  
Quotas of age and gender were used to make the age and gender distribution of the controls 
similar to the case distribution of all the cancers. The expected numbers were based on RNCE 
data from previous years. Overall, there was at least one control by case in all the age and 
gender strata, for each type of cancer. Controls younger than one year were overrepresented to 
increase power in that category. 
The quotas also ensured that the control group had the same distribution as the overall French 
population for the number of children aged <15 years living in the household, conditional on 
age, based on data from the National statistics office (INSEE).  
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Figure 3: Case recruitment by contact to parents in the hospital departments 
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Figure 4: Flowchart of the phone calls dialled for the recruitment of controls 
31 
 
 
2.2 Data collection and data management 
The same trained interviewers carried out the interviews with the mothers of case and control 
children using structured questionnaires with computer-assisted telephone interviewing. The 
questionnaire elicited information on demographic and socioeconomic characteristics, 
childhood environment and lifestyle, familial and personal medical history, and history of 
pregnancy.  
2.2.1 Perinatal characteristics 
2.2.1.1 Birth-weight and gestational age 
The mothers were asked about the child’s birth-weight and gestational age. For this question, 
the mothers were advised to consult the relevant pages of the child’s personal heath record, 
which were available for over 95% of cases and 98% of controls.  
Birth-weight was classified with cut-offs in grams (< 2,500, 2,500–2,999, 3,000–3,499, 
3,500–3,999, 4,000) comparable with those used by the French national perinatal surveys. 
Gestational age was classified as: pre-term (< 37 complete weeks of pregnancy), post-term 
(42 weeks or more) and two at-term categories (37–39 and 40–41 weeks). Using these data, 
we estimated fetal growth using the birth-weight Z-score based on gender-specific percentiles 
for birth-weight by gestational age in weeks from a large French cohort by the Association 
des Utilisateurs de Dossiers Informatisés en Pédiatrie, Obstétrique et Gynécologie 
(AUDIPOG)[98]. Using the standard definitions, fetal growth was classified as small (SGA, < 
10th percentile), appropriate (AGA, 10th through the 90th percentile), or large for gestational 
age (LGA, > 90th percentile) 
2.2.1.2 Congenital malformations 
 Mothers were asked if the child was diagnosed at birth with congenital malformations. If so, 
details of the type and site of malformations were collected. 
The congenital malformations were coded using the International Classification of Diseases, 
10th Revision (ICD-10) [99] by two independent researchers (Paula Rios and Helen Bailey). 
The coding process was reviewed by a third researcher (Jacqueline Clavel) when doubts or 
disagreement. All the coders were blind to case-control status. Then, the children with only 
minor or unspecified malformations were excluded in accordance with the European 
Surveillance of Congenital Anomalies (EUROCAT) recommendations [100]. 
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2.2.1.3 Maternal history and folic acid supplementation 
The mothers were asked if they took any vitamin, mineral or folic acid supplements three 
months before pregnancy or in the 1st, 2nd or 3rd trimester of pregnancy. If yes, they were 
asked to name the specific product.  
The use of vitamin, mineral or folic acid supplements was considered as a binary (ever/never), 
and by trimester from three months before pregnancy to birth, taking as reference category the 
absence of supplementation in any of those periods. We also used a more specific 
classification, defining “substantiated” folic acid supplementation as supplementation 
reported for the relevant period with a valid product name, and “unsubstantiated” 
supplementation as supplementation reported for the relevant time period but with no valid 
name given.  
The mothers were asked about their age at the index child’s birth, the parity of that pregnancy 
and if they had difficulty becoming pregnant. Difficulty becoming pregnant was defined as 
taking more than one year to conceive the index child and/or the need to consult a doctor 
and/or the need for the mother or father to undergo fertility treatment, which could influence 
intake of folic acid. In the latter case, the mother was asked to specify the type of treatment.  
2.2.1.4 Breastfeeding 
Mothers were asked if they breastfed the index child and if yes, for how long. Breastfeeding 
was defined as having breastfed for at least three days after birth. Ever breastfed children 
were categorized by breastfeeding duration (<3 months, 3-5 months and 6 months or more). 
In order to properly address breastfeeding in relation to the development of neuroblastoma, 
analyses were limited to children aged six months or older at diagnosis or at the reference date 
for controls (269 case and 1589 control children), so that the cases and controls would have 
had the opportunity of being breastfed for up to six months.  
2.2.2 Environmental exposures related to parental habits 
2.2.2.1 Pesticides 
The mother was asked if she used herbicides (‘‘weed killers’’), fungicides, or insecticides 
(and whether they were used indoors, for gardening or outdoors, or on pets). She was also 
asked if she was exposed to any type of pesticides in the workplace. The ESTELLE study 
included additional questions about maternal pesticide use in the three months prior to 
conception and after birth, and whether there had been any professional pest control 
treatments of the home.  
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Pesticide exposure was categorized into the following groups: None, any pesticide (declined 
in any insecticide, any herbicide or any fungicide) and categories based on whether the 
mothers reported that they had been used alone (only insecticides, only herbicides and only 
fungicides) or in combination with other pesticides (insecticides + other pesticides, only 
herbicides and fungicides). The reported use of insecticides was categorized based on the 
place of application declared by the mothers (indoor use, gardening and outdoor, for pets). 
The maternal professional exposure was considered as a dichotomous variable (yes/no) based 
on the maternal report of being exposed to pesticides at the workplace.  
2.2.2.2 Tobacco smoking and alcohol 
The mothers were asked whether they had smoked cigarettes during the pregnancy with the 
index child, and if yes, their average daily consumption. The ESTELLE study included 
additional questions about their smoking habits in the three months before the pregnancy and 
in each trimester of pregnancy, which was used for analyses by time window. 
Mothers were also asked if the father of the index child smoked during the year before to her 
pregnancy. To validate the maternal responses about paternal exposures, a small convenience 
subset of ESTELLE fathers also did a telephone interview about their exposures. The fathers 
of 134 childhood cancer cases and 174 controls were interviewed about their exposures, 
which included the same questions about their smoking habits as had been asked in the 
maternal interview. 
Maternal and paternal tobacco smoking were analyzed as dichotomous variables (ever/never) 
and as quantitative variables depending on the reported cigarettes per day (CPD). Maternal 
and paternal average daily consumptions were grouped in three categories based on the 
tertiles among smoking control parents. The cut-offs were: 0; 1-4; 5-9 and ≥10 CPD for 
mothers and 0; 1-9; 10-15 and > 15 CPD for fathers. The joint effect of maternal and paternal 
smoking was also analyzed (neither parent, only mother, only father, both). 
Mothers were asked about alcohol consumption (wine, beer/cider, and spirits) during 
pregnancy and to quantify their consumption if applicable. In the Estelle study, they were also 
asked specifically about consumption in the first trimester. Alcohol consumption was 
categorized three ways: a dichotomous variable (ever/never), a quantitative variable (cut-offs 
defined a priori as following: nil, <1, 1-2 or >2 glasses per week), and by type (wine, beer or 
cider, spirits). 
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2.3 Statistical methods 
2.3.1 Case-control analyses  
We first analyzed study-specific ORs and 95% confidence intervals (CIs) using unconditional 
logistic regression methods. The analyses on perinatal risk factors of neuroblastoma were 
performed using STATA software (STATA version 11, StatCorp LP, College Station TX), 
while the analysis on environmental exposures were performed using SAS software (SAS 
version 9; SAS Institute Inc., Cary, NC, USA).  
In addition to exploring differences by case–control status, we explored the differences of 
each of the key exposure variables by study among the controls to see if there had been 
changes in parental characteristics and behavior between the study time periods. In pooled 
analyses of the ESCALE and ESTELLE studies, between-study heterogeneity was 
systematically tested by fitting an interaction term between the study and the exposure of 
interest. 
All the models included the study matching factors child’s age and gender and, for the pooled 
analyses, the indicator of the study of origin. Because of the particular distribution of 
neuroblastoma cases, only cases and controls younger than six years old were included in the 
pooled analysis of the ESCALE and ESTELLE studies (91.3% of included cases). To avoid 
possible residual confounding by age, the first year of age was split into quarters (< 3 months, 
3–5 months, 6–8 months, 9–11 months), the second year into semesters (12–17 months, 18–
23 months), and the other ages were kept as single years (2, 3, 4 and 5 years). 
Sociodemographic variables paternal and maternal age at the child’s birth, maternal 
education, birth order and degree of urbanization of the place of residence were assumed a 
priori to be potential confounders because of their possible relationship with unmeasured 
confounders and their possible influence on parents’ participation in the studies. They were 
tested to determine whether they met the empirical definition of confounding (i.e. independent 
association with both the exposure of interest and with neuroblastoma). All the models 
included birth order, maternal age and urban status of the area of residence in addition to 
matching variables (child’s age and sex) and the study of origin (ESCALE or ESTELLE).  
For the analyses of maternal household use of pesticides during pregnancy, the type of 
housing was also retained as a potential confounder. The analyses on maternal and paternal 
smoking were mutually adjusted for these factors. 
Tests for linear trend were computed for quantitative variables (e.g. breastfeeding duration, 
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number of cigarettes per day, number of glasses of alcohol per week). First, the deviation 
from linearity was tested by a likelihood ratio test, comparing the model with the newly 
generated quantitative variable, where subjects in each class of the categorical variables were 
assigned the median value of that class, to the full model with the categorical variable. If 
linearity was not rejected, the p value of the trend was determined by testing the slope of the 
quantitative variable using a Wald-test.  
We performed additional analyses by age at diagnosis (<18 months/≥18 months) and by 
MYCN status (amplified/non-amplified). For the study of the maternal use of household 
pesticides during pregnancy, we also performed stratified analysis on urban/rural status of the 
area of residence, and maternal level of education (less than baccalaureate/baccalaureate or 
higher). 
2.3.2 Meta-analysis on maternal smoking and alcohol consumption during pregnancy 
A systematic review on maternal smoking and alcohol consumption during pregnancy was 
performed following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines[101] (see Supplementary material).  
The main author (Paula Rios) undertook the study selection, data abstraction and assessment 
of study quality of the systematic review process. In case of doubts about study inclusions or 
estimates extraction, these were discussed with co-authors (Jaqueline Clavel and Helen 
Bailey).  
The Medline and Embase databases were searched from inception to October 2018. 
Studies were included if they were published in English, French or Spanish. In addition, all 
references cited in original studies and reviews were manually searched. 
To be included in the meta-analysis, each study was required to:  
1. Be an original report.  
2. Be a cohort or case–control study that presented ORs and corresponding 95% CIs for 
the association between maternal smoking and alcohol consumption during pregnancy 
and risk of childhood neuroblastoma (or provide data that allowed these to be 
calculated).  
3. Include pediatric neuroblastoma cases (less than 19 years old) 
Exclusion criteria for studies were:  
1. Studies reporting “parental” consumption without specifying whether this was 
maternal or paternal exposure. 
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2. Studies exclusively reporting maternal smoking or alcohol consumption but not 
related to around the pregnancy time window.  
3. Studies reporting estimates on “All childhood cancers” but not specifying numbers or 
estimates for neuroblastoma.  
The extracted study characteristics for meta-analysis encompassed: publication year, study 
time frame, study design, study size, recruitment source, and source of exposure information, 
age at diagnosis, matching variables, effect measures and confounders.  
We used random effects, precision-based weighting to calculate the summary OR with our 
results. Statistical heterogeneity between studies was assessed using the Cochrane Q test. 
Publication bias was assessed via inspection of the funnel plot and formal testing for funnel 
plot asymmetry using Egger’s test. 
In the assessment of the quality of included studies, and as to evaluate comparability of cases 
and controls on the basis of design, age at diagnosis was set a priori as the most important 
matching or adjusting factor in the Newcastle-Ottawa Quality scale[102].  
In the assessment of the possibility of bias in study designs, conduct and analyses, we used 
the Joanna Briggs checklists for case-control studies[103].  
Sensitivity analysis were performed by stratifying our analysis by study type (studies based on 
record linkage/interview) and by excluding studies with lower quality scores (Newcastle-
Ottawa Quality scale <7). 
2.3.3 Statistical power 
Power calculations were done for the 351 cases included in the pooled analysis of the 
ESCALE and ESTELLE studies. The calculations assumed a 5% level of significance and the 
estimate for the prevalence for each exposure was based on that reported by the National 
Perinatal Survey (ENP) performed during the same time periods and EUROCAT for the 
prevalence of congenital malformations. Power calculations were not possible with regards to 
household use of pesticides as no information about the exposure on the general population 
was available for the relevant time period. Table 8 shows the relative risk that this study had 
the power to detect at the >80% level. 
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Table 8: Statistical power 
Prevalence of 
exposure 
Examples of activity, time period, person with 
this level of prevalence in the control series 
Odds ratio 
Minimum Maximum 
0.4 Folic acid supplementation during pregnancy 0.7  
0.2 Smoking, alcohol consumption during pregnancy 
Folic acid supplementation before pregnancy 
 
0.6 
1.5 
0.07 Preterm (< 37 weeks) 
LBW (< 2500 g) 
HBW (> 4000 g) 
1.8  
0.03 Congenital malformations 2.2  
LBW: low birth-weight; HBW: high birth-weight 
 
2.3.4 Sensitivity analysis 
Since controls were recruited from a sample of landline telephone numbers, sensitivity 
analyses were performed excluding case mothers with no landline at home (restricted to 
ESTELLE, the only study for which these data were collected). Landline subscribers might be 
different from mobile phone only owners in terms of age and other unknown characteristics.  
With regards to birth-related characteristics, analyses were performed after exclusion of 
multiple births (related to lower birth weight and length) and children born following in vitro 
fertilization (whose mother was more likely to have received folic acid supplementation). 
Finally, children with genetic syndromes (one case and 3 controls) were excluded in 
sensitivity analyses on congenital malformations. 
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3 Results 
3.1 Case-control comparability  
The study included 357 cases (174 in ESCALE, 183 in ESTELLE) and 1783 (949 in ESCALE 
and 834 in ESTELLE) controls aged less than six years. The MYCN oncogene was amplified in 
64 cases (17.9 %), not amplified in 270 cases (75.6%) and non-informative (NI) in 23 cases 
(6.4%). The amplification of MYCN was more frequent among older children (11% of the cases 
under 18 months of age versus 25% of the older cases). Overall case participation rates were 
81.2% for ESCALE and 92.2% for ESTELLE. 
The ESCALE and ESTELLE studies included cases of leukemia, lymphoma, brain tumors, 
neuroblastoma, Wilms’ tumor and hepatoblastoma. In both studies the cases and the controls 
were generally similar on sociodemographic characteristics (Table 9), although the cases tended 
to be younger, with younger mothers and in more urban areas than the controls. The control 
sampling was performed so that the control group would have the same age distribution as the 
complete group of childhood cancer cases in the ESCALE and ESTELLE studies, and not 
specifically neuroblastoma. However, there were at least two controls for each case in each age 
stratum. The participation rates were 71.2% for ESCALE and 85.5% for the ESTELLE study. 
 
3.2 Between-study heterogeneity 
The prevalence of some of the exposures of interest differed between the studies. Control mothers 
in the ESTELLE study lived more often in less populated areas and were more highly educated 
than those in the ESCALE study. They were also more likely to have used pesticides at home 
(39.6% for ESTELLE and 32.2% for ESCALE; p value for heterogeneity < 0.01). 
Fewer control mothers reported drinking alcohol (24.5 vs. 36.6%, p value <0.001) during the 
index pregnancy in the ESTELLE study than in the ESCALE study, while there were no 
differences in the reported prevalence of maternal smoking (19.3% in ESCALE and 20.4% in 
ESTELLE).  
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Table 9: Characteristics of the cases and controls of the ESCALE and ESTELLE studies 
  ESCALE (2003-2004)   ESTELLE (2010-2011)   POOLED 
  Cases   Controls   Cases   Controls   Cases   Controls 
(n=174)  (n=949)  (n=183)  (n=834)  (n=357)  (n=1783) 
  N %   N %   N %   N %   N %   N % 
MYCN status                      
Non-amplified 131 75.3     139 76.0     270 75.6    
Amplified 34 19.5     30 16.4     64 17.9    
Missing 9 5.2     14 7.6     23 6.4    
Age (years)                  
< 1 74 42.5  187 19.7  70 38.2  188 22.5  144 40.3  375 21 
1 36 20.7  182 19.2  37 20.2  123 14.7  73 20.4  305 17 
2 30 17.2  153 16.1  35 19.1  148 17.7  65 18.2  301 16.9 
3 13 7.5  166 17.5  21 11.5  139 16.7  34 9.5  305 17.1 
4 11 6.3  145 15.3  12 6.6  131 15.7  23 6.4  276 15.5 
5 10 5.7  116 12.2  8 4.4  105 12.6  18 5  221 12.4 
<18 months 93 53.4  283 29.8  95 51.9  261 31.3  188 52.7  544 30.5 
≥18 months 81 46.5  666 70.2  88 48.1  573 68.7  169 47.3  1239 69.5 
Birth order                  
First born 86 49.4  520 54.7  100 54.6  446 53.5  186 52.1  966 54.2 
Second or more 88 50.6  429 45.2  83 45.3  388 46.5  171 47.9  817 45.8 
Maternal age at child’s birth (years)              
< 25 31 17.8  80 8.4  25 13.7  86 10.3  56 15.7  166 9.3 
25-29 61 35.1  314 33.1  70 38.2  250 30  131 36.7  564 31.6 
30-34 54 31.0  360 37.9  50 27.3  293 35.1  104 29.1  653 36.6 
≥ 35 28 16.1  195 20.5  38 20.8  205 24.6  66 18.5  400 22.4 
Maternal 
education 
 
                
< Baccalaureate 55 31.6  319 33.6  50 27.3  203 24.3  105 29.4  522 29.3 
   Baccalaureate  32 18.4  195 20.5  44 24  192 23  76 21.3  387 21.7 
> Baccalaureate  87 50.0  435 45.8  88 48.1  439 52.6  175 49.0  874 49.0 
Missing 0 0  0 0  1 0.5  0 0  1 0.3  0 0 
Size of urban unit of residence (inhabitants)          
< 5000 57 32.8  360 37.9  59 32.2  351 42.1  116 32.5  711 39.9 
5000-99,999 36 20.1  211 22.2  43 23.5  174 20.9  79 22.1  385 21.6 
100,000-1,999,999 41 23.6  233 24.5  50 27.3  158 18.9  91 25.5  391 21.9 
Paris unit 37 21.3  145 15.3  30 16.4  149 17.9  67 18.8  294 16.5 
Missing 3 1.7       1 0.5   2 0.2   4 1.1   2 0.1 
 
3.3 Perinatal characteristics 
3.3.1 Gestational age, birth-weight and congenital malformations 
There was no significant association between gestational age or birth-weight and neuroblastoma. 
SGA and LGA were both associated with neuroblastoma (ORs 1.4 95% [CI 1.0–2.0] and 1.5 95% 
CI [1.1–2.2], respectively) (Table 10). The associations were specially marked for children 
younger than 18 months (ORs 1.7 [95% CI 1.0–3.1] and 2.0 [95% CI 1.2–3.3], respectively).  
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Overall, congenital malformations were reported slightly more often for cases (4%) than for 
controls (3%), and the association tended to be more marked, although based on small numbers, 
when the child had two or more malformations (OR 6.3 [95% CI 1.3–29]). The most frequently 
reported sites of malformations were the skeletal and genitourinary systems. Lastly, the 
association between malformations and neuroblastoma was only observed in children aged <18 
months (OR 3.6 [95% CI 1.3–8.9]). Results were similar when the analysis by subgroups defined 
by case MYCN amplification status was performed.  
3.3.2 Maternal intake of folic acid, vitamins or minerals during the periconceptional 
period  
There was an inverse association with maternal use of any supplement containing folic acid, 
vitamins or minerals in the three months before conception (OR 0.5 [95% CI 0.3–0.9]) (Table 
11). There was little change when the analysis was restricted to substantiated supplements 
containing folic acid (OR 0.4 95% CI 0.2–1.1). There was no association with the use of 
supplements during the other trimesters of pregnancy. There was no association between 
neuroblastoma and difficulty becoming pregnant or the use of fertility treatments for the index 
pregnancy, although based on small numbers (Table 12).  
3.3.3 Breastfeeding 
The breastfeeding analysis was restricted to the 1,589 controls and 269 cases who were aged 6 
months or older (Table 13). The cases were breastfed less often than the controls (OR 0.7 [95% 
CI 0.5–1.0]) but there was no evidence of a decrease in risk with increasing breastfeeding 
duration. The inverse trend was significant when the association was restricted to the cases with 
MYCN amplification (p values for trend< 0.01) 
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Table 10: Birth related characteristics, congenital malformations and risk of neuroblastoma. Pooled analysis of the ESCALE and ESTELLE 
studies. 
 All neuroblastomas  Age <18 months  Age ≥18 months 
 Controls Cases OR 95%CI  Controls Cases OR 95%CI  Controls Cases OR 95%CI 
 
n % n %    n % n %    n % n %   
Gestational age (weeks)                   
<37  126 7.1 32 9.0 1.2 [0.8-1.9]  39 7.2 17 9.0 1.0 [0.5-1.9]   87 7.0 15 8.9 1.4 [0.7-2.5] 
37-39 652 36.6 136 38.1 1.0 Ref  217 39.9 79 42.0 1.0 Ref  435 35.1 57 33.7 1.0 Ref 
40-41 942 52.8 176 49.3 0.9 [0.7-1.2]  270 49.6 89 47.3 0.8 [0.6-1.2]  672 54.2 87 51.5 1.1 [0.7-1.5] 
≥ 42  35 2.0 3 1.0 *   12 2.2 1 0.5 *   23 1.8 2 1.2 *  
Missing 28 1.6 10 2.8 - -  6 1.1 2 1.1 - -  22 1.7 8 4.7 - - 
Birth-weight (grams)                     
<2500 105 5.6 25 7.0 1.2 [0.9-1.7]  31 5.7 11 5.8 1.3 [0.6-2.9]  74 5.9 14 8.2 1.4 [0.7-2.6] 
2500-2999  342 19.2 73 20.4 1.3 [0.8-2.2]  102 18.7 45 23.9 1.6 [1.0-2.6]  240 19.4 28 16.6 0.9 [0.6-1.5] 
3000-3499 683 38.3 123 34.4 1.0 Ref  210 38.6 59 31.4 1.0 Ref  473 38.2 64 37.9 1.0 Ref 
3500-3999 494 27.7 95 26.6 1.1 [0.8-1.5]  143 26.3 46 24.4 1.3 [0.8-2.1]  351 28.3 49 29.0 1.0 [0.6-1.5] 
≥ 4000 159 8.9 40 11.2 1.4 [0.9-2.2]  58 10.6 26 13.8 1.8 [1.0-3.2]  101 8.1 14 8.3 1.1 [0.6-2.1] 
Missing   1 0.3 -     1 0.5          
Fetal growth                     
SGA 200 11.2 46 12.9 1.4 [1.0-2.0]  47 8.6 25 13.3 1.7 [1.0-3.1]  153 12.3 21 12.4 1.2 [0.7-2.0] 
AGA 1366 76.6 249 69.7 1.0 Ref  430 79.0 128 68.1 1.0 Ref  936 75.5 121 71.6 1.0 Ref 
LGA 189 10.6 51 14.3 1.5 [1.1-2.2]  61 11.2 32 17.0 2.0 [1.2-3.3]  128 10.3 19 11.3 1.1 [0.7-2.0] 
Missing 28 1.6 11 3.1 - -  6 1.1 3 1.6 - -  22 1.8 8 4.7 - - 
Malformations                     
No 1736 97.5 344 96.3 1.0 Ref  535 98.3 179 95.2 1.0 Ref  1201 96.9 165 97.6 1.0 Ref 
Any  47 2.5 13 3.6 1.6 [0.8-3.0]  9 1.6 9 4.8 3.6 [1.3-8.9]  38 3.1 4 2.4 0.8 [0.3-2.3] 
1 43 2.4 10 2.8 1.3 [0.6-2.6]  9 1.6 8 4.2 2.9 [1.1-7.9]  34 3.1 2 1.0 *  
≥ 2 4 0.2 3 0.8 * 
 
   1 0.5 *   4 0.3 2 1.0 *  
Cardiovascular  13 0.7 1 0.3 *                
Digestive 1 0.1 1 0.3 *                
Genitourinary 15 0.8 6 1.7 2.2 [0.8-6.0]               
Skeleton 14 0.8 3 0.9 *                
CNS 0 - 1 0.3 *                
Head and neck 4 0.2 1 0.3 *                
Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by logistic regression models adjusted for age and sex, birth-order, maternal age, urban status of the area of residence and study, after prior testing of 
heterogeneity between the ESCALE and ESTELLE studies. 
* Too few cases to fit model 
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Table 11: Maternal supplementation of folic acid, vitamins or minerals around the index pregnancy and risk of neuroblastoma (ESTELLE study 
only) 
 
Preconception period 
 
First trimester 
 
Second trimester 
 
Third trimester 
 
At any time 
 
Co Ca OR 95% CI 
 
Co Ca OR 95% CI 
 
Co Ca OR 95% CI 
 
Co Ca OR 95% CI 
 
Co Ca OR 95% CI 
Never 496 107 1.0 Ref 
 
496 107 1.0 Ref 
 
496 107 1.0 Ref 
 
496 107 1.0 Ref 
 
496 107 1.0 Ref 
Vitamin supplementation 107 16 0.5 [0.3-0.9] 
 
206 53 0.9 [0.6-1.4] 
 
201 43 0.8 [0.5-1.2] 
 
176 40 0.8 [0.6-1.3] 
 
338 76 0.8 [0.6-1.2] 
   Folic acid substantiated1 45 7 0.4 [0.2-1.1] 
 
86 24 0.9 [0.5-1.5] 
 
71 19 0.9 [0.5-1.6] 
 
63 18 0.9 [0.5-1.7] 
 
118 30 0.8 [0.5-1.4] 
   Folic acid unsubstantiated2 48 8 0.6 [0.3-1.4] 
 
95 25 1.0 [0.6-1.7] 
 
79 18 0.9 [0.5-1.7] 
 
78 17 0.9 [0.5-1.7] 
 
150 35 0.9 [0.6-1.5] 
   Without folic acid  14 1 
 
  25 4 
 
  51 6 
 
  38 5 
 
  70 11 
 
 
Only in another period 231 60       132 23       137 33       162 36               
Ca: cases; Co: controls; Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by logistic regression models adjusted for age and sex, birth-order, maternal age, urban status of the 
area of residence and study 
1
 supplementation reported for the relevant period with a valid product name 
2 supplementation reported for the relevant time period but with no valid name given 
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Table 12: Maternal reproductive history and risk of neuroblastoma. Pooled analysis of the ESCALE and ESTELLE studies. 
  All neuroblastomas   Age <18 months   Age ≥18 months 
 
Controls Cases OR1 95%CI  Controls Cases OR1 95%CI  Controls Cases OR1 95%CI 
 n=1783 n=357    n=544 n=188    n=1239 n=169   
  n % n %       n % n %       n % n %     
Difficulty to get pregnant                     
    No 1498 84.0 299 83.7 1.0 Ref  446 82.0 158 84.0 1.0 Ref  1052 84.9 141 83.4 1.0 Ref 
    Yes 285 16.0 58 16.3 1.0 [0.6-1.3]  98 18.0 30 16.0 0.8 [0.5-1.3]  187 15.1 28 16.6 1.1 [0.7-1.7] 
Use of fertility treatment for the index child                 
    No 1669 93.6 335 93.8 1.0 Ref  512 94.1 175 93.1 1.0 Ref  1157 93.4 160 94.7 1.0 Ref 
    Yes 114 6.4 22 6.2 1.0 [0.6-1.6]  32 5.9 13 6.9 1.2 [0.6-2.4]  82 6.6 9 5.3 0.8 [0.4-1.3] 
Type of fertility treatment                     
    No 1669 93.6 335 93.8 1.0 Ref  512 94.1 175 93.1 1.0 Ref  1157 93.4 160 94.7 1.0 Ref 
    Stimulation only 47 2.6 12 3.4 1.2 [0.6-2.3]  13 2.4 8 4.2 1.7 [0.7-4.4]  34 2.7 4 2.4 0.8  
    In vitro fertilization 33 1.8 4 1.1 *   11 2.0 2 1.1 *   22 1.8 2 1.2 *  
    Artificial insemination 15 0.8 1 0.3 *   2 0.4 1 0.5 *   13 1 - - - - 
    Another technique 16 0.9 5 1.4 1.2 [0.4-3.7]  5 0.9 2 1.1 1.2 [0.3-6.9]  11 0.9 3 1.8 *  
    Missing 3 0.2           1 0.2           2 0.2         
1Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by logistic regression models adjusted for age and sex, birth-order, maternal age, urban status of the area of residence and 
study, after prior testing of heterogeneity between the ESCALE and ESTELLE studies. * Too few cases to fit model
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Table 13: Breastfeeding and risk of neuroblastoma. Pooled analysis of the ESCALE and ESTELLE studies (children older than 6 months) 
  All neuroblastomas  MYCN -  MYCN +  < 18 months  ≥ 18 months 
 
Co1 Ca1 OR2 95% CI 
 
Ca OR3 95% CI 
 
Ca OR3 95% CI 
 
Co Ca OR2 95% CI 
 
Co Ca OR2 95% CI 
Breastfeeding                       
Never 642 118 1.0 Ref  78 1.0 Ref  31 1.0 Ref  118 40 1.0 Ref  524 78 1.0 Ref 
Ever 947 151 0.7 [0.5-1.0]  109 0.8 [0.6-1.1]  30 0.6 [0.3-1.0]  232 60 0.6 [0.4-1.0]  715 91 0.8 [0.6-1.1] 
Breastfeeding duration                        
Never breastfed 642 118 1.0 Ref  78 1.0 Ref  31 1.0 Ref  118 40 1.0 Ref  524 78 1.0 Ref 
< 3 months 348 64 0.8 [0.6-1.1]  40 0.7 [0.5-1.1]  17 0.9 [0.5-1.6]  88 23 0.5 [0.3-1.0]  260 41 1.0 [0.6-1.5] 
3-5 months 293 42 0.6 [0.4-1.0]  31 0.7 [0.4-1.1]  8 0.5 [0.2-1.2]  82 21 0.5 [0.3-1.1]  211 21 0.7 [0.4-1.1] 
≥ 6 months 287 42 0.7 [0.5-1.1]  35 0.9 [0.6-1.4]  5 0.3 [0.1-0.9]  51 13 0.7 [0.3-1.5]  236 29 0.7 [0.4-1.2] 
Missing 19 3    3        11 3    8  
 
 
  
  p-trend=0.06       p-trend <0.01        p-trend=0.1 
Ca: cases; Co: controls;  
1N=269 case and 1589 control children aged less than six years. 
2Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by logistic regression models adjusted for age and sex, birth-order, maternal age, urban status of the area of residence and 
study, after prior testing of heterogeneity between the ESCALE and ESTELLE studies. 
3Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by polytomous logistic regression models adjusted for age, sex and birth-order, maternal age, urban status of the area of 
residence and study  
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3.4 Environmental exposures related to parental habits  
3.4.1 Exposure to pesticides  
3.4.1.1 Household use of pesticides  
Overall, maternal use pesticide during pregnancy was reported for 43.7% of the cases and 
35.7% of the controls (Table 14). Insecticides were the most commonly used (40.6% of cases 
and 33.9% of the controls) and they were mostly used alone. Their use was mainly reported 
indoors (80.0% of insecticides use in cases and 81.0% in controls). Mothers rarely used 
herbicides or fungicides and they most often also used insecticides.  
The maternal use of any type of pesticide during pregnancy was associated with the risk of 
neuroblastoma (OR 1.5 [95% CI 1.2–1.9]). There was a positive association with the use of 
insecticides alone (OR 1.4 [95% CI 1.1–1.9]) or insecticides with other pesticides (OR 2.0 
[95% CI 1.1–3.4]). There was no between-study heterogeneity except for herbicide use 
(pooled OR 2.0 [95% CI 1.1–3.7]); ESCALE (OR 3.8 [95% CI 1.8–8.0]); ESTELLE (OR 1.1 
[95% CI 0.4–3.2]); p value for interaction = 0.07). 
Although based on less than 10 exposed cases, the maternal use of any fungicide during 
pregnancy was associated with increased risk of neuroblastoma among cases with MYCN 
amplification (OR 4.3 [95% CI 1.6-11.5] (Table 14).  
The use of any herbicide or fungicide was associated with neuroblastoma in children older 
than 18 months, but the associations cannot be dissociated from that with insecticide and 
either herbicide or fungicide use. 
Among the controls, the prevalence of pesticide use varied by urban/rural status, but not by 
maternal level of education, and the results did not change when stratification for either of 
these factors was used instead of adjustment. 
Maternal use of pesticides before and after pregnancy and the use of professional pest control 
treatments at home were not collected in the ESCALE study. In the ESTELLE study, more 
than a quarter of the mothers reported pesticide use during all three time periods (29.0% of the 
cases and 27.6% of the controls) and very few mothers reported the use during pregnancy 
only (6.0% of cases and 3.5% of controls). This precluded specific analyses by time window. 
3.4.1.2 Maternal occupational exposure and pest control treatments at home 
Maternal occupational pesticide exposure during pregnancy was associated with the risk of 
neuroblastoma (OR 2.0 [95% CI 1.0–4.0), although the frequency of exposure was low (3.6% 
of cases and 1.8% of controls).  
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No association was found with professional pest control treatments at home during pregnancy 
(OR 1.2 [95% CI 0.5–2.8]) 
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Table 14: Maternal use of household pesticides during pregnancy and risk of neuroblastoma. Pooled analysis of the ESCALE and ESTELLE 
studies. 
 Controls All neuroblastoma MYCN – MYCN + 
 n % n % OR1 95% CI n % OR2 95% CI n % OR2 95% CI 
Maternal use of pesticides               
None 1112 62.4 198 55.5 1.0 Ref 155 57.4 1.0 Ref 32 50.0 1.0 Ref 
Any pesticide 636 35.7 156 43.7 1.5 [1.2-1.9] 113 41.8 1.4 [1.1-1.9] 31 48.4 1.7 [1.0-2.9] 
               
Any insecticide 604 33.9 145 40.6 1.5 [1.1-1.9] 105 38.9 1.4 [1.1-1.9] 28 43.7 1.6 [0.9-2.7] 
Any herbicide 61 3.4 20 5.6 2.0 [1.1-3.7] 14 5.2 1.9 [0.9-3.6] 3 4.7 *  
Any fungicide 50 2.8 14 3.9 1.6 [0.8-3.1] 7 2.6 1.1 [0.5-2.6] 6 9.4 4.3 [1.6-11.5] 
             
 
 
Only insecticides  537 30.1 125 35 1.4 [1.1-1.9] 93 34.4 1.4 [1.0-1.9] 23 35.9 1.5 [0.8-2.6] 
Only herbicides  13 0.7 5 1.4 1.5 [0.4-4.8] 5  1.8 1.9 [0.6-6.2] 0 0 *  
Only fungicides  19 1.1 6 1.7 1.7 [0.7-4.6] 3 1.1 *  3 4.7 *  
Insecticides + other pesticides 67 3.8 20 5.6 2.0 [1.1-3.4] 12 4.4 1.6 [0.8-3.1] 5 7.8 2.4 [0.9-6.8] 
Only herbicides and fungicides 0  0          
 
 
             
 
 
             
 
 
Use of insecticides               
Indoor use 489 27.4 116 32.5 1.5 [1.1-2.0] 81 30.0 1.4 [1.0-1.9] 25 39.1 1.8 [1.0-3.1] 
Gardening and outdoor use 57 3.2 13 3.6 1.3 [0.7-2.5] 7 2.6 0.9 [0.4-2.1] 3 4.7 *  
For pets  224 12.6 49 13.7 1.3 [0.9-1.9] 37 13.7 1.3 [0.9-2.0] 10 15.6 1.2 [0.5-2.8] 
     
 
       
 
 
Missing 35 1.9 3 0.8   2 0.7   1 1.6   
               
1Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by logistic regression models adjusted for age and sex, birth-order, maternal age, urban status of the area of residence and 
study, after prior testing of heterogeneity between the ESCALE and ESTELLE studies. 
 
2Odds ratios (OR) and 95% confidence intervals (95%CI) estimated by polytomous logistic regression models adjusted for age, sex and birth-order, maternal age, urban status of the area of 
residence and study after prior testing of heterogeneity between the ESCALE and ESTELLE studies. 
* Too few cases to fit model 
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Table 15: Maternal use of household pesticides and risk of neuroblastoma by age at diagnosis. Pooled analysis of the ESCALE and ESTELLE 
studies. 
 
Age < 18 months Age  ≥ 18 months 
 
Cases  Controls OR1 95% CI  Cases Controls OR1 95% CI  
 
n=188 % n=544 %   n=169 % n=1239 %   
Maternal use of pesticides             
None 114 60.6 369 67.8 1.0 Reference 84 49.7 743 59.9 1.0 Reference 
Any pesticide 73 38.8 166 30.5 1.5 [1.0-2.1] 83 49.1 470 37.9 1.6 [1.1-2.2] 
             
Any insecticide 65 34.6 155 28.5 1.4 [0.9-2.0] 80 47.3 449 36.2 1.6 [1.1-2.3] 
Any herbicide 7 3.7 22 4.0 1.1 [0.4-3.1] 13 7.7 39 3.1 3.4 [1.6-7.1] 
Any fungicide 5 2.7 15 2.8 1.0 [0.3-3.3] 9 5.3 35 2.8 2.3 [1.0-5.1] 
         
Only insecticides 62 32.9 134 24.6 1.5 [1.0-2.2] 63 37.3 403 32.5 1.4 [1.0-2.0] 
Only herbicides2 4 2.1 7 1.3   1 0.6 6 0.5 *  
Only fungicides2 4 2.1 4 0.7   2 1.2 15 1.2 *  
Insecticides + other pesticides 3 1.6 21 3.9 *  17 10.0 46 3.7 3.4 [1.8-6.5] 
Only herbicides and fungicides 0  0    0  0    
         
Use of insecticide          
Indoor use 50 26.6 121 22.2 1.5 [1.0-2.2] 66 39.0 368 29.7 1.6 [1.1-2.3] 
Gardening and outdoor use 8 4.3 23 4.2 1.5 [0.6-3.6] 5 2.9 34 2.7 1.2 [0.4-3.2] 
For pets 23  12.2 58 10.7 1.3 [0.7-2.3] 26 15.4 166 13.4 1.3 [0.8-2.2] 
         
Missing 1 0.5 9 1.6 
 
 2 1.2 26 2.1 
 
 
1Odds ratios (OR) and 95% confident intervals (CI) estimated by unconditional logistic regression models adjusted for children age and sex, study, maternal age, birth order, size of the urban 
unit of residence and  type of housing during pregnancy, after prior testing of heterogeneity between the ESCALE and ESTELLE studies. *Too few cases to fit model 
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3.4.2 Parental smoking and maternal alcohol consumption during pregnancy 
3.4.2.1 Parental smoking during pregnancy 
Maternal smoking during pregnancy was slightly more often reported for the cases (24.1%) 
than for the controls (19.7%), with an OR of 1.3 [95% CI 0.9 -1.7] (Table 16). There was no 
trend with the average number of cigarettes smoked per day (OR for 5 CPD increase was 1.1 
[95% CI 1.0–1.3]). The prevalence of smoking among mothers was similar between the 
ESCALE and ESTELLE studies. In the ESTELLE study, most of the mothers that reported 
having smoked during pregnancy started before conception and smoked during the whole 
pregnancy. Maternal smoking before and during pregnancy were highly correlated which 
precluded specific analysis by time window (Spearman’s rho =0.69).  
Paternal tobacco consumption during pregnancy was not associated with the risk of 
neuroblastoma as an independent exposure (OR 1.1 [95% CI 0.9-1.4], but having both parents 
reported as having smoked during pregnancy was associated with neuroblastoma (OR 1.5 
[95% CI 1.1-2.1]) (Table 16). The maternal average daily consumption of cigarettes did not 
differ significantly according to whether only the mother or both parents were reported 
smokers (mean 5.7 CPD versus 6.1 CPD, respectively). However, the percentage of mothers 
who smoked was higher when the fathers also smoked (34.4% versus 10%, results not 
tabulated). The associations seemed to be only present among children younger than 18 
months (OR 1.4 [95% CI 0.9–2.2]) vs. (OR 1.1 [95% CI 0.7–1.7]) among older children, but 
interaction with age was not significant (p-value for interaction 0.4) (Table 16). Although 
based on small numbers, the analyses did not reveal differences by MYCN status (results not 
tabulated). 
3.4.2.2 Maternal alcohol consumption during pregnancy  
Maternal alcohol consumption during pregnancy was not associated with the risk of 
neuroblastoma (OR 1.0 [95 % CI 0.8–1.4] (Table 17). There was no interaction between 
maternal smoking and alcohol consumption (p-value=0.4). The results were similar with 
regards to different types of beverages and there was no increasing risk with increasing 
alcohol consumption or differences by age at diagnosis or MYCN status (results not 
tabulated).  
.
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Table 16: Association between neuroblastoma and parental smoking for the whole sample and according to age group. Pooled analysis of the 
ESCALE and ESTELLE studies. 
  Total   < 18 months   ≥ 18 months 
 
Co (%) Ca (%) OR1 [95% CI]  Co(%) Ca (%) OR1 [95% CI]  Co (%) Ca (%) OR1 [95% CI] 
Maternal smoking during pregnancy 2            
None 80.3 75.9 1.0 Ref  75 82.2 1.0 Ref  76.9 79.4 1.0 Ref 
Any 19.7 24.1 1.3 [0.9-1.7]  25 17.8 1.4 [0.9-2.2]  23.1 20.5 1.1 [0.7-1.7] 
< 5 cigarettes/day 7.2 9 1.2 [0.7-1.8]  10.1 7.5 1.3 [0.7-2.4]  7.7 7 1.1 [0.6-2.1] 
5-9 cigarettes/day 6 7.3 1.3 [0.8-2.2]  7.4 4.6 1.8 [0.9-3.8]  7.1 6.6 1.1 [0.6-2.0] 
≥10 cigarettes/day 4.8 5.3 1.3 [0.7-2.2]  5.3 4 1.4 [0.6-3.1]  5.3 5.2 1.1 [0.5-2.3] 
Per 5 cigarettes/day    1.10 [1.0-1.3]    1.03 [0.98-1.09]    1.01 [0.96-1.07] 
Paternal smoking in the year before birth 2            
None 57.9 53.5 1.0 Ref  52.7 62.3 1.0 Ref  54.4 55.9 1.0 Ref 
Any 40.8 44.5 1.1 [0.9-1.4]  45.7 37.1 1.2 [0.8-1.8]  43.2 42.4 1.0 [0.7-1.4] 
< 10 cigarettes/day 9 12.3 1.3 [0.9-2.0]  13.3 10.5 1.4 [0.8-2.4]  11.2 8.1 1.4 [0.8-2.4] 
10-15 cigarettes/day 16.1 14.8 0.9 [0.6-1.3]  16 15.6 1.2 [0.7-1.9]  13.6 16.4 0.8 [0.5-1.3] 
> 15 cigarettes/day 16.3 18.5 1.3 [0.9-1.8]  17.5 11.2 1.8 [1.0-2.9]  19.5 18.5 1.1 [0.7-1.7] 
Per 10 cigarettes/day   1.00 [0.99-1.02]    1.01 [0.98-1.03]    0.99 [0.97-1.01] 
Maternal smoking during pregnancy and paternal smoking in the year before birth2      
Neither parent 52.6 48.7 1.0 Ref  47.9 56.4 1.0 Ref  49.7 50 1.0 Ref 
Only mother 6 4.8 0.9 [0.5-1.6]  4.8 5.9 1.0 [0.5-2.3]  4.7 6 0.8 [0.4-1.7] 
Only father 27.8 25.8 1.0 [0.8-1.4]  26.1 25.4 1.2 [0.8-1.8]  25.4 28.3 0.9 [0.6-1.3] 
Both parents 13.5 18.8 1.5 [1.1-2.1]   19.7 11.8 1.9 [1.2-3.1]   17.7 14 1.2 [0.8-1.9] 
 
1 Odd ratio (OR) and 95 confident intervals (95% CI) estimated by unconditional logistic regression adjusted for age, sex and birth-order, maternal age, urban status of the area of residence and 
study of origin, after prior testing of heterogeneity between the ESCALE and ESTELLE studies. 
2 ORs on maternal and paternal smoking were mutually adjusted 
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Table 17: Association between neuroblastoma and alcohol consumption during pregnancy. 
Pooled analysis of the ESCALE and ESTELLE studies. 
  
Controls Cases OR [95% CI] 
  
N % N %     
Maternal alcohol drinking during pregnancy    
Never 1293 72.5 268 75.1 1.0 Ref 
Ever 490 27.2 88 24.6 1.0 [0.8-1.4] 
Missing 0  1 0.3   
Glasses per week       
None 1293 72.5 268 75.1 1.0 Ref 
<1 225 12.6 50 14 1.1 [0.8-1.6] 
1-2 110 6.2 12 3.4 0.6 [0.3-1.2] 
>2 143 8.0 22 6.2 1.0 [0.6-1.6] 
Missing 12 0.7 4 1.1   
Types of alcohol       
None 1293 72.5 268 75.1 1.0 Ref 
Wine 330 18.5 54 15.1 0.9 [0.6-1.3] 
Beer or cider 167 9.4 34 9.5 1.2 [0.8-1.9] 
Spirits 189 10.6 31 8.7 0.8 [0.5-1.2] 
1Odd ratio (OR) and 95 confident intervals (95% CI) estimated by unconditional logistic regression adjusted for age, sex and 
birth order, maternal age, urban status of the area of residence and study
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3.4.2.3 Meta-analyses on maternal smoking and alcohol consumption 
The results of the search strategy are summarized in Figure 5. Of the 973 articles identified by 
the algorithm-based search, 929 were deemed irrelevant using their title or abstract. The full 
texts of the potentially eligible 41 remaining publications were obtained and assessed using 
the eligibility criteria, leading to the exclusion of 28 studies for various reasons (see 
Supplementary material). 
We identified thirteen studies (5 record linkage and 8 case-control studies) that provided data 
on maternal smoking during pregnancy and seven of them also presented data on maternal 
alcohol consumption.  Their details and main findings are summarized in Table 18.  
Ratings according to the Newcastle-Ottawa Quality scale spanned between 6 and 9. All the 
included studies ensured comparability of cases and controls on the basis of study design. 
Despite the variability of exposure ascertainment among included studies, the same data 
collection method was used for cases and controls within individual studies; no study, 
however, had validated alcohol consumption records or used structured interviews blinded as 
to case/control status. With regards to risk of bias assessment, five studies presented 
insufficient data regarding the comparability of cases and controls. Funnel plots did not 
provide any evidence of publication bias and Egger test was not significant (p-value= 0.2). 
The summary OR for maternal smoking during pregnancy was 1.1 [95% CI 1.0-1.3] (Figure 
6). Between-study heterogeneity was low (I2= 17.3 %). The funnel plot did not provide any 
evidence of publication bias and Egger test was not significant (p-value= 0.2).  
The analyses did not suggest any association between maternal alcohol consumption during 
pregnancy and neuroblastoma, with a summary OR of 1.0 [95% CI 0.9–1.2] (Figure 7). 
Funnel plot were performed but there were insufficient studies.   
Slightly lower estimates were observed on meta-analysis of maternal smoking and 
neuroblastoma when only record linkage studies were included, compared with interview 
based studies. However, results may be interpreted with caution because based on only five 
studies (See supplementary material). Results did not change when studies with less than 7 in 
the Newcastle-Ottawa Quality scale were excluded.  
3.4.3 Sensitivity analysis 
All the results remained unchanged after exclusion of the ESTELLE cases with no telephone 
landline. No changes were observed after exclusion of multiple births, children born 
following in vitro fertilization and children with genetic syndromes.
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Figure 5: Search strategy on meta-analyses of maternal smoking, alcohol consumption and 
risk of neuroblastoma 
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Table 18: Included studies on the meta-analysis about maternal smoking, alcohol consumption and neuroblastoma. 
Study Cases and controls selection Maternal consumption during pregnancy (ever/never)    
Author, country,  
year of case accrual 
Cases Controls Smoking Alcohol drinking Matched factors/Adjustments 
Source n Source n Crude OR 
 [95% CI]a 
Adjusted OR 
[95% CI] 
Crude OR  
[95% CI]a 
Adjusted OR 
[95% CI] 
  
Data obtained by record linkage         
Johnson et al, 2008  
US (1976-2004)[46]  
Cancer Registry 
Minnesota state 
155 Birth Registry 8752 1.4 [0.9-2.2] 1.4 [0.9-2.3] 1.1 [0.4-3.5] - year of birth, sex 
Chow et al, 2003 
US (1980-1992)[48] 
Cancer Registry 
Washington state 
240 Birth Registry 2400 0.8 [0.6-1.2] 0.8 [0.6-1.2] - - year of birth, sex/ gestational 
age, birth-weight, parental age, 
ethnicity, maternal residence 
McLaughlin et al, 2009 
US (1985-2001)[49] 
Cancer Registry 
New York state 
529 Birth Records 12010 - 1.0 [0.7-1.3] - 1.2 [0.5-2.6] date of birth, sex 
        
Stavrou et al, 2009 
Australia,  (1994-
2005)[104]  
Cancer Registry 
New South Wales 
122 Midwives data 
collection 
1045966 0.8 [0.5-1.3] 1.0 [0.6-1.7]  
- 
 
- 
children age and sex, maternal 
age, birth-weight, gestational 
age, socioeconomics, maternal 
hypertension, gestational 
diabetes, preeclampsia 
Heck et al, 2016 
USA (2007-2013)[105] 
Cancer Registry 238 Birth certificates 40356 1.1 [0.5-2.4] 1.2 [0.5-2.5] - - year of birth/ maternal ethnicity, 
maternal education 
 California state           
Data obtained by Interview 
Kramer et al, 1987  
US (1970-1979)[92] 
Cancer Registry 
Great Delaware 
valley 
93 General 
population  
93 1.3 [0.8-2.1]   1.4 [0.9-2.2]   date of birth, race, area code,  
Buck et al, 2001  
US (1976-1987)[45]  
Cancer Registry 
New York state 
155 Birth Registry 310 1.3 [0.8-2.1] 1.4 [0.9-2.1] 1.2 [0.8-1.9] 1.2 [0.8-1.9] year of birth, parity, maternal 
age, smoking and alcohol 
consumption 
Sorahan et al, 1994 
UK (1977-1981)[106] 
Cancer Registry 93 Birth Registry 93 - 1.0 [0.8-1.3] - - date of birth, sex 
                  
Schwartzbaum et al, 1992 
US (1979-1986)[93]  
Hospital Cancer 
Registry 
101 Hospital Cancer 
Registry 
690 - 1.9 [1.1-3.2] - 0.7 [0.4-1.1] age, race, maternal age, social 
class, exposure to x-ray, 
miscarriage, others (not 
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specified) 
Schuz et al, 2001 
Germany (1988-1993)[23] 
Cancer Registry 183 Residents 
database 
1785 1.4 [1.0-1.9] - 0.9 [0.6-1.3] - age, sex, year of birth /SES, 
degree of urbanization 
               
Pang et al, 2003 
UK (1992-1994)[107]  
Cancer Registry 188 Family Health 
Services 
database 
6987 - 0.9 [0.6-1.3] - - age, sex, parental age, 
deprivation score 
             
Yang et al, 2000 
US (1992-1994)[24]  
Oncology Group 538 General 
population 
538 1.2 [0.9-1.6] 1.1 [0.8-1.4] 1.1 [0.9-1.4] 1.1 [0.8-1.4] date of birth /sex, race, maternal 
education, household income in 
the birth year 
Parodi et al, 2014 
Italy (1998-2001)[43] 
Oncology Group 153 National health 
service database 
1044 1.4 [0.9-2.2] 1.2 [0.7-2.1] - - Gender, date of birth, area of 
residence/ maternal age and 
maternal education 
France (2003-2004 and 
2010-2011) 
Cancer Registry 357 General 
population  
1783 1.3 [1.0-1.7] 1.3 [0.9-1.7] 0.9 [0.7-1.1] 1.0 [0.8-1.4]  age, sex, maternal age, study of 
origin 
a Calculated using raw numbers stated in the published paper.  
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Figure 6: Forest plot. Studies on maternal smoking and risk of neuroblastoma 
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Figure 7: Forest plot. Maternal alcohol consumption during pregnancy and risk of neuroblastoma. 
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4 Discussion 
4.1 Summary of main findings 
The aim of this study was to investigate whether specific birth-related characteristics and 
environmental exposures around pregnancy were related with the risk of childhood 
neuroblastoma. Because the embryonic characteristics of neuroblastoma and the early age at 
onset suggests that exposures before birth may play a role in disease development, the 
periconceptional period was the assessed as the key time period. Most of the studied 
exposures were investigated during pregnancy as a proxy for fetal exposures, while the year 
before conception and after birth were used to assess parental and childhood exposures, 
respectively. The exposures of interest in this study were chosen on the basis of previous 
research that suggested a biologically plausible association with neuroblastoma in the 
offspring.  
Our main findings on perinatal factors were the positive associations with being born either 
small or large for gestational age and with having a congenital malformation, and the inverse 
associations with breastfeeding and maternal use of supplements containing folic acid, 
vitamins or minerals in the preconceptional period. Our findings did not support the 
association between neuroblastoma and gestational age, difficulty becoming pregnant or 
undergoing fertility treatment.  
Our main findings on environmental exposures related to parental lifestyle were the increased 
risk with the maternal use of pesticides and maternal smoking during pregnancy. No 
associations were observed with paternal smoking in the year before pregnancy or maternal 
alcohol consumption during pregnancy.  
 
4.2 Internal validity 
Like all case-control interview-based studies, our study is exposed to a risk of selection and 
recall bias, measurement error and potential confounding.  
4.2.1 Selection bias 
The ESCALE and ESTELLE studies were designed to minimize bias in case and control 
selection. The cases were ascertained by a nationwide cancer registry, which has a high 
degree of completeness and all the diagnosis were verified before inclusion of cases. Since 
case children were excluded if they had died or were in palliative care, a bias may have 
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occurred if the exposures of interest were associated with the children’s prognosis. For 
example, some major malformations may have increased the risk of death. Then the true 
association should be stronger than the observed association in our study. As expected, the 
proportion of cases ineligible because this reason was smaller under 18 months of age than for 
those aged 18 months or more as these children have better survival. A bias may have 
occurred if the exposures would be expected to be stronger after 18 months. There is no 
known evidence of such effects, and the age-stratified analyses did not provide evidence of 
substantial differences in the associations between neuroblastoma and maternal exposures.  
The controls were randomly selected from the same population as cases. Controls were 
recruited from landline subscribers, who may differ in age and socioeconomic status from 
non-subscribers. The extent of possible bias was limited in France where telephone coverage 
was high during the years of recruitment[108]. The two studies had been designed to include 
landline owners who request to be unlisted (“liste rouge”), because they often belong to the 
highest socioeconomic categories. In the ESTELLE study, 24% of case families were not 
landline subscribers and the proportion is likely to have been lower for the ESCALE study. In 
the ESTELLE study, we were able to restrict the analyses to the case families that, like the 
control families, were landline subscribers, which did not change the findings.  
Non-response or refusal is an important source of participation bias. In our study, the 
proportion of participants was higher for eligible cases (86.5%) than for eligible controls (77.1 
%). Because no demographic information was available about non-participants, we do not 
know if these children were different from the study sample.  
It is known that subjects who refuse to participate in case-control studies may have a different 
exposure distribution from those who do participate[109]. In that case, if the factor of interest 
is under-represented in the control population, it may result in a spurious positive association 
due to selection bias and non-response bias. Similarly, if the exposure of interest is over 
represented among controls, the estimates may tend to the null. In our study, the control 
mothers were generally older than mothers reported in the National Perinatal Surveys 
(ENP)[110] conducted during the same time periods as the ESCALE and ESTELLE studies 
(i.e. 20% mothers were older than 35 years old in ESCALE and only 16% in the ENP 
performed in 2003; 25% in ESTELLE versus 19% in the ENP 2010) (Table 19). Control 
mothers were also older compared with case mothers. It has been shown in previous 
studies[111] that participation  of younger mothers tend to be low among control families 
despite adequate sampling frame and satisfactory response rate among controls. Although 
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maternal age is not thought to be related to neuroblastoma, all the analyses were adjusted on 
maternal age in an effort to account for this participation bias. The prevalence of several other 
reported characteristics were comparable to those reported by the ENP, namely the 
distribution of gestational age and high weight children (> 4000 g at birth), maternal 
education level, and the prevalence of use of fertility treatments. The prevalence of reported 
folic acid intake during pregnancy during pregnancy or preconception in the ESTELLE study 
was similar to the 2010 ENP.  
Similarly, the prevalence of congenital malformations among controls was comparable with 
the prevalence of congenital malformations in the general population reported by the 
European Surveillance of Congenital Anomalies Register (EUROCAT)[112]. Information 
was not collected for children who had died or were in palliative care, which may have biased 
the study of association with congenital malformations. 
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Table 19: Comparison between reported prevalence of exposures in the ESCALE-ESTELLE 
studies and National Surveys 
 Year 
 ENP 2003 ESCALE ENP 2010 ESTELLE 
Maternal education % % % % 
Less than secondary 36 34 28 24 
Secondary 21 20 20 23 
More than secondary 43 46 52 53 
 
    
Maternal age (years)     
< 25 19 18 17 10 
25-29 33 35 33 30 
30-34 32 31 31 35 
≥ 35 16 20 19 25 
 
    
Folic acid intake     
Before/during pregnancy Not stated - 40 41 
Before pregnancy Not stated - 15* 13 
 
    
Fertility treatment for the 
index pregnancy 
    
In-vitro fertilization 1.7 1.8 2.3 2.0 
Artificial insemination 0.6 0.8 1.0 0.9 
Hormonal stimulation 2.4 2.5 2.0 3.0 
     
     
Maternal smoking during 
pregnancy 
    
 
20 19 18 20 
 
    
Maternal alcohol intake 
during pregnancy 
    
 
Not stated - 20 20 
 
    
Breastfeeding 62 55 68 65 
 
    
Gestational age     
< 37   weeks 7 7 7 7 
37-39 weeks 45 37 47 39 
40-41 weeks 46 54 44 53 
> 42 2 1 2 0.3 
     
Birth-weight     
< 2500 g 6 8 5 7 
2500-3999 g 85 85 86 86 
≥4000 g 8 7 9 7 
* From Tort et al[113]  
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4.2.2 Misclassification bias 
Non-differential misclassification 
Errors in the measurement of variables are unavoidable in studies where exposures are self-
reported, particularly when the information is obtained retrospectively. In the present context, 
the delay between exposure and interview was relatively short, which may have reduced 
recall difficulties.  
Since most of the mothers had the child’s personal health records (over 95% of cases and 98% 
of controls) in their hands, gestational age and birth-weight were unlikely to be misclassified.  
On the other hand, the interviews could not elicit all the characteristics of specific exposures 
and, given their complexity, it is likely that mothers may not have been able to determine the 
agent of true interest. For example, mothers might not be aware that supplementation products 
for pregnancy contained folic acid, or even that the supplementation product contained a 
product other than folic acid.  
A woman’s total plasma folate level is determined by multiple factors. Dietary folate might be 
high among mothers that did not report folic acid intake around pregnancy. Dietary folate is 
absorbed differently from supplemental folic acid and as well as naturally occurring folate. In 
this study, we were not able to assess the dietary folate intake. In the same line, exposure 
opportunity and the intensity of pesticide exposure depends on many factors (nature, 
frequency and amount of pesticides used, methods of application, time spent in the exposed 
place, etc.) that could not be collected in the interviews. These types of exposure 
misclassification are likely to be randomly distributed among cases and it may tend to 
minimize the strength of an association, if present.  
With regards to congenital malformations, interview-based studies are subjects to non- 
differential misclassification bias as they use unconfirmed information on birth defects. In our 
study, two independent reviewers with medical background assessed the maternal responses 
about congenital malformations. The reviewers were blinded to the case-controls status of 
children. 
Paternal smoking was assessed through the maternal report of the father’s tobacco 
consumption. This could introduce a bias if the provided information was not accurate. In this 
study, the extent of the bias is limited since in the subset used for validation, agreement 
between maternal and paternal responses was high with regards to both ever smoking and 
number of cigarettes smoked per day[114]. Furthermore, control parents were also similar to 
the source population in the same age group in terms of tobacco smoking, when compared to 
estimates from the 2005 and 2010 French Health Barometer surveys[115]. For example, 
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42.5% and 44.3% of fathers reported regular smoking during the ESCALE and ESTELLE 
studies, respectively. This is similar to 42.6% and 47.7% of men of similar age (26-34 years) 
that reported regular smoking in 2005 and 2010, respectively.  
 
Recall bias 
The main concern about interview-based case-control studies is that the mothers of cases may 
recall previous exposures differently than the mothers of controls. The ESCALE and 
ESTELLE studies were designed to reduce the risk of recall bias by the use of computer-
assisted standardized interviews conducted by the same trained interviewers, 
contemporaneously and in identical conditions for cases and controls, although not blind to 
the case-control status. For example, over-declaration of malformations among neuroblastoma 
cases in which case mothers are more likely to remember minor defects than control mothers, 
may introduce differential classification bias in case-control studies. In order to limit this 
potential bias, we have excluded minor anomalies that are not always truly congenital in 
origin, sometimes associated with immaturity at birth, and have lesser medical or functional 
consequences. The criteria for exclusion were based on EUROCAT group 
recommendations[100], as the group’s experience showed that the definition, diagnosis and 
reporting of minor malformations vary considerably, while major malformations are less 
liable to differential recall bias. Despite the fact that recall bias cannot be completely ruled 
out, other studies based on birth records provide support for the validity of our findings[44], 
[47], [48], [53], [59], [60]. Another concern was the fact that medical diagnosis of some types 
of malformation may be more frequent among cases. For example, since most of 
neuroblastoma tumors are located in the abdominal cavity, the use of tomography scan for 
risk stratification may also lead to the diagnosis of an asymptomatic malformation, such as 
renal agenesis. Although we cannot exclude this possibility, a specific question was included 
in the ESTELLE study and none of the cases declared that the malformation had been 
diagnosed in the context of another pathology. 
Pesticide exposure and maternal smoking can also be subject to recall bias, and the direction 
of the bias is impossible to foresee. Mothers of cases may have been thinking more deeply 
and have less under-reported pesticide exposures than control mothers. The opposite scenario 
may also be possible and a true association may be underestimated. Deleterious effects of 
maternal smoking during pregnancy are well known and potential carcinogenic effects of 
pesticides raise concern in society. As social desirability is known to influence self-report of 
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substance abuse[116] case mothers may under-report these exposures if they try to deny any 
responsibility for the disease.  
 
4.2.3 Confounding 
The detailed questionnaires of the ESCALE and ESTELLE studies allowed for the 
consideration of multiple potential confounding. After reviewing the literature about potential 
risk factors of neuroblastoma, potential confounders were selected and tested if they met the 
empiric criteria of confounder (that is being associated with both the exposure of interest and 
the occurrence of the disease). All the analyses were adjusted on children age and sex, which 
were the matching variables. All the models of the pooled analysis accounted for the study 
effect to take into consideration the variations between the ESCALE and ESTELLE studies.  
As discussed above, control mothers were older than cases mothers and older than the general 
population of women giving birth. This could reflect the underrepresentation in our studies of 
young mothers without landline using mobile phone only. However, a high proportion of 
French homes had landlines at the time of the study[108], and in the ESTELLE study, 
exclusion of the case mothers with mobile phone only did not compensate the age difference 
between cases and controls. All our analyses were adjusted for maternal age at birth of the 
index child. Maternal education and degree of urbanization of the area of residence were also 
included as they may have been associated to control selection. 
Despite adjustment for maternal age and other factors in the final models, there is the 
possibility that some residual confounding remained or that there was confounding by 
unmeasured factors.  
 
4.2.4 Statistical power of this analysis 
Since the ESCALE and ESTELLE studies were designed as to be pooled, with similar defined 
exposures, this is one of the largest studies of neuroblastoma at present. Therefore, the study 
had overall power for detecting the association between neuroblastoma and the studied 
exposures, except for the pre-conceptional intake of folic acid supplements since the 
prevalence of the exposure was still low during the ESTELLE study period and no data was 
available during the ESCALE study period.  
On the contrary, our study did not have enough power with regards to stratified analysis by 
age at diagnosis, or by sub-groups of MYCN status of cases. Therefore, findings based on 
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small sub-groups of cases, such as the inverse trend of neuroblastoma risk with increased 
breastfeeding duration among MYCN amplified cases, may be due to chance.  
It is worth noting that despite the fact that multiple tests have been performed, our analyses 
were based on a priori hypotheses suggested by the current literature and supported by 
biological plausibility.  
 
4.3 Comparation with literature 
4.3.1 Birth-weight, gestational age and fetal growth 
Our findings support the hypothesis that link neuroblastoma with fetal growth disorders. In 
this study, the odds ratios were slightly higher when gestational age was considered, 
suggesting that the risk of cancer may be principally related to fetal growth, rather that birth-
weight per se. Harder et al [50] conducted a meta-analysis of 11 studies, conducted between 
1987 and 2016, and reported that a birth-weight > 4,000 g was consistently associated with an 
increased risk of neuroblastoma across studies. In addition, five of the included studies [38], 
[46]–[49] also analyzed fetal growth, with three studies reporting associations with fetal 
growth anomalies, which is in line with our findings. The association with high birth-weight 
was also reported by a large meta-analysis of studies from the UK and USA[117]. The 
biological hypothesis regarding the mechanisms underlying associations between fetal growth 
anomalies and neuroblastoma risk remains speculative. The association with fetal overgrowth 
may be related to the observation that embryonic tumors such as neuroblastoma are more 
frequent among children with overgrowth disorders, such as Beckwith-Wiedemann 
syndrome[118]. The syndrome is caused by overexpression of the gene for insulin-like growth 
factor IGF2, which is suspected to play a role in the development of several childhood 
malignancies[40]. However, the overexpression of IGF2 would not explain the association 
with low birth-weight that we and Johnson et al.[46] have observed. In the meta-analysis, 
Harder et al[50] suggested that the observed association with low birth-weight might be 
related to recall bias, since studies using interview data reported stronger associations than 
those using registries as the data source. A child born with low birth-weight may be subject to 
more medical care than a child with normal or high birth-weight.  
4.3.2 Congenital malformations 
We found a positive association between neuroblastoma and congenital malformations. This 
finding is consistent with previous publications[43], [44], [47], [48], [53], [57], [60] and 
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strengthens the hypothesis that developmental factors could have an etiological role in 
neuroblastoma. 
A previous Swedish study cohort[44] found that the association with congenital 
malformations was only present among younger children (<18 months at diagnosis), which is 
consistent with our findings. The underlying explanation is not clear. As it has been shown 
that some genetic alterations are different among younger and older neuroblastoma cases (i.e 
MYCN amplification is more frequent among children >18 months), it may reflect different 
genetic conditions involved in both congenital malformations and childhood neuroblastoma. 
However, it could also arise from unmeasured confounding or differential recall bias between 
the mothers of younger and older children. 
Since our study included only one case and three control children with genetic syndromes and 
results did not change after their exclusion in sensitivity analysis, our findings support the 
associations between neuroblastoma and non-chromosomal congenital malformations. The 
associations between chromosomal congenital malformations and childhood cancer are 
consistently reported in literature. Some of these associations are well documented, especially 
those between childhood cancer and chromosomal syndromes (i.e. leukemia and Down 
syndrome[119] or Wilm’s tumor and Beckwith-Weidemann syndrome[120]). Two recent 
record linkage studies[60], [121] analyzed the association between neuroblastoma and non-
chromosomal malformations using data from high-quality registers. Their results are 
consistent with ours. The US case-control study[60] found that non-chromosomal 
malformations were associated to a moderate increase of neuroblastoma risk OR 1.9 [ 95% CI 
1.3-2.8]. Finally, an Australian study cohort[121] found a positive association between 
childhood cancer among children younger than four years old and congenital malformations 
that were not known to be related to a cancer (OR 1.7 [95% CI 1.3-2.4]. They reported a 
positive association with neuroblastoma, but confident intervals were wide as based only in 
five exposed cases (OR 1.4 [95% CI 0.6-3.5]). 
The biological plausibility of relationships between birth defects and childhood cancer is 
supported by recent studies (reviewed in[31]) suggesting that disruption of normal 
developmental processes may be linked with oncogenesis.  
Further investigation is needed. However, since the associations between childhood cancer 
and congenital malformations have long been consistently reported, new research on the topic 
may identify new approaches to clarify the underlying mechanisms of the observed 
associations as well as replicate previous findings. Wellesley et al[122] highlighted the fact 
71 
 
that current research on congenital malformations etiology, like our study, is based on the 
ICD classification system, which uses body systems for classification categories which  does 
not take account of new knowledge in clinical genetics. The authors suggest that, for 
etiological research, new classification methods should be developed based on presumed 
etiological commonality. This could allow a better understanding of the etiology of congenital 
malformations and further investigation of those cases where a yet unknown environmental 
element could be important. Furthermore, it is hoped that the study of the association of 
childhood cancer and congenital anomalies will lead to identification of new genes that are 
involved in development and cancer. 
 
4.3.3 Maternal intake of folic acid, vitamins or minerals 
Our study suggests that maternal folic acid; vitamin or mineral supplementation in the 
preconception period may reduce the incidence of neuroblastoma. In line with these findings, 
a significant reduction in neuroblastoma incidence was observed in Canada after mandatory 
flour fortification with folic acid was instituted[65]. Moreover, two US case-control 
studies[66], [67], also reviewed in Goh et al.[123] concluded that periconceptional folic acid 
supplementation, three months before pregnancy and early in pregnancy, should be 
recommended. By contrast, a recent study performed by Mortensen et al [68] found no 
association between supplemental folic acid before and/or pregnancy and neuroblastoma[68]. 
Although this large nation-wide study included almost 800 children with cancer, results on 
neuroblastoma were based on only 71 cases and lack of power cannot be completely ruled 
out.  
As discussed in Chapter 1, the periconceptional folic acid supplementation has been shown to 
reduce the risk of neural tube defects by almost three-quarters [61]. Neural tube defects arise 
from the same embryonic structures as neuroblastoma. The biological plausibility of the 
associations derives from evidence that folic acid derivatives are essential for the synthesis of 
nucleic acids and amino acids, cell division, tissue growth, and DNA methylation. In our 
study, the potential protective effect was only observed when supplementation started before 
pregnancy. One explanation for this finding could be that the inception, migration, divergence 
and maturation of neural crest progenitors occurs early in pregnancy (between 3rd and 5th 
week of gestation) a critical period of time when most women may still not know they are 
pregnant. The association may also result from confounding since the women who began 
supplementation prior to pregnancy may differ in terms of profile and lifestyle from those 
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who did not use supplements or started them after discovering they were pregnant. A study by 
Tort et al, based on the French 2010 National Perinatal Survey[113] showed that women who 
took folic acid supplements before pregnancy were more likely to be: older; married or 
cohabiting; European; non-smokers; with a body mass index less than 25. Folic acid use 
during preconception was also higher in low-parity highly educated women. However, the 
cases and controls in our study were similar in terms of maternal education and parity, and the 
estimates were adjusted for maternal age. Since health promotion campaigns on folic acid 
intake during pregnancy started in France after the ESCALE study period, the low frequency 
of supplementation in both cases and controls in that study (only two cases and three controls 
reported the use of folic acid or vitamin/mineral supplements in the pre-conception period) 
prevented supplementation being addressed in that study. 
Only half of the mothers who reported folic acid supplementation during the preconception 
period could name a valid folic acid product. However, the imprecision was similar for case 
and control mothers, and there was little change in the estimates when only those mothers 
were analysed. Although various constituents of the multivitamin supplements may have been 
responsible for the protective effects, only 2% of controls and 1% of cases reported using a 
supplement not containing folic acid during the preconception period. 
 
4.3.4 Maternal reproductive history before the index pregnancy 
This study did not find any association between fertility treatments and neuroblastoma and as 
such is consistent with the results of a large British cohort study[124]. In our study the 
estimates were very close to unity and do not suggest any increased risk of neuroblastoma. 
However, the findings were based on small numbers of exposed subjects and cannot be 
interpreted as meaning there is no risk. The literature remains discordant. A Danish cohort 
study suggested that maternal fertility treatment with progesterone before childbirth might 
increase the risk of sympathetic nervous system tumors[125]. Additionally, a meta-analysis by 
the same author, based on five studies of neuroblastoma, found an increased risk of 
neuroblastoma among children born after fertility treatment (OR 4.0 [95% CI 1.24–
13.18])[126].  
 
4.3.5 Breastfeeding  
Our finding of an inverse relationship with breastfeeding is consistent with a large US study, 
which reported an association of the same order of magnitude (OR 0.63 [95% CI 0.41– 
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0.96])[57]. The association between breastfeeding and neuroblastoma has been less 
documented than the association with leukemia or brain tumors. A meta-analysis published in 
2005[127], which reported a 41% reduction in the risk of neuroblastoma, relied on only  three 
studies[73]–[75], two of which[74], [75] involved <45 cases each. 
The hypotheses with respect to underlying biological mechanisms are unclear at present. 
Greaves’ hypothesis [128] regarding childhood leukemia suggests that breast milk may play 
an important role in the prevention of childhood leukemia by actively stimulating or 
modulating the immune system and promoting its development in early life. However, an 
infectious etiology and a role of immunological modifiers in neuroblastoma development 
have not been prominent hypotheses. Epigenetic mechanisms have also been suggested based 
on the contribution of some human milk compounds to metabolic and differentiation 
processes, and to the development of the infant’s immune system[129]. 
The proportion of control mothers who reported breastfeeding during the ESCALE study 
(55%) was lower than the reported by the ENP (62%), while the proportion was similar 
between ESTELLE study (65%) and the 2010 ENP report (68%).  
The differences between our studies and the relevant ENPs could be related to different 
definitions, which was breast-feeding for at least three days in our studies, while in the ENP, 
it was the breast-feeding status in the maternity unit.  In our studies, it is plausible that women 
who breast-fed for a short duration did not report it. The increased breastfeeding prevalence 
between the ESCALE and ESTELLE studies was similar to the observed trend between 2003 
and 2010 
The increased breastfeeding prevalence between the ESCALE and ESTELLE studies was 
similar to the observed trend between 2003 and 2010. However, we cannot dismiss the 
possibility that our results might be influenced by residual confounding by socioeconomic 
status or other unmeasured characteristics associated with participation among controls.  
 
4.3.6 Maternal use of household pesticides 
Our findings suggest that the maternal use of household pesticides during pregnancy may be 
associated with an increased risk of neuroblastoma. Only two previous studies have assessed 
the relationship between household use of pesticides and neuroblastoma.  In a large US case–
control study, Daniels et al.[25] also reported modest associations (OR around 1.5) with the 
use of pesticides at home or in the garden during the preconception-pregnancy period or 
childhood. Consistent with our findings, this study showed similar estimates irrespective of 
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the MYCN status, which does not support the potential for pesticides to act through different 
pathways in the two subtypes. In that study, the estimates were stronger among older children. 
Since the use of pesticides at home may be associated with similar patterns over the life span, 
the stronger associations observed in older children may reflect the effect of longer period of 
exposures to pesticides. Previous studies have also suggested that different etiologic factors 
may be specific to age at neuroblastoma diagnosis[23], [47], [130]. In our study, there was a 
suggestion of difference by age with the use of herbicides and fungicides. However, this was 
based on small numbers and the confidence intervals in the two groups overlapped 
substantially. Another study conducted in Germany by Schuz et al[23] found an association 
between neuroblastoma and the use of household pesticides after the child’s birth, but did not 
investigate pesticide exposure during pregnancy. 
Despite the homogeneity of exposure definition among these previous studies and ours, 
differences were observed with regards to the assessed time-period. In the US study, positive 
associations were observed when both parents reported pesticide use between the month 
before pregnancy and diagnosis date (or equivalent date for controls), but not when only the 
preconception-pregnancy period was assessed. Up to 70% of parents reported ever use of 
pesticides in the US study, which was consistent with the reported prevalence in the 
ESTELLE study (60% for any use of pesticides before or during pregnancy, or after birth). 
Because the use of pesticides was correlated between time periods (preconception, pregnancy, 
and childhood), we cannot conclude that exposure specifically during pregnancy was 
associated with neuroblastoma. It is possible that patterns of exposure are related to lifetime 
habits, which are consistent throughout the periconceptional period and later in childhood. 
The German study only assessed household pesticide use after birth. The reported prevalence 
of household pesticides use was much lower (10%). In the ESTELLE study, 10% of control 
mothers reported having use household pesticides only after pregnancy, but as discussed 
above, pesticide use was strongly correlated between time periods. 
This study had limited ability to investigate associations with pesticides other than 
insecticides since the majority of mothers who reported any pesticide use (94%) reported 
using insecticides, either alone or combined with herbicides or fungicides. A French cohort 
study[131] performed between 2002-2006 found pesticides in up to 84% of urine samples 
from pregnant women living in the Bretagne region. Organophosphate insecticides were the 
most frequently observed pesticides among the 3 pesticides families that were investigated 
(triazine herbicides, organophosphate and carbamate insecticides).  
75 
 
We could not identify the active ingredients in the products used as in our study we only 
asked women about the category of pesticide as we thought this would be recalled with 
greater accuracy than the actual product name. Commercial household pesticides often 
contain multiple active ingredients, all which may have different properties including 
potentially carcinogenic actions. In our study, we mainly focused on maternal use of 
pesticides at home. However, the mothers may be exposed to other direct or indirect sources 
of pesticides, which we did not account for, like the paternal use of household pesticides or 
other sources of environmental exposure. 
Previous studies have found consistency between self-reported pesticide treatments and 
pesticides concentrations in dust[132] and that agreement about pesticides exposure between 
parents did not differ by case–control status[25], suggesting no differential recall based on 
motivation of case parents.  
It is biologically plausible that maternal pesticide exposure during pregnancy could be 
associated with the risk of neuroblastoma. It has been shown that maternal exposure during 
pregnancy can lead to fetal exposure since these compounds or their residues pass through the 
placenta and can be found in cord blood, infant hair, and meconium[133], [134].The potential 
underlying mechanisms are still unknown. Some individual pesticides have been classed as 
‘‘probable or possible carcinogens’’ by the IARC[78], [79]. In addition, because of the 
similarity of brain biochemistry, some insecticides that target the nervous system of insects 
may also be neurotoxic to humans[135].  
Despite the biological plausibility of an association and the consistency with the literature, our 
findings raise concern about how to interpret the lack of variation by broad type of pesticide, 
by geographical area and by time-period.  
Pesticides are a heterogeneous group of substances with diverse biological targets and modes 
of action. Therefore, a common biological effect such as carcinogenicity seems unlikely. 
However, interpretations may also consider the fact that childhood cancers are complex and 
multi-step diseases and a unique biological pathway is also unlikely. Carcinogenicity may be 
the consequence of different mutagenic or immunotoxic properties of pesticides that could 
impair different biological processes. As observed in our study, participants might be exposed 
to multiple types of pesticides, with unknown cumulative effects and between which there 
may be interactions.  
The fact that pesticide use patterns was too similar in each of the three time periods 
(preconception-pregnancy-after birth) might explain the homogeneity of results across the 
three studies despite the fact that they assessed different time periods.  
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The lack of variation across different countries and study periods is also worth noting. The US 
and the German studies covered the late eighties and early nineties, while the ESCALE and 
ESTELLE studies where performed at least ten year later. The active ingredients of pesticides 
and practices of use may vary over time and by geographical area. However, household use of 
insecticides may be subject to less variation than agricultural use of pesticides. Unless not 
identical, the molecules are likely to be similar. For example, insecticides where the also the 
most frequent household pesticide reported by the Northern California Childhood Leukemia 
Study, and identification of chemical classes showed that up to 77% were pyrethroids[136]. 
Finally, we cannot rule out recall bias as all the studies on household pesticide exposure and 
neuroblastoma relied on self-report. Since literature on household use of pesticides and 
neuroblastoma is scarce, further studies with a better exposure assessment are needed.  
 
4.3.7 Professional pesticides exposure 
Consistent with our findings, associations between neuroblastoma and maternal occupational 
exposure to pesticides were reported in two case–control studies in the US[23], [82]. In a 
cohort study in Norway, an increased risk of neuroblastoma was observed in offspring of 
parents having worked with field vegetables[85]. However, these findings should be 
interpreted with caution since they were based on small numbers. In two of these studies[82], 
[85] like in ours, estimates were based on less than ten exposed cases and could represent a 
chance finding. Literature on paternal occupational exposure to pesticides is not supportive of 
an association with neuroblastoma as shown in a meta-analysis conducted by Moore et 
al.[87]. A large Texan case–control study estimated residential exposures to pesticides due to 
neighboring agricultural activities and found no association[137]. However, estimates were 
inconsistent between low and high level of exposure and were based on less than 15 exposed 
cases. A meta-analysis performed by Vinson et al[138] reported an OR 1.7 [95% CI 1.1-2.5] 
with parental occupational exposure to pesticides. However, results on neuroblastoma where 
not clearly stated and did not distinguish between paternal and maternal exposure.  
 
4.3.8 Parental smoking and alcohol consumption 
With regards to parental smoking, the main finding of the ESCALE and ESTELLE studies 
was the slight positive association between maternal smoking during pregnancy and the risk 
of neuroblastoma. By contrast, no association with maternal alcohol consumption or paternal 
smoking around pregnancy was observed. 
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Our meta-analysis also suggested a slight but significant association between neuroblastoma 
and maternal smoking during pregnancy. This is consistent with the two previous meta-
analyses by Chu et al.[139] (OR = 1.3 [95% CI 1.0–1.6]) and Müller-Schulte et al.[94] (OR = 
1.2 [95% CI 1.0–1.4], which included almost the same studies. Our meta-analysis added 
nearly 500 cases from an Australian study[104] and the ESCALE and ESTELLE studies. 
Yang et al.[24], whose findings were consistent with ours, also accounted for MYCN status. 
Their findings do not support the potential for maternal smoking to act through different 
pathways in the two subtypes. 
Paternal tobacco smoking has been shown to be associated with increases in DNA damage, 
aneuploidies, and mutations in sperm and may act as a human germ cell mutagen[140]. 
Despite this, our study did not support the link between paternal smoking around pregnancy 
and the risk of neuroblastoma as did two previous studies[24], [107]. 
The meaning of the apparent stronger association between maternal smoking and 
neuroblastoma when both parents smoked is still unclear. We first hypothesized that when 
both parents smoked the mothers may have been heavier smokers, but there was no difference 
with regards to the quantity of cigarettes smoked per day. However, the prevalence of tobacco 
consumption was higher among mothers when the fathers also smoked. Yang et al.[24] also 
found a slightly stronger association when both parents smoked (OR 1.3 [95% CI 0.9–2.0]) 
compared to only mothers (OR 1.1 [95% CI 0.8–1.4]. Consistent with our findings, previous 
studies did not support the link between maternal alcohol intake during pregnancy and 
neuroblastoma[23], [24], [46], [49], [93]. 
 
4.4 Public health implications 
This thesis adds weights to the existing evidence that some perinatal exposures may play a 
role in NB development. This has implications for parents, health care professionals and 
politicians.  
Since it is recommended that women take folic acid supplements prior to conception and 
continue in early pregnancy, timing is one of the biggest challenges with regards to folic acid 
supplementation. In France, recommendations on the preconceptional intake of folic acid 
should be strengthened among women of childbearing age. The 2016 ENP reported a 
significant increase of the prevalence of preconceptional folic acid supplementation among 
women compared to 2010[141]. Fifteen per cent of mothers reported folic acid intake before 
pregnancy in 2010 and 23% in 2016 (p < 0.001). However, the challenging is still enormous 
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since overall 80% of women do not benefits of this effective preventive measure nowadays, 
far below the level reported in other high-income countries, as shown by an Australian study 
which reported 51% of women had taken folic acid supplements during the preconception 
period as far back as 2009[142]. The National Institute for Prevention and Health Education 
(INPES) advocates that health professionals should prescribe a daily intake of folic acid to 
women from the time they start to planning to get pregnant and until the 12th week of 
amenorrhea[143]. Nevertheless, opportunity for this action seems limited as only 35% of 
women declared a preconceptional medical consultation and 28% an early consultation once 
they knew they were pregnant[141]. Furthermore, this measure does not take account 
unplanned pregnancies.   
Additional strategies should be considered to reach a bigger proportion of women. As 
previously discussed, folates are naturally present in some foods. However, to achieve the 
equivalent of 400 μg folic acid through dietary food folate intake may be difficult and most of 
the time requires behavioural change. Governments should evaluate the feasibility and 
efficacy of a mandatory food fortification program in their specific context. If successful, this 
measure also has the advantage of reach hard to reach groups [144] since it has been shown 
that women who take folic acid during the periconceptional period tend to be older, better 
educated and from high socioeconomic categories[113]. 
Women should be advised to avoid pesticide exposure around pregnancy and there is a need 
to limit the use of pesticides in homes as well as public and private spaces where women and 
children might be exposed, such as parks, child care centres and schools. In 2005, the 
National Institute for Agronomic research (INRA) in collaboration with Cemagref released an 
expert’s report on demand of the Ministry for Ecology and Sustainable Development 
(MEDD)[145]. The report provides a detailed analysis of existing data for evaluating the 
magnitude of pesticides use in France, as well as to estimate population-level exposure. It also 
proposes several strategies to reduce the use of pesticides in France, as well as its 
environmental impact. The report drew on previous international experiences such as the US 
Integrated Pest Management program[146] in order to propose better strategies for the French 
context.  
National efforts are being implemented to achieve these goals. However, the implementation 
of changes is taking longer than planned.  The European Union has adopted a common 
framework in line with sustainable development recommendations. In France, the Ecophyto 
program aimed to halve the agricultural use of pesticides. In 2015, Ecophyto II program 
extended the achievement of this goal to 2025.  
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Further efforts should be made to limit tobacco consumption among prospective parents and 
supporting smoking cessation during pregnancy. After a significant reduction of maternal 
smoking during pregnancy over the period 2003-2010[107] the 2016 ENP[141] reported an 
stagnation of the prevalence of maternal tobacco consumption during pregnancy (overall 
17%). It is worthy to note that the report states that less than half of pregnant women who 
declared tobacco consumption declared to have benefit from medical advice or professional 
support for smoking cessation. Finally, current practices should continue to support 
breastfeeding, which is reported nowadays by almost 65% of women.  
 
4.5 Implications for etiological research 
This thesis adds to the existing knowledge about risk factors for neuroblastoma. Specifically, 
it supports the hypothesis that malignant tumors may be initiated during fetal development. 
However, there are still many unanswered questions. 
The rarity of neuroblastoma and the lack of precision on measurement of some exposures are 
the main limitations to overcome.  It is hoped that several ongoing projects will help to 
improve our understanding of neuroblastoma etiology. 
For instance, international consortiums such as the CLIC+, which expands the Childhood 
Leukemia International Consortium, aim to achieve better statistical power by pooling data 
from good-quality studies conducted by different countries. Some of these, like the ESCALE 
and ESTELLE studies, have collected biological samples that will allow to study genetic 
predisposition to neuroblastoma and interactions between genetic and environmental factors 
Finally, recent studies[147], [148] and governmental programs[149] have been undertaken  to 
improve  the quality of pesticide exposures assessment. However, the challenges are still great 
in regards to childhood cancer research, since cohort studies are not feasible and the 
characterization of pesticides exposure relies on retrospective data collection.
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5 Conclusion 
Our findings support the hypothesis that fetal growth anomalies and congenital malformations 
could increase the risk of neuroblastoma, which may suggest defective embryogenesis. They 
also add to the evidence that neuroblastoma is related to maternal use of household pesticides 
and to maternal smoking, which are additional reasons for advising and helping pregnant 
women to limit these exposures in this period. Further investigations are needed to clarify the 
role of folic acid supplementation and breastfeeding, given their potential importance in 
neuroblastoma prevention. 
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Neuroblastoma (NB), an embryonic tumour arising from neural crest cells, is the most common malignancy among infants. The
aetiology of NB is largely unknown. We conducted a pooled analysis to explore whether there is an association between NB
and preconception and perinatal factors using data from two French national population-based case-control studies. The moth-
ers of 357 NB cases and 1783 controls younger than 6 years, frequency-matched by age and gender, responded to a tele-
phone interview that focused on demographic, socioeconomic and perinatal characteristics, childhood environment, life-style
and maternal reproductive history. Unconditional logistic regression was used to estimate pooled odds ratios and 95% confi-
dence intervals. After controlling for matching variables, study of origin and potential confounders, being born either small
(OR 1.4 95% CI 1.0-2.0) or large (OR 1.5 95% CI 1.1–2.2) for gestational age and, among children younger than 18 months,
having congenital malformations (OR 3.6 95% CI 1.3–8.9), were significantly associated with NB. Inverse associations were
observed with breastfeeding (OR 0.7 95% CI 0.5–1.0) and maternal use of any supplements containing folic acid, vitamins or
minerals (OR 0.5 95% CI 0.3–0.9) during the preconception period. Our findings reinforce the hypothesis that fetal growth
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order to clarify the role of folic acid supplementation and breastfeeding, given their potential importance in NB prevention.
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Introduction
Neuroblastoma (NB) is the most common extra-cranial solid
tumour in childhood. Every year, 140–150 cases aged 15 years
or younger are diagnosed in France.1 NB is the most frequently
diagnosed neoplasm during infancy, 40% of cases are diagnosed
before the age of 1 year and 85% before the age of 5 years.2
NB is a malignant embryonal tumour of the neural crest cells.
The neural crest develops early during embryonal development
and differentiates to create the sympathetic nervous system. The
trademark of NB is its clinical heterogeneity, characterised by
contrasting patterns of clinical behaviour. The tumour may
spontaneously regress in some patients while progressing in
others, despite intensive multimodality therapy.3 The risk assess-
ment algorithm combines clinical variables such as age at diag-
nosis, with specific biologic variables as histological category and
the status of N-myc proto-oncogene (MYCN). MYCN amplifi-
cation is a genetic aberration that occurs in about 20% of prima-
ry tumours and it is one of the strongest independent adverse
prognostic factors.4 Some predictor factors such as MYCN status
and age at diagnosis may have aetiological relevance since some
studies have found that some exposures in pregnancy were more
strongly related to NB at an earlier age of diagnosis.5–7
The aetiology of NB is largely unknown. Familial NB is rare
and accounts for only approximately 1% of all NB cases.8 Genetic
predisposition cannot fully explain the origin of NB. The embry-
onic nature of NB and the early age at diagnosis suggest a role of
intrauterine and neonatal factors. Some previous studies have
focused on newborn characteristics like gestational age6,7,9–11 and
birth weight, but the results are inconsistent and most of them do
not distinguish between the effects of birth weight per se,11–13 and
rate of fetal growth.6,14–18 Several co-occurring congenital condi-
tions have been described: Beckwith-Wiedemann syndrome, Von
Recklinghausen syndrome and Hirschsprung’s disease. In addi-
tion, some studies have reported a positive association with con-
genital malformations,10,15,19 while maternal use of folic acid,
vitamins or minerals during pregnancy20–22 and breastfeed-
ing23,24 may potentially be protective.
We evaluated whether there was an association between
maternal and neonatal characteristics and the risk of NB, based
on two population-based case-control studies: ESCALE and
ESTELLE. The ESCALE study, conducted by our group in
2003–2004, reported a positive association with congenital
malformations.25 Because the numbers were limited, the
ESTELLE study, conducted in 2010–2011, was designed for
pooling with the ESCALE study in order to increase the power
for the investigation of gestational age, fetal growth, congenital
malformations, maternal use of fertility treatments, vitamin,
mineral and folic acid supplementation in the periconceptional
period, and breastfeeding, which were the focus of this paper.
Material and Methods
Study population
The ESCALE26 and ESTELLE27 studies were two nationwide
population-based case-control studies using the French
National registry of childhood cancers (RNCE), and sup-
ported by the Societe Franc¸aise de lutte contre les Cancers de
l’Enfant et de l’Adolescent (SFCE).
The cases were children aged <15 years and residing in
mainland France at the time they were newly diagnosed with
cancer. The ESCALE study included cases of NB, leukaemia,
lymphoma and malignant brain tumour diagnosed in 2003–
2004, while the ESTELLE study included cases of NB, leukae-
mia, lymphoma, malignant brain tumour, Wilm’s tumour
and hepatoblastoma diagnosed in 2010–2011. The present
paper focuses on NB in children under 6 years old.
In both studies, the cases were ineligible if they had been
adopted or if their biological mother had died, was absent or
did not speak French (n5 21), had a serious social problem
or psychiatric disorder (n5 5), or could not be interviewed
for ethical reasons because the child was in palliative care or
had died (n5 22). Information on the MYCN amplification
subtype was obtained subsequently from the RNCE. During
the two study periods, 500 cases of NB were diagnosed,
276 in 2003–2004 and 224 in 2010–2011. The present analy-
sis was limited to 357 cases aged less than six years (91.3% of
included cases). Overall case participation rates were 81.2%
for ESCALE and 92.2% for ESTELLE (Fig. 1).
The population controls were children free from cancer
selected contemporaneously using quota-sampling methods.
Quotas were used to obtain, overall, at least one control per
case in ESCALE and at least one control per case for each year
of age, gender, and type of cancer in ESTELLE, based on the
expected numbers derived from the RNCE. In both studies, the
quotas also ensured that the control group had the same distri-
bution as the overall population for the number of children
aged <15 years living in the household, conditionally on age.
In the same way as for the cases, the children who had been
adopted, or whose biological mother had died or did not speak
What’s new?
Neuroblastoma is the most common extracranial solid tumor in children, yet little is known about its etiology. The vast majori-
ty of neuroblastomas are not inherited, suggesting that neuroblastoma risk is influenced by other factors, particularly certain
preconception or perinatal factors. Here, in a population-based case-control study of 357 neuroblastoma patients, congenital
malformations and small or large size for gestational age were associated with increased neuroblastoma risk. By contrast,
breastfeeding and preconception supplementation with vitamins or minerals were inversely associated with risk. The findings
confirm previous links between neuroblastoma, abnormal fetal growth, and congenital malformations while highlighting poten-
tial protective factors.
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French were not eligible as controls. The procedure for control
sampling was slightly different for the two studies: in the
ESCALE study, a base of 60,000 phone numbers was randomly
extracted from the national telephone directory. The set was
representative of the population in terms of the administrative
regions and urbanization. By incrementing each number by 1,
a new set of 60,000 numbers was generated. The new set
included unlisted numbers and had geographic and demo-
graphic distributions similar to those of the initial set (same
first six digits, which indicate the location of the line). In the
ESTELLE study, telephone numbers were randomly generated
and dialled over the 2-year subject recruitment period. The
participation rates were 71.2% and 85.5%, respectively. The
present analyses were limited to 1783 controls aged <6 years at
the reference date (57.5% of those recruited). Figure 2 shows
the steps in the control recruitment process in the ESCALE
and ESTELLE studies.
Data Collection
Case and control mothers were interviewed using a standard-
ized telephone interview conducted by trained interviewers
and lasting 50 min. In both studies, the interview included
questions on demographic and socioeconomic characteristics,
childhood environment and life-style, familial and personal
medical history and parental occupational history.
Mothers were asked about their age at the index child’s
birth, the parity of that pregnancy, if they had difficulty
becoming pregnant and if they took vitamin, mineral or folic
acid supplements three months before pregnancy or in the
1st, 2nd or 3rd trimester of pregnancy. In ESTELLE, the
mothers were also asked the name of the supplement. Gesta-
tional age and birth weight of the index children, breastfeed-
ing duration, and whether the child was diagnosed with a
congenital malformation and, if so, details of the type and
site of malformations were also collected. As a memory aid,
the mothers were advised to consult the relevant pages of the
child’s personal health record during the interview.
Data Management
Difficulty becoming pregnant was defined as taking more
than one year to conceive the index child and/or the need to
consult a doctor and/or the need for the mother or father to
undergo fertility treatment. In the latter case, the mother was
asked to specify the type of treatment. The use of vitamin,
mineral or folic acid supplements was considered as a binary
variable (ever/never), and by trimester from three months
before pregnancy to birth, taking as reference category the
absence of supplementation in any of those periods. We also
used a more specific classification, defining ‘substantiated’
folic acid supplementation as supplementation reported for
Figure 1. Case participation
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the relevant time period with a valid product name, and
‘unsubstantiated’ supplementation as supplementation
reported for the relevant time period but with no valid name
given.
Gestational age was classified as: pre-term (<37 complete
weeks of pregnancy), post-term (42 weeks or more) and two
at-term categories (37–39 and 40–41 weeks). Birth weight
was classified with cut-offs in grams (<2,500, 2,500–2,999,
3,000–3,499, 3,500–3,999, 4,000) comparable with those
used by the French national perinatal surveys.28 Fetal growth
was estimated by using the birth weight Z-score based on
gender-specific percentiles for birth weight by gestational age
in weeks from a large French cohort.29 The categories were
defined using classical Z-score cut-offs, i.e. from the 10th
through the 90th percentile for the category appropriate for
gestational age (AGA), <10th percentile for small for gesta-
tional age (SGA) and >90th percentile for large for gestation-
al age (LGA).
The congenital malformations were coded using the Inter-
national Classification of Diseases, 10th Revision (ICD-10),30
with the coder blind to case-control status. Then, children
with only minor anomalies or unspecified anomalies were
excluded in accordance with the European Surveillance of
Congenital Anomalies (EUROCAT) recommendations.31
Breastfeeding was defined as having been breastfed for at
least three days after birth and ever breastfed children were
also categorized by duration (<3 months, 3–5 months and 6
months or more).
Statistical Analyses
Study-specific odds ratios (OR) and pooled OR and their
95% confidence intervals (95% CI) were estimated by uncon-
ditional logistic regression (STATA version 11, StatCorp LP,
College Station TX). All the models included the stratification
variables: child’s age and gender, and, for the pooled analyses,
the indicator of study of origin. To avoid possible residual
confounding by age and because of the particular age distri-
bution of NB, the first year of age was split into trimesters
(< 3 months, 3–5 months, 6–8 months, 9–11 months), the
second year into semesters (12–17 months, 18–23 months),
and the other ages were kept as single years (2, 3, 4 and 5
years).
Figure 2. Control recruitment
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Between-study heterogeneity was tested by regression
models with and without an interaction term between specific
study and exposure. Because the findings of the individual
studies were similar, only the results of the pooled analysis
are presented herein.
The following variables were considered a priori to be
potential confounders and were tested to determine whether
they met the empirical definition of confounding (indepen-
dent association with both the exposure and outcome): pater-
nal and maternal age at the child’s birth, maternal level of
education, birth-order and degree of urbanization of the place
of residence. Of these, maternal age, birth-order and degree
of urbanization of the place of residence were retained in all
the models.
In order to properly address breastfeeding in relation to
the development of NB, analyses were limited to children
aged six months or older at diagnosis or at the reference date
for controls, so that the cases and controls would have had
the opportunity of being breastfed for up to six months.
At the time of the ESCALE study, the frequency of folic
acid supplementation in France was very low. Therefore, we
only presented the data from the ESTELLE study in this
paper.
Additional analyses were conducted by subgroups of NB
defined by age at diagnosis (age <18 months and 18
months) and MYCN oncogene amplification status (MYCN
amplified and MYCN not amplified).
Since controls were recruited from a sample of landline
phone numbers, sensitivity analyses were performed exclud-
ing case mothers with no landline at home (restricted to
ESTELLE as ESCALE cases were not asked this question).
Finally, multiple births and children born following in vitro
fertilization were excluded from the analysis of fetal growth
and folic acid supplementation, in order to control for possi-
ble confounding by the use of fertility treatments.
Results
Overall, 357 NB cases (174 in ESCALE, 183 in ESTELLE)
and 1783 controls (949 in ESCALE and 834 in ESTELLE)
under six years of age were included in the pooled analysis.
Table 1 shows the main characteristics of all participants by
individual study and for the pooled sample. The MYCN
oncogene was amplified in 64 cases (18%), not amplified in
270 cases (76%) and non-informative (NI) in 23 cases (6%).
In both studies the cases and the controls were generally sim-
ilar, except that the cases were more likely to be younger, be
first born, to have younger mothers and more likely to live in
an urban area than the controls. Because the sampling was
performed to enable analyses of multiple childhood cancer
diagnoses, the control group had the same age distribution as
the whole ESCALE and ESTELLE case population. There
were at least two controls for each case in each age stratum.
There was no association between NB and difficulty
becoming pregnant or use of fertility treatments for the index
pregnancy (Table 2). There was no significant association
between gestational age or birth weight and NB. SGA and
LGA were both associated with NB (ORs 1.4 95% CI 1.0–2.0
and 1.5 95% CI 1.1–2.2, respectively). The associations were
specially marked for children younger than 18 months (ORs
1.7 95% CI 1.0–3.1 and 2.0 95% CI 1.2–3.3, respectively).
Overall, congenital malformations were reported slightly
more often for cases (4%) than for controls (3%), and the
association tended to be more marked, although based on
small numbers, when the child had two or more malforma-
tions (OR 6.3 95% CI 1.3–29). The most frequently reported
sites of malformations were the skeletal and genitourinary
systems. Lastly, the association between malformations and
NB was only observed in children aged <18 months (OR 3.6
95% CI 1.3–8.9). Results were similar when the analysis by
subgroups defined by case MYCN amplification status was
performed (results not shown).
The breastfeeding analysis was restricted to the 1,589 con-
trols and 269 cases who were aged 6 months or older (Table
3). The cases were breastfed less often than the controls (OR
0.7 95% CI 0.5–1.0) but there was no evidence of a decrease
in risk with increasing breastfeeding duration. The inverse
trend was significant when the association was restricted to
the cases with MYCN amplification (p values for
trend< 0.01).
There was an inverse association with maternal use of any
supplement containing folic acid, vitamins or minerals in the
three months before conception (OR 0.5 95% CI 0.3–0.9;
Table 4). There was little change when the analysis was
restricted to substantiated supplements containing folic acid
(OR 0.4 95% CI 0.2–1.1). There was no association with the
use of supplements during the other trimesters of pregnancy
(Table 4). The analysis of subgroups defined by age at diag-
nosis (dichotomised at 18 months) and by case MYCN
amplification status showed only minor heterogeneity of
effect (results not shown).
The results remained unchanged after exclusion of the
ESTELLE cases with no telephone landline or after exclusion
of multiple births and children born following in vitro fertili-
zation (results not shown).
Discussion
The main findings of this study consist in the positive associ-
ations with being born either small or large for gestational
age, the positive association with having a congenital malfor-
mation, and the inverse associations with breastfeeding and
maternal use of supplements containing folic acid, vitamins
or minerals in the preconception period. No association with
difficulty becoming pregnant or with the use of fertility treat-
ments was observed.
Harder et al32 conducted a meta-analysis of 11 studies
and reported that a birth weight> 4,000 g was consistently
associated with an increased risk of NB across studies. In
addition, six of the included studies6,14–18 also analyzed fetal
growth, with four studies reporting associations with fetal
growth anomalies, which is in line with our findings. The
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association with high birth weight was also reported by a
large recent meta-analysis of data from the UK and USA.33
In this study, the odds ratios were slightly higher when gesta-
tional age was considered, suggesting that the risk of cancer
may be principally related to fetal growth, rather that birth
weight per se. The biological hypothesis regarding the mecha-
nisms underlying associations between fetal growth anomalies
and NB risk remains speculative. The association with fetal
overgrowth may be related to the observation that embryonic
tumours like NB are more frequent among children with
overgrowth disorders, such as Beckwith-Wiedemann syn-
drome.34 The syndrome is caused by overexpression of the
gene for insulin-like growth factor IGF2, which is suspected
to play a role in the development of several childhood malig-
nancies.35 However, the overexpression of IGF 2 would not
explain the association with low birth weight that we and
others14,18 have observed. In the meta-analysis, Harder
et al.32 suggested that the observed association with low birth
weight might be related to recall bias, since studies using
interview data reported stronger associations than those using
registries as the data source.
We found a positive association between congenital mal-
formations and NB among children aged <18 months. This
finding is consistent with previous publications.10,15,19,36,37
Over diagnosis of malformations among NB cases or a differ-
ential recall bias in which case mothers are more likely to
remember minor defects than control mothers, may intro-
duce differential classification bias in case-control studies. In
order to limit this potential bias, we have excluded minor
anomalies that are not always truly congenital in origin,
sometimes associated with immaturity at birth, and have less-
er medical or functional consequences. The criteria for exclu-
sion were based on EUROCAT group recommendations,31 as
the group’s experience showed that the definition, diagnosis
and reporting of minor malformations vary considerably,
while major malformations are less liable to differential recall
bias. Despite the potential influence of exposure misclassifica-
tion and recall bias, other studies based on birth records pro-
vide support for the validity of our findings.10,15 The
association observed with congenital malformations strength-
ens the hypothesis that developmental factors could have an
aetiological role in NB.
Our finding of an inverse relationship with breastfeeding
is consistent with a large US study, which reported an associ-
ation of the same order of magnitude (OR 0.63 95% CI 0.41–
0.96).24 The association between breastfeeding and NB has
been less documented than the association with leukemia or
brain tumors. A meta-analysis published in 2005,38 which
reported a 41% reduction in the risk of neuroblastoma, relied
on only 3 studies,23,39,40 two of which39,40 involved <45 cases
each. The hypotheses with respect to underlying biological
mechanisms are unclear at present. Graves’ hypothesis
regarding childhood leukaemia41 suggests that breast milk
may play an important role in the prevention of childhood
leukemia by actively stimulating or modulating the immune
system and promoting its development in early life. However,
an infectious aetiology and a role of immunological modifiers
in NB development have not been prominent hypotheses.
Epigenetic mechanisms have also been suggested based on
the contribution of some human milk compounds to meta-
bolic and differentiation processes, and to the development of
the infant’s immune system.42
Our study suggests that maternal folic acid; vitamin or
mineral supplementation in the preconception period may
reduce the incidence of NB. The main limitation with regard
to the interpretation of this finding is the retrospective design
of the study and its potential reporting bias. Only half of the
mothers who reported folic acid supplementation during the
preconception period could name a valid folic acid product.
However, the imprecision was similar for case and control
mothers, and there was little change in the estimates when
only those mothers were analyzed.
Although various constituents of the multivitamin supple-
ments may have been responsible for the protective effects,
only 2% of controls and 1% of cases reported using a supple-
ment not containing folic acid during the preconception peri-
od. In line with these findings, a significant reduction in NB
incidence was observed in Canada after mandatory flour for-
tification with folic acid was instituted.20 Moreover, two US
case-control studies,21,43 also reviewed in Goh et al.22 con-
cluded that periconceptional folic acid supplementation, three
months before pregnancy and early in pregnancy, should be
recommended. By contrast, a recent Norwegian data linkage
study found no association between supplemental folic acid
before and/or pregnancy and NB. However, with only 71
cases of NB, the study had insufficient power to specifically
investigate preconceptional supplementation.44
Periconceptional folic acid supplementation has been
shown to reduce the risk of neural tube defects by almost
three-quarters.45 Neural tube defects arise from the same
embryonic structures as NB. The biological plausibility of the
associations derives from evidence that folic acid derivatives
are essential for the synthesis of nucleic acids and amino
acids, cell division, tissue growth, and DNA methylation. In
our study, the potential protective effect was only observed
when supplementation started before pregnancy. One expla-
nation for this finding could be that the inception, migration,
divergence and maturation of neural crest progenitors occurs
early in pregnancy (between 3rd and 5th week of gestation)46,
a critical period of time when most women may still not
know they are pregnant. The association may also result
from confounding since the women who began supplementa-
tion prior to pregnancy may differ in terms of profile and
lifestyle from those who did not use supplements or started
them after discovering they were pregnant. The French 2010
National Perinatal Survey47 showed that women who took
folic acid supplements before pregnancy were more likely to
be: older; married or cohabiting; European; non-smokers;
with a body mass index less than 25. Folic acid use during
preconception was also higher in low-parity highly-educated
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women. However, the cases and controls in our study were
similar in terms of maternal education and parity, and the
estimates were adjusted for maternal age. In France, health
promotion campaigns encouraging prenatal folic acid supple-
mentation began in 2004, after the ESCALE study period.
The low frequency of supplementation in both cases and
controls in that study (only two cases and three controls
reported the use of folic acid or vitamin/mineral supplements
in the pre-conception period) prevented supplementation
being addressed in that study.
This study did not find any association between fertility
treatments and NB and as such is consistent with the results
of a large British cohort study.48 In our study the estimates
were very close to unity and do not suggest any increased
risk of NB. However, the results are based on small numbers
of exposed subjects and cannot be interpreted as meaning
there is no risk. The literature remains discordant. A Danish
cohort study suggested that maternal fertility treatment with
progesterone before childbirth might increase the risk of
sympathetic nervous system tumours.49 Additionally, a meta-
analysis by the same author, based on five studies of NB,
found an increased risk of NB among children born after fer-
tility treatment (OR5 4.04 95% CI 1.24–13.18).50
Our study has the same limitations as all case-control
interview-based studies, which are inherently exposed to a
risk of selection bias and recall bias. However, during the
interview, women were asked to consult the child’s personal
health record, which was available for over 95% of cases and
98% of controls.
Despite the number of controls our study was underpow-
ered for some analysis and findings based on small subgroups
of cases, like MYCN amplified cases, may be due to chance.
At the same time, as evidence from previous studies showed
that age at diagnosis and MYCN status are highly correlat-
ed,51 our findings about congenital malformations and fetal
growth anomalies being more strongly associated with NB
among children aged <18 months may be related to MYCN
status or other genetic or biologic risks that are yet undiscov-
ered or unproven, and not necessarily with the age at
diagnosis.
However, our study also has several strengths. Since the
ESCALE and ESTELLE studies were designed to be pooled,
with uniformly defined exposures, this is one of the largest
studies of NB at present. In this population-based study,
cases were ascertained by a nationwide cancer registry, which
has a high degree of completeness. The overall participation
rate of the controls was high and we also adjusted our analy-
sis for factors that might be associated with control participa-
tion like maternal age and degree of urbanization. The
controls were very similar to the French general population,
when compared with the national perinatal surveys,28 with
regard to maternal level of education, perinatal characteristics
such as birth weight and gestational age, and the use of fertil-
ity treatments. The use of a complete and standardized
questionnaire enabled investigation of several exposures and
potential confounders in detail, while reducing potential dif-
ferential misclassifications.
In conclusion, the results from this pooled analysis of the
ESCALE and ESTELLE studies support the hypotheses that
fetal growth anomalies and congenital malformations are
related to NB. The results also suggest protective effects of
breastfeeding and preconception use of folic acid supple-
ments, which need further investigation. If these findings
were replicated, intensifying current health policies with
regard to those practices could be important for NB
prevention.
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Abstract
Purpose Neuroblastoma (NB) is an embryonic tumor that
occurs almost exclusively in infancy and early childhood.
While considerable evidence suggests that it may be ini-
tiated during embryonic development, the etiology of NB is
still unknown. The aim of this study was to explore whe-
ther there is an association between maternal use of
household pesticides during pregnancy and the risk of NB
in the offspring.
Methods We conducted a pooled analysis of two French
national-based case–control studies. The mothers of 357
NB cases and 1,783 controls younger than 6 years, fre-
quency-matched by age and gender, responded to a
telephone interview that focused on sociodemographic and
perinatal characteristics, childhood environment, and life-
style. Unconditional logistic regression was used to esti-
mate pooled odds ratios and 95% confidence intervals.
Results After controlling for matching variables, study of
origin, and potential confounders, the maternal use of any
type of pesticide during pregnancy was associated with NB
(OR 1.5 [95% CI 1.2–1.9]). The most commonly used type
of pesticides were insecticides and there was a positive
association with their use alone (OR 1.4 [95% CI 1.1–1.9])
or with other pesticides (OR 2.0 [95% CI 1.1–3.4]).
Conclusions Although there is the potential for recall bias
due to the study design, our findings add to the evidence of
an association between the household use of pesticides and
NB. Until a better study design can be found, our findings
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add yet another reason why to advise pregnant women to
limit pesticide exposure during the periconceptional period.
Keywords Neuroblastoma  Pesticides  Risk factors 
Childhood cancer  Case–control study
Abbreviations
ESCALE Etude Sur les Cancers et les Leuce´mies de
l’Enfant
ESTELLE Etude Sur les Tumeurs Embryonnaires,
Leuce´mies et Lymphomes de l’Enfant
MYCN N-myc proto-oncogene
NB Neuroblastoma
RNCE Registre National des Cancers de L’Enfant
SFCE Socie´te´ Franc¸aise de lutte contre les Cancers
de l’Enfant et de l’Adolescent
Introduction
Neuroblastoma (NB) is a malignant embryonal tumor of
the neural crest cells that occurs almost exclusively in
infancy and early childhood. Forty percent of NB cases are
diagnosed before the age of one year and 85% before the
age of five years [1].
The etiology of NB remains unknown. A genetic pre-
disposition of NB has been suggested after the observation
of rare familial cases (1% of NB cases) and a possible
association with congenital malformations [2, 3]. Consid-
erable progress has been made recently in the germ line and
somatic genetic characterisation of patients and tumors [4].
However, genetic predisposition cannot fully explain its
origin and other factors may be involved in NB develop-
ment [5].
Considerable evidence suggests that NB may be initi-
ated in utero during sympathoadrenal development [6]. The
undifferentiated stem cells from the neural crest progeni-
tors may persist in crest-derived tissues awaiting stimula-
tion or reactivation in response to environmental or cellular
cues [7]. Prenatal exposure to pesticides may be one such
risk factor. A possible association between pesticides and
NB was first suggested more than 30 years ago in relation
to exposures to chlordane or heptachlor [8], which are
active ingredients in many household and garden pesti-
cides. An association between pesticide exposure and NB
is plausible as more than 25 chemical compounds used in
pesticides have been classed as potential human carcino-
gens [9, 10]. In addition, previous studies have showed that
they pass through the placenta leading to fetal exposure
[11, 12].
Literature about the subject is scarce. Only two pre-
vious studies [13, 14] have shown associations between
NB and use of household pesticides during the
preconception period, pregnancy, or in early childhood.
Studies looking at parental occupational exposure to
pesticides are heterogeneous in exposure definition and in
findings. Some studies have suggested an increased risk of
NB with maternal occupational exposure to pesticides
during pregnancy [15] or at any time during the precon-
ception-pregnancy period or childhood [14, 16], while a
meta-analysis found no association with paternal occu-
pational exposure to pesticides at any time [17]. A large
cohort study [18] suggested an increased risk of NB in
offspring of farm holders, while a registry-based study
using geographic information [19] did not support an
association with residence exposure to pesticides related
to neighboring agricultural activities.
The aim of this study was to investigate whether the
maternal use of household pesticides during pregnancy was
associated with the risk of NB in her child. For these
analyses, we pooled data from two large case–control
studies, ESCALE and ESTELLE, which were conducted
by the same investigators in France.
Materials and methods
Study population
The ESCALE and ESTELLE studies have been descri-
bed in detail elsewhere [2]. Briefly, they were two
nationwide population-based case–control studies, which
were conducted with the support of the Socie´te´ Franc¸aise
de lutte contre les Cancers de L’Enfant et l’Adolescent
(SFCE).
The cases, which were directly identified from the
French national registry of childhood cancer (RNCE), were
children younger than 15 years old who lived in France at
the time they were newly diagnosed with cancer. The
ESCALE study included cases of NB, lymphoma, leuke-
mia, and malignant brain tumor diagnosed in 2003–2004.
The ESTELLE study included cases of NB, leukemia,
lymphoma, childhood brain tumor, Wilms’ tumor, and
hepatoblastoma diagnosed in 2010–2011.
Overall case participation rates were 81.2% for
ESCALE and 92.2% for ESTELLE. Information on the
MYCN amplification subtype was obtained subsequently
from the RNCE.
The population controls were children free from cancer
randomly selected from the French population using quota-
sampling methods who were recruited by telephone during
the same time periods. The participation rates were 71.2
and 85.5%, respectively.
In both studies, the cases and the controls were ineli-
gible if their biological mother was unavailable, did not
speak French, or had a serious psychosocial problem. In
1126 Cancer Causes Control (2017) 28:1125–1132
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addition, 22 cases, 9 out of 248 cases under 18 months
(3.6%) and 13 out of 252 cases aged 18 months or more
(5.2%), were not eligible to maternal interview for ethical
reasons because they had died or were in palliative care.
The present paper focuses on NB in children under six
years old (91.3% of cases).
Data collection
Trained interviewers conducted standardized telephone
interviews with the biological mothers of cases and con-
trols, which lasted approximately 50 min. The interviews
used similar scripts and were performed in the same con-
ditions in the two studies. They focused on socioeconomic
characteristics, prenatal and childhood environment expo-
sures, familial and personal medical history.
In regards to pesticide exposures during pregnancy, the
mother was asked if she used herbicides (‘‘weed killers’’),
fungicides, or insecticides (and whether they were used
indoors, for gardening or outdoors, or on pets). The mother
was also asked if she was exposed to any type of pesticides
in the workplace.
The ESTELLE study included additional questions
about maternal pesticide use in the three months prior to
conception and after birth, and whether there had been any
professional pest control treatments of the home.
Data analysis
Study-specific odds ratios (ORs) and pooled ORs and 95%
confidence intervals (95% CIs) were estimated by uncon-
ditional logistic regression (SAS version 9; SAS Institute
Inc., Cary, NC, USA). All the models included the study
matching factors: child’s age and gender, and, for the
pooled analyses, the indicator of the study of origin.
The socioeconomic variables tested as potential con-
founders were: maternal level of education, size of the
urban unit of residence, maternal age at child’s birth, birth
order, and the type of housing during pregnancy. We also
tested fetal growth, congenital malformations, and breast-
feeding that were significantly associated with NB in pre-
vious analyses [2]. In the final model, only maternal age,
birth order, size of the urban unit of residence, and the type
of housing were retained.
Between-study heterogeneity was systematically tested
by fitting an interaction term between the study and the
exposure of interest.
We performed additional analyses stratified by age at
diagnosis (\18 months/C18 months), MYCN status (am-
plified/non-amplified), urban/rural status of the area of
residence, and maternal level of education (less than bac-
calaureate/baccalaureate or higher).
Due to a small number of children with a congenital
malformation, possible confounding was accounted for by
excluding these children rather than by adjustment. Finally,
sensitivity analyses were also conducted in the ESTELLE
study by excluding the cases whose mother did not have a
landline at home since they could not have been selected as
controls (the information was not available in the ESCALE
study).
Results
The pooled analysis included 357 cases (174 from
ESCALE and 183 from ESTELLE) and 1,783 controls
(949 from ESCALE and 834 from ESTELLE) younger
than six years old (Table 1). Among cases, MYCN was
amplified in 17.9% (11% of the cases under 18 months of
age and in 25% of the older cases), non-amplified in 75.6%,
and non-informative in 6.4%.
Case–control comparability
In both studies the cases were more likely to be younger,
first born, to live in an urban area, and to have younger
mothers than the controls (Table 1).
Between-study heterogeneity
Control mothers in the ESTELLE study lived more often in
less populated areas and were more highly educated than
those in the ESCALE study (Table 1). They were also
more likely to have used pesticides at home (p\ 0.01)
(results not tabulated).
Pesticides use
Overall, maternal use of any pesticide during pregnancy
was reported for 43.7% of the cases and 35.7% of the
controls. Insecticides were the most commonly used
(40.6% of cases and 33.9% of the controls) and they were
mostly used alone. Their use was mainly reported indoors
(80.0% of insecticides use in cases and 81.0% in controls).
Mothers rarely used herbicides or fungicides and they often
also used insecticides.
The maternal use of any type of pesticide during preg-
nancy was associated with the risk of NB (OR 1.5 [95% CI
1.2–1.9]). There was a positive association with the use of
insecticides alone (OR 1.4 [95% CI 1.1–1.9]) or insecti-
cides with other pesticides (OR 2.0 [95% CI 1.1–3.4]).
There was no between-study heterogeneity except for
herbicide use (pooled OR 2.0 [95% CI 1.1–3.7]); ESCALE
(OR 3.8 [95% CI 1.8–8.0]); ESTELLE (OR 1.1 [95% CI
0.4–3.2]); p value for interaction = 0.07).
Cancer Causes Control (2017) 28:1125–1132 1127
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Maternal occupational pesticide exposure during preg-
nancy was associated with the risk of NB (OR 2.0 [95% CI
1.0–4.0), although the frequency of exposure was low
(3.6% of cases and 1.8% of controls) (data not tabulated).
The results were similar whether or not MYCN was
amplified (Table 2), and when the analyses were stratified
by age at diagnosis (Table 3). Among the controls, the
prevalence of pesticide use varied by urban/rural status, but
not by maternal level of education, and the results did not
change when stratification for either of these factors was
used instead of adjustment (Supplementary Table 1);
Table 1 Characteristics of the cases and controls of the ESCALE and ESTELLE studies
ESCALE (2003–2004) ESTELLE (2010–2011) POOLED
Cases
(n = 174)
Controls
(n = 949)
Cases
(n = 183)
Controls
(n = 834)
Cases
(n = 357)
Controls
(n = 1,783)
n % n % n % n % n % n %
MYCN status
Non-amplified 131 75.3 139 76.0 270 75.6
Amplified 34 19.5 30 16.4 64 17.9
Missing 9 5.2 14 7.6 23 6.4
Age (years)
\1 74 42.5 187 19.7 70 38.2 188 22.5 144 40.3 375 21.0
1 36 20.7 182 19.2 37 20.2 123 14.7 73 20.4 305 17.0
2 30 17.2 153 16.1 35 19.1 148 17.7 65 18.2 301 16.9
3 13 7.5 166 17.5 21 11.5 139 16.7 34 9.5 305 17.1
4 11 6.3 145 15.3 12 6.6 131 15.7 23 6.4 276 15.5
5 10 5.7 116 12.2 8 4.4 105 12.6 18 5.0 221 12.4
Sex
Boys 88 50.6 429 45.2 83 45.4 388 46.5 171 47.9 817 45.8
Girls 86 49.4 520 54.8 100 54.6 446 53.5 186 52.1 966 54.2
Birth order
1 89 51.1 402 42.4 91 49.7 345 41.4 180 50.4 747 41.9
2 or more 85 48.9 547 57.6 92 50.3 489 58.6 177 49.6 1,036 58.1
Maternal age at child’s birth (years)
\25 31 17.8 80 8.4 25 13.7 86 10.3 56 15.7 166 9.3
25–29 61 35.1 314 33.1 70 38.2 250 30.0 131 36.7 564 31.6
30–34 54 31.0 360 37.9 50 27.3 293 35.1 104 29.1 653 36.6
C35 28 16.1 195 20.5 38 20.8 205 24.6 66 18.5 400 22.4
Maternal education
\Baccalaureate 55 31.6 319 33.6 50 27.3 203 24.3 105 29.4 522 29.3
Baccalaureate 32 18.4 195 20.5 44 24.0 192 23.0 76 21.3 387 21.7
[Baccalaureate 87 50.0 435 45.8 88 48.1 439 52.6 175 49.0 874 49.0
Missing 0 0 0 0 1 0.5 0 0 1 0.3 0 0
Size of urban unit of residence (population)
\5,000 57 32.8 360 37.9 59 32.2 351 42.1 116 32.5 711 39.9
5,000–99.999 36 20.1 211 22.2 43 23.5 174 20.9 79 22.1 385 21.6
100.000–1.999.999 41 23.6 233 24.5 50 27.3 158 18.9 91 25.5 391 21.9
Paris unit 37 21.3 145 15.3 30 16.4 149 17.9 67 18.8 294 16.5
Missing 3 1.7 0 0 1 0.5 2 0.2 4 1.1 2 0.1
Type of housing during pregnancy
Apartment 78 44.8 379 39.9 77 42.1 324 38.8 155 43.4 703 39.4
House or farm 96 55.1 570 60.1 105 57.3 506 60.7 201 56.3 1,076 60.3
Missing 0 0 0 0 1 0.5 4 0.5 1 0.3 4 0.2
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Table 2 Maternal use of pesticides during pregnancy and risk of neuroblastoma
Controls
n = 1,783
All NB cases
n = 357
ORa 95% CI MYCN—
n = 270
ORa 95% CI MYCN ?
n = 64
ORa 95% CI
n % n % n % n %
Maternal use of any pesticides
None 1,112 62.4 198 55.5 1.0 Reference 155 57.4 1.0 Reference 32 50.0 1.0 Reference
Any pesticide 636 35.7 156 43.7 1.5 1.2–1.9 113 41.8 1.4 1.1–1.9 31 48.4 1.7 1.0–2.9
Any insecticide 604 33.9 145 40.6 1.5 1.1–1.9 105 38.9 1.4 1.1–1.9 28 43.7 1.6 0.9–2.7
Any herbicide 61 3.4 20 5.6 2.0 1.1–3.7 14 5.2 1.9 0.9–3.6 3 4.7 1.8 0.5–6.5
Any fungicide 50 2.8 14 3.9 1.6 0.8–3.1 7 2.6 1.1 0.5–2.6 6 9.4 4.3 1.6–11.5
Only insecticides 537 30.1 125 35 1.4 1.1–1.9 93 34.4 1.4 1.0–1.9 23 35.9 1.5 0.8–2.6
Only herbicides 13 0.7 5 1.4 1.5 0.4–4.8 5 1.8 1.9 0.6–6.2 0 0
Only fungicides 19 1.1 6 1.7 1.7 0.7–4.6 3 1.1 1.2 0.3–4.4 3 4.7 5.2 1.4–19.8
Insecticides ? other pesticides 67 3.8 20 5.6 2.0 1.1–3.4 12 4.4 1.6 0.8–3.1 5 7.8 2.4 0.9–6.8
Only herbicides and fungicides 0 0
Use of insecticides
Indoor use 489 27.4 116 32.5 1.5 1.1–2.0 81 30.0 1.4 1.0–1.9 25 39.1 1.8 1.0–3.1
Gardening and outdoor use 57 3.2 13 3.6 1.3 0.7–2.5 7 2.6 0.9 0.4–2.1 3 4.7 1.6 0.5–5.8
For pets 224 12.6 49 13.7 1.3 0.9–1.9 37 13.7 1.3 0.9–2.0 10 15.6 1.2 0.5–2.8
Missing 35 1.9 3 0.8 2 0.7 1 1.6
Pooled analyses of the ESCALE and ESTELLE studies
a Odds ratios (OR) and 95% confident intervals (CI) estimated by unconditional logistic regression models adjusted for children age and sex,
study, maternal age, birth order, size of the urban unit of residence, and type of housing during pregnancy
Table 3 Maternal use of pesticides during pregnancy and risk of neuroblastoma by age at diagnosis
Age\18 months Age C18 months
Cases Controls ORa 95% CI Cases Controls ORa 95% CI
n = 188 % n = 544 % n = 169 % n = 1,239 %
Maternal use of pesticides
None 114 60.6 369 67.8 1.0 Reference 84 49.7 743 59.9 1.0 Reference
Any pesticide 73 38.8 166 30.5 1.5 1.0–2.1 83 49.1 470 37.9 1.6 1.1–2.2
Any insecticide 65 34.6 155 28.5 1.4 0.9–2.0 80 47.3 449 36.2 1.6 1.1–2.3
Any herbicide 7 3.7 22 4.0 1.1 0.4–3.1 13 7.7 39 3.1 3.4 1.6–7.1
Any fungicide 5 2.7 15 2.8 1.0 0.3–3.3 9 5.3 35 2.8 2.3 1.0–5.1
Only insecticides 62 32.9 134 24.6 1.5 1.0–2.2 63 37.3 403 32.5 1.4 1.0–2.0
Only herbicides 4 2.1 7 1.3 1.4 0.3–5.9 1 0.6 6 0.5 1.6 0.2–14.7
Only fungicides 4 2.1 4 0.7 3.1 0.7–13.7 2 1.2 15 1.2 1.1 0.3–5.0
Insecticides ? other pesticides 3 1.6 21 3.9 0.5 0.1–1.9 17 10.0 46 3.7 3.4 1.8–6.5
Only herbicides and fungicides 0 0 0 0
Use of insecticide
Indoor use 50 26.6 121 22.2 1.5 1.0–2.2 66 39.0 368 29.7 1.6 1.1–2.3
Gardening and outdoor use 8 4.3 23 4.2 1.5 0.6–3.6 5 2.9 34 2.7 1.2 0.4–3.2
For pets 23 12.2 58 10.7 1.3 0.7–2.3 26 15.4 166 13.4 1.3 0.8–2.2
Missing 1 0.5 9 1.6 2 1.2 26 2.1
a Odds ratios (OR) and 95% confident intervals (CI) estimated by unconditional logistic regression models adjusted for children age and sex,
study, maternal age, birth order, size of the urban unit of residence, and type of housing during pregnancy
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neither did the exclusion of children with congenital mal-
formations change the results.
Maternal use of pesticides before and after pregnancy and
the use of professional pest control treatments at home were
not collected in the ESCALE study. In the ESTELLE study,
more than a quarter of the mothers reported pesticide use
during all three time periods (29.0% of the cases and 27.6%
of the controls) and very few mothers reported the use
during pregnancy only (6.0% of cases and 3.5% of controls).
This precluded specific analyses by time window.
No association was found with professional pest control
treatments at home during pregnancy (OR 1.2 [95% CI
0.5–2.8]) (data not tabulated).
Finally, in the ESTELLE study, the results were
unchanged in sensitivity analysis excluding the cases with
no telephone landline.
Discussion
Our findings suggest that the maternal use of pesticides
during pregnancy may be associated with an increased risk
of NB.
In a large US case–control study, Daniels et al. [13] also
reported modest associations (OR around 1.5) with the use
of pesticides at home or in the garden during the precon-
ception-pregnancy period or childhood. Consistent with
our findings, this study showed similar estimates irrespec-
tive of the MYCN status, which does not support the
potential for pesticides to act through different pathways in
the two subtypes. In that study, the estimates were stronger
among older children. Since the use of pesticides at home
may be associated with life-patterns, the stronger associa-
tions observed in older children may reflect the effect of
longer period of exposures to pesticides. Previous studies
have also suggested that different etiologic factors may be
specific to age at NB diagnosis [14, 20, 21]. Our study
found no difference by age for the most prevalent expo-
sures, pesticides and specifically insecticides. While there
was a suggestion of differences by age with the use of
herbicides and fungicides, this could be a chance finding
since based on small numbers, the confidence intervals in
the two groups overlapped substantially.
Another study conducted in Germany by Schu¨z et al.
[14] found an association between NB and the use of
household pesticides after the child’s birth, but did not
investigate pesticide exposure during pregnancy.
Consistent with our findings, associations between NB
and maternal occupational exposure to pesticides were
reported in two case–control studies in the USA [15, 16].
In a cohort study in Norway, an increased risk of NB was
observed in offspring of parents having worked in field
vegetable [18]. However, these findings should be
interpreted with caution since they are based on small
numbers. In two of these studies [16, 18], like in ours,
estimates were based on less than ten exposed cases and
could represent a chance finding. Literature on paternal
occupational exposure to pesticides is not supportive of an
association with NB as shown in a meta-analysis con-
ducted by Moore et al. [17]. A large Texan case–control
study estimated residential exposures to pesticides due to
neighboring agricultural activities and found no associa-
tion [19]. However, estimates were inconsistent between
low and high level of exposure and were based on less
than 15 exposed cases.
It is biologically plausible that maternal pesticide
exposure during pregnancy could be associated with the
risk of NB. Pregnancy represents a critical window of
exposure since some explanatory hypotheses suggest that
NB is initiated in utero during the sympathoadrenal
development from the neural crest [6]. It has been shown
that maternal exposure during pregnancy can lead to fetal
exposure since these compounds pass through the placenta
and can be found in cord blood, infant hair, and meconium
[11, 22]. The potential underlying mechanisms are still
unknown. Many pesticides are suspected to have different
mutagenic or immunotoxic properties and some individual
pesticides have been classed as ‘‘probable or possible
carcinogens’’ by the International Agency for Research on
Cancer [9, 10]. In addition, because of the similarity of
brain biochemistry, some insecticides that target the ner-
vous system of insects may also be neurotoxic to humans
[23]. However, in our study, because the use of pesticides
was correlated between time periods (preconception,
pregnancy, and childhood) we cannot identify pregnancy as
a true critical period of exposure. It is possible that patterns
of exposure are related to lifetime habits, which are nor-
mally consistent throughout the periconceptional period
and later in childhood.
A limitation of our study is that the majority of mothers
who reported any pesticide use (94%) actually used
insecticides, either alone or combined with herbicides or
fungicides, which limited our ability to investigate asso-
ciations with pesticides other than insecticides. In addition,
we could not identify the active ingredients in the products
used as in our study we only asked women about the cat-
egory of pesticide as we thought this would be recalled
with greater accuracy than the actual product name.
Commercial household pesticides often contain multiple
active ingredients, all which may have different properties
including potentially carcinogenic actions. In our study we
mainly focused on maternal use of pesticides at home.
However, the mothers may be exposed to other direct or
indirect sources of pesticides which we did not account for,
like the paternal use of household pesticides or other
sources of environmental exposure.
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As expected, the proportion of cases ineligible because
they had died or were receiving palliative care was smaller
under 18 months of age than for those aged 18 months or
more. This may have introduced a selection bias if age was
related to opportunity of pesticide exposure. However, the
age-stratified analyses did not provide evidence of sub-
stantial differences in the associations between NB and
maternal use of pesticides. As no information on exposure
was available on cases and controls that refused to partic-
ipate, we do not know if these children were comparable to
the study sample. To overcome these limitations, we
stratified our analysis for different factors that may have
been related to control participation to limit selection bias.
Finally, the study of pesticides exposure relied on
maternal self-report, which may involve both non-differ-
ential and differential bias. Because of the particular dis-
tribution of NB (52.7% of the cases younger than
18 months) the lapse of time between the exposure time
and the interview was short, which may have limited non-
differential measurement error, and which may not be the
case for other childhood cancers. In our study, trained
interviewers using highly structured questionnaires con-
ducted interviews with the aim of reducing potential dif-
ferential misclassifications. Despite this, it cannot be
excluded because case mothers may have tended to think
more deeply about their possible exposures than control
mothers. Previous studies have found consistency between
self-reported pesticide treatments and pesticides concen-
trations in dust [24] and that agreement about pesticides
exposure between parents did not differ by case–control
status [13], suggesting no differential recall based on
motivation of case parents. Furthermore, our findings
stratified by urban status were similar, despite differences
in the reported prevalence of pesticide use across these
strata.
Our studies also have several strengths. The ESCALE
and ESTELLE studies were designed to be pooled with
uniformly defined exposures, which facilitated the pooling
process, making this one of the largest investigations of NB
at present. In these population-based studies, the control
participation rate was high and the cases were identified
from a nationwide cancer registry, which has a high degree
of completeness.
In conclusion, this pooled analysis adds to the evidence
of an association between NB and maternal use of pesti-
cides during pregnancy, in household or occupation.
Because data were obtained retrospectively by question-
naire, recall bias is possible, particularly for domestic use.
Replication by other large epidemiological studies with
different designs is important. However, until a better study
design can be found, our findings add yet another reason
why to advise pregnant women to limit pesticide exposure
during the periconceptional period.
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Supplementary Table 1: Maternal use of pesticides during pregnancy and risk of 
neuroblastoma  – Pooled analyses of the ESCALE and ESTELLE studies stratified by 
socio-demographic characteristics. 
 
 
 Cases   Controls OR 95% CI  
  n %  n %   
Size of urban unit1 
            
 
 
<5000 inhabitants        
No use of 
pesticides 
63 54.3  414 58.2 1.0 Reference 
Any pesticide 52 44.8  284 39.9 1.3 0.8-1.9 
Any insecticide 50 43.1  271 38.1 1.3 0.8-1.9 
Missing 1 0.9  13 1.8   
        
≥5000 inhabitants        
No use of 
pesticides 
135 57.0  697 65.1 1.0 Reference 
Any pesticide 100 42.2  351 32.8 1.6 1.2-2.3 
Any insecticide 92 38.8  332 31.0 1.6 1.2-2.2 
Missing 2 0.8  22 2.1   
        
Maternal education2        
≤ Baccalaureate        
No use of 
pesticides 
81 44.5  325 35.7 1.0 Reference 
Any pesticide 99 54.4  566 44.5 1.5 1.1-2.2 
Any insecticide 76 41.8  309 34.0 1.5 1.0-2.2 
Missing 2 1.1  18 2.0   
        
> Baccalaureate        
No use of 
pesticides 
75 42.9  311 35.6 1.0 Reference 
Any pesticide 99 56.6  546 42.9 1.4 1.0-2.0 
Any insecticide 69 39.4  295 33.7 1.4 1.0-2.0 
Missing 1 0.6 
  17 1.9     
1
 Odds ratios (OR) and 95% confident intervals (CI) estimated by unconditional logistic regression 
models adjusted for age, sex, study, maternal age, birth order and type of housing during pregnancy. 
 
2
 OR and 95% CI estimated by unconditional logistic regression models adjusted for age, sex, study, 
maternal age, birth order, size of the urban unit of residence and type of housing during pregnancy. 
 
Parental smoking, maternal alcohol consumption during
pregnancy and the risk of neuroblastoma in children. A pooled
analysis of the ESCALE and ESTELLE French studies
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Neuroblastoma (NB) is the most common extra-cranial tumour in children. Little is known about the aetiology of NB. The early age at
onset and the embryonic nature suggest a role for perinatal exposures. We conducted a pooled analysis of two French national
population-based case–control studies to explore whether there was an association between parental smoking and alcohol
consumption and the risk of NB. The mothers of 357 NB cases and 1,783 controls from general population, frequency matched by
age and sex, were interviewed on demographic, socioeconomic and perinatal characteristics, maternal reproductive story, and life-
style and childhood environment. Unconditional logistic regression was used to estimate pooled odds ratios and 95% confidence
intervals. A meta-analysis of our findings with those of previous studies was also conducted. Maternal smoking during pregnancy
was slightly more often reported for the cases (24.1%) than for the controls (19.7%) (OR 1.3 [95% CI 0.9–1.7]; summary OR from
meta-analysis 1.1 [95% CI 1.0–1.3]. Paternal smoking in the year before child’s birth were not associated with NB as independent
exposure (OR 1.1 [95% CI 0.9–1.4] but the association was stronger when both parents reported having smoked during pregnancy
(OR 1.5 [95% CI 1.1–2.1]. No association was observed with maternal alcohol intake during pregnancy (OR 1.0 [95% CI 0.8–1.4],
summary OR from meta-analysis 1.0 [95% CI 0.9–1.2]. Our findings provide some evidence of an association between maternal
smoking during pregnancy and NB and add another reason to recommend that women refrain from smoking during pregnancy.
Introduction
Neuroblastoma (NB) is a malignant tumour that arises from
the embryonal neural crest cells during the sympathetic ner-
vous system development. It is the most common diagnosed
cancer during infancy and the majority of cases are diagnosed
before the age of 5 years.1 The trademark of NB is its clinical
heterogeneity characterised by contrasted patterns of progno-
sis and clinical behaviour. Younger children at diagnosis have
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better survival rates and less often overexpress the MYCN
oncogene.2 MYCN amplification is a genetic aberration that
occurs in about 20% of primary tumours and it is one of the
strongest independent adverse prognostic factors.
Little is known about the aetiology of NB. In rare cases,
neuroblastoma can occur in a context of malformation syn-
dromes (like Hirschsprung’s disease). NB might also occur in
the context of genetic predisposition, with constitutional
mutations in ALK or PHOXB having been reported.3 The
early onset of NB after birth and its embryonal characteristics
suggest a role of perinatal factors and environmental expo-
sures during the periconceptional period. Tobacco smoke and
alcohol consumption are of interest as potential risk factors as
the International Agency on Research on Cancer has classed
tobacco smoke and its metabolites as proven carcinogens to
humans (Group 1).4,5 Tobacco smoke is a human germ cell
mutagen and its compounds also can cross the placenta lead-
ing to foetal exposure.6 Teratogen and carcinogenic effects
have also been shown with regards to alcohol consumption.5
Previous studies have shown associations between maternal
smoking or alcohol consumption during pregnancy and the risk
of childhood cancer, however only a small number addressed
NB.7–19 The studies on NB and maternal smoking, which mainly
had less than 200 cases were included in two recent meta-ana-
lyses20,21 which suggested a positive association between maternal
smoking during pregnancy and NB. In an effort to improve pre-
cision, we pooled data from two nationwide case–control studies
conducted in France by the same investigators. The aim of these
analyses was to evaluate if there was an association between
parental smoking, maternal alcohol consumption during preg-
nancy and the risk of NB.
Methods
The ESCALE and ESTELLE studies were two separate nation-
wide population-based case–control studies conducted by the
same investigators in France. The study designs have been pre-
viously described elsewhere.22 Both studies included cases of
NB, lymphoma, leukaemia and malignant brain tumour. The
ESTELLE study additionally included cases of Wilm’s tumour,
hepatoblastoma and non-malignant brain tumours. This article
focuses on NB.
Study population
The cases were children, younger than 15 years old who were
living in mainland France and were diagnosed with a childhood
cancer in 2003–2004 (ESCALE) and 2010-2011(ESTELLE).
Eligible cases were directly identified from the French
National Registry of Childhood Cancer (RNCE). The defini-
tion of a case was any child diagnosed with NB (Group 4 of
the International Classification of Childhood Cancer Third
edition).23 Ineligible cases were those who had died or were
receiving palliative care (n = 22) and those whose biological
mother were not available (orphans and adopted children),
could not speak French (n = 21) or had major psychosocial
problems (n = 5). Information on the MYCN amplification
subtype was obtained subsequently from the RNCE.
Controls were recruited by telephone and the methods have
been previously described in detail.24 They were children free
from cancer randomly selected from the general French popu-
lation and frequency matched by sex and age. Quota-sampling
methods were applied to ensure the sample was representative
of children aged less than 15 years. Like cases, controls were
ineligible if the biological mother was not available for inter-
view or did not speak French.
Because of the particular age distribution of NB cases, the
present paper focuses on NB in children under 6 years old
(91.3% of cases).
Data collection
Data were collected from the biological mothers of cases and
controls by trained interviewers using computer assisted tele-
phone interviews. The interview included questions on socio-
demographic characteristics, prenatal and childhood environment
exposures, familial and personal medical history.
In both studies, the mothers were asked whether they had
smoked cigarettes during the pregnancy with the index child,
and if yes, their average daily consumption. They were asked
the same questions with regards to the paternal consumption
of cigarettes. The ESTELLE study included additional ques-
tions about their smoking habits in the 3 months before the
pregnancy and in each trimester of pregnancy. A convenience
subset of ESTELLE fathers was also interviewed about their
smoking habits in order to validate the maternal responses
about paternal exposures24. Mothers were asked about alcohol
consumption (wine, beer/cider, and spirits) during pregnancy
and to quantify their consumption if applicable. In the Estelle
study, they were also asked specifically about consumption in
the first trimester.
Data management
Maternal and paternal tobacco smoking were analysed as
dichotomous variables (ever/never) and also as quantitative
What’s new?
Neuroblastoma strikes early in life, which suggests an influence from risk factors that occur before birth. Here, the authors
looked at parental smoking and alcohol drinking in a large population sample in France. Cases were collected by a nationwide
registry, so the sample was very complete, and included 357 cases of neuroblastoma. The analysis revealed no association
between maternal alcohol drinking and the cancer, nor between neuroblastoma and paternal smoking. They did identify a
slight positive association with maternal smoking, and the effect was stronger if both parents smoked.
2 Parental smoking, alcohol consumption and risk of neuroblastoma
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variables depending on the reported quantity of cigarettes.
Cigarettes smoked per day were grouped in three categories
based on the tertiles among control parents who smoked.
The cut-offs were: nil; <5; 5–9 and ≥10 cigarettes per day
(CPD) for mothers and nil; <10; 10–15 and >15 CPD for
fathers.
For ESTELLE mothers, we also analysed the tobacco expo-
sures by time window (three months before the index preg-
nancy and for each trimester of pregnancy). Finally, the joint
effect of maternal and paternal smoking was analysed (neither
parent, only mother, only father, both).
Alcohol consumption was examined in different forms: a
dichotomous variable (ever/never), a quantitative variable
(cut-offs defined a priori as following: nil, <1, 1–2 or >2
glasses per week), and by type (wine, beer or cider, spirits).
Statistical analyses
The odds ratios (OR) and their 95% confidence intervals (95%
CI) were estimated using unconditional logistic regression
models (SAS software; version 9; SAS Institute Inc., Cary,
NC, USA).
All the analyses were adjusted for the matching variables
age and sex, and for the study of origin. We tested the follow-
ing factors to see if they met the empirical criteria for con-
founding (i.e. if they were independently associated with the
exposure and the outcome): maternal age, paternal age, and
maternal education, degree of urbanisation of the area of resi-
dency, birth-weight and birth-order. Only maternal age was
retained in the final model. All the analyses on maternal and
paternal smoking were mutually adjusted. The number of ciga-
rettes smoked per day (CPD) was also analysed as continuous
Table 1. Characteristics of the cases and controls of the ESCALE and ESTELLE studies
ESCALE (2003–2004) ESTELLE (2010–2011) POOLED
Cases Controls Cases Controls Cases Controls
(n = 174) (n = 949) (n = 183) (n = 834) (n = 357) (n = 1,783)
N % N % N % N % N % N %
MYCN status
Non-amplified 131 75.3 139 76.0 270 75.6
Amplified 34 19.5 30 16.4 64 17.9
Missing 9 5.2 14 7.6 23 6.4
Age (years)
<1 74 42.5 187 19.7 70 38.2 188 22.5 144 40.3 375 21.0
1 36 20.7 182 19.2 37 20.2 123 14.7 73 20.4 305 17.0
2 30 17.2 153 16.1 35 19.1 148 17.7 65 18.2 301 16.9
3 13 7.5 166 17.5 21 11.5 139 16.7 34 9.5 305 17.1
4 11 6.3 145 15.3 12 6.6 131 15.7 23 6.4 276 15.5
5 10 5.7 116 12.2 8 4.4 105 12.6 18 5.0 221 12.4
<18 months 93 53.4 283 29.8 95 51.9 261 31.3 188 52.7 544 30.5
≥18 months 81 46.5 666 70.2 88 48.1 573 68.7 169 47.3 1,239 69.5
Maternal age at child’s birth (years)
<25 31 17.8 80 8.4 25 13.7 86 10.3 56 15.7 166 9.3
25–29 61 35.1 314 33.1 70 38.2 250 30.0 131 36.7 564 31.6
30–34 54 31.0 360 37.9 50 27.3 293 35.1 104 29.1 653 36.6
≥35 28 16.1 195 20.5 38 20.8 205 24.6 66 18.5 400 22.4
Maternal education
<Baccalaureate 55 31.6 319 33.6 50 27.3 203 24.3 105 29.4 522 29.3
Baccalaureate 32 18.4 195 20.5 44 24.0 192 23.0 76 21.3 387 21.7
>Baccalaureate 87 50.0 435 45.8 88 48.1 439 52.6 175 49.0 874 49.0
Missing 0 0 0 0 1 0.5 0 0 1 0.3 0 0
Size of urban unit of residence (population)
<5,000 57 32.8 360 37.9 59 32.2 351 42.1 116 32.5 711 39.9
5,000–99.999 36 20.1 211 22.2 43 23.5 174 20.9 79 22.1 385 21.6
100.000–1.999.999 41 23.6 233 24.5 50 27.3 158 18.9 91 25.5 391 21.9
Paris unit 37 21.3 145 15.3 30 16.4 149 17.9 67 18.8 294 16.5
Missing 3 1.7 0 0 1 0.5 2 0.2 4 1.1 2 0.1
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variable for an increase of 5 CPD for mothers and 10 CPD for
fathers.
We systematically tested between-study heterogeneity by fit-
ting an interaction term between the study and the exposure of
interest and we explored the differences of each of the key
exposure variables by study among the controls to see if there
had been changes in parental behaviours between the study
time periods. Because the findings by individual studies were
similar, only the results for the pooled analyses are presented in
this paper.
The tests for trend were computed for each quantitative
variable of interest (number of cigarettes per day and number
of glasses of alcohol per week). First, the deviation from line-
arity was tested by a likelihood ratio test, comparing the
model with the newly generated quantitative variable, where
subjects in each class of the categorical variables were assigned
the median value of that class, to the full model with the cate-
gorical variable. If linearity was not rejected, the p value of the
trend was determined by testing the slope of the quantitative
variable using a Wald-test.
Additional analyses were conducted among subgroups of
NB defined by age at diagnosis (<18 months/ ≥18 months)
and by tumour MYCN oncogene amplification status (MYCN- /
MYCN+), which are established clinically relevant entities.
Polytomus logistic regression was used to estimate ORs by NB
MYCN status.
Sensitivity analyses were conducted excluding cases whose
families did not have a landline since controls were recruited
from a sample of landline telephone numbers (data only col-
lected for the ESTELLE study).
We then conducted a meta-analysis of our findings on
maternal smoking and alcohol consumption during pregnancy
with published findings of relevant previous studies performed
flowing the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (see Supporting Infor-
mation Material 1: Systematic Review study protocol and find-
ings). We searched PubMed and Embase for original studies
published from inception to October 2018. We used random
effects, precision-based weighting to calculate the summary OR
with our results. Statistical heterogeneity between studies was
assessed using the Cochrane Q test. We assessed publication bias
via inspection of the funnel plot and formal testing for funnel
plot asymmetry using Egger’s test.
Results
The study included 357 NB cases younger than 6 years
(174 from ESCALE and 183 from ESTELLE) and 1,783 controls
(949 from ESCALE and 834 from ESTELLE). The proportion
of cases and controls aged less than 18 months was 53 and
30%, respectively (Table 1). MYCN was amplified in 11% of
the cases younger than 18 months at diagnosis and 25% of the
older cases.
Case–control comparability
Because the control sampling was performed in both studies
to enable analyses of multiple childhood cancer diagnoses, the
NB cases were younger than the controls (Table 1). There
were at least two controls for each case in each age stratum.
The cases had younger mothers and were more often living in
an urban area than the controls.
Parental smoking
Maternal smoking during pregnancy was slightly more often
reported for the cases (24.1%) than for the controls (19.7%),
Table 3. Association between neuroblastoma and maternal alcohol consumption during pregnancy
Cases (n = 357) Controls (n = 1,783)
OR [95% CI]N % N %
Maternal alcohol drinking during pregnancy
Never 268 75.1 1,293 72.5 Reference
Ever 88 24.6 490 27.2 1.0 [0.8–1.4]
Missing 1 0.3 0
Glasses per week
None 268 75.1 1,293 72.5 Reference
<1 50 14 225 12.6 1.1 [0.8–1.6]
1–2 12 3.4 110 6.2 0.6 [0.3–1.2]
>2 22 6.2 143 8.0 1.0 [0.6–1.6]
4 1.1 12 0.7
Types of alcohol
Wine 54 15.1 330 18.5 0.9 [0.6–1.3]
Beer or cider 34 9.5 167 9.4 1.2 [0.8–1.9]
Spirits 31 8.7 189 10.6 0.8 [0.5–1.2]
Pooled analysis of the ESCALE and ESTELLE studies.
Odd ratio (OR) and 95 confident intervals (95% CI) estimated by unconditional logistic regression adjusted for age, sex, maternal age and study of
origin.
Rios et al. 5
Int. J. Cancer: 00, 00–00 (2019) © 2019 UICC
C
an
ce
r
E
p
id
em
io
lo
g
y
T
a
b
le
4
.
C
h
a
ra
ct
e
ri
st
ic
s
o
f
st
u
d
ie
s
in
cl
u
d
e
d
in
m
e
ta
-a
n
a
ly
se
s
o
f
m
a
te
rn
a
l
sm
o
k
in
g
a
n
d
a
lc
o
h
o
l
co
n
su
m
p
ti
o
n
d
u
ri
n
g
p
re
g
n
a
n
cy
a
n
d
ri
sk
o
f
n
e
u
ro
b
la
st
o
m
a
S
tu
d
y
C
a
se
s
a
n
d
co
n
tr
o
ls
se
le
ct
io
n
M
a
te
rn
a
l
co
n
su
m
p
ti
o
n
d
u
ri
n
g
p
re
g
n
a
n
cy
(e
ve
r/
n
e
ve
r)
A
u
th
o
r,
co
u
n
tr
y,
C
a
se
s
C
o
n
tr
o
ls
S
m
o
k
in
g
A
lc
o
h
o
l
d
ri
n
k
in
g
ye
a
r
o
f
ca
se
a
cc
ru
a
l
S
o
u
rc
e
n
S
o
u
rc
e
n
C
ru
d
e
O
R
A
d
ju
st
e
d
O
R
[9
5
%
C
I]
C
ru
d
e
O
R
A
d
ju
st
e
d
O
R
[9
5
%
C
I]
M
a
tc
h
e
d
fa
ct
o
rs
/A
d
ju
st
m
e
n
ts
[9
5
%
C
I]
1
[9
5
%
C
I]
1
D
a
ta
o
b
ta
in
e
d
b
y
re
co
rd
li
n
k
a
g
e
Jo
h
n
so
n
e
t
a
l.
,2
0
0
8
[9
]
C
a
n
ce
r
R
e
g
is
tr
y
1
5
5
B
ir
th
R
e
g
is
tr
y
8
,7
5
2
1
.4
[0
.9
–
2
.2
]
1
.4
[0
.9
–
2
.3
]
1
.1
[0
.4
–
3
.5
]
-
Ye
a
r
o
f
b
ir
th
,
se
x
U
S
A
(1
9
7
6
–
2
0
0
4
)
M
in
n
e
so
ta
st
a
te
C
h
o
w
e
t
a
l.
,
2
0
0
3
[1
3
]
C
a
n
ce
r
R
e
g
is
tr
y
2
4
0
B
ir
th
R
e
g
is
tr
y
2
,4
0
0
0
.8
[0
.6
–
1
.2
]
0
.8
[0
.6
–
1
.2
]
-
-
Ye
a
r
o
f
b
ir
th
,
se
x/
g
e
st
a
ti
o
n
a
l
a
g
e
,
b
ir
th
w
e
ig
h
t,
p
a
re
n
ta
l
a
g
e
,
e
th
n
ic
it
y,
m
a
te
rn
a
l
re
si
d
e
n
ce
U
S
A
(1
9
8
0
–
1
9
9
2
)
W
a
sh
in
g
to
n
st
a
te
M
cL
a
u
g
h
li
n
e
t
a
l.
,
2
0
0
9
C
a
n
ce
r
R
e
g
is
tr
y
5
2
9
B
ir
th
R
e
co
rd
s
1
2
,0
1
0
-
1
.0
[0
.7
–
1
.3
]
-
1
.2
[0
.5
–
2
.6
]
D
a
te
o
f
b
ir
th
,
se
x
U
S
A
(1
9
8
5
–
2
0
0
1
)
[1
2
]
N
e
w
Yo
rk
st
a
te
S
ta
vr
o
u
e
t
a
l.
,
2
0
0
9
[1
7
]
C
a
n
ce
r
R
e
g
is
tr
y
1
2
2
M
id
w
iv
e
s
d
a
ta
co
ll
e
ct
io
n
1
,0
4
5
,9
6
6
0
.8
[0
.5
–
1
.3
]
1
.0
[0
.6
–
1
.7
]
-
-
C
h
il
d
re
n
a
g
e
a
n
d
se
x,
m
a
te
rn
a
l
a
g
e
,
b
ir
th
w
e
ig
h
t,
g
e
st
a
ti
o
n
a
l
a
g
e
,
so
ci
o
e
co
n
o
m
ic
s,
m
a
te
rn
a
l
h
yp
e
rt
e
n
s
io
n
,
g
e
st
a
ti
o
n
a
l
d
ia
b
e
te
s,
p
re
e
cl
a
m
p
si
a
A
u
st
ra
li
a
,
(1
9
9
4
–
2
0
0
5
)
N
e
w
S
o
u
th
W
a
le
s
H
e
ck
e
t
a
l.
,
2
0
1
6
[1
9
]
C
a
n
ce
r
R
e
g
is
tr
y
2
3
8
B
ir
th
ce
rt
ifi
ca
te
s
4
0
,3
5
6
1
.1
[0
.5
–
2
.4
]
1
.2
[0
.5
–
2
.5
]
-
-
Ye
a
r
o
f
b
ir
th
/
m
a
te
rn
a
l
e
th
n
ic
it
y,
m
a
te
rn
a
l
e
d
u
ca
ti
o
n
U
S
A
(2
0
0
7
–
2
0
1
3
)
C
a
li
fo
rn
ia
st
a
te
D
a
ta
o
b
ta
in
e
d
b
y
In
te
rv
ie
w
K
ra
m
e
r
e
t
a
l.
,
1
9
8
7
[7
]
C
a
n
ce
r
R
e
g
is
tr
y
9
3
G
e
n
e
ra
l
p
o
p
u
la
ti
o
n
(R
D
D
)
9
3
1
.3
[0
.8
–
2
.1
]
1
.4
[0
.9
–
2
.2
]
D
a
te
o
f
b
ir
th
,
ra
ce
,
a
re
a
co
d
e
,
U
S
A
(1
9
7
0
–
1
9
7
9
)
G
re
a
t
D
e
la
w
a
re
va
ll
e
y
B
u
ck
e
t
a
l.
,
2
0
0
1
[8
]
C
a
n
ce
r
R
e
g
is
tr
y
1
5
5
B
ir
th
R
e
g
is
tr
y
3
1
0
1
.3
[0
.8
–
2
.1
]
1
.4
[0
.9
–
2
.1
]
1
.2
[0
.8
–
1
.9
]
1
.2
[0
.8
–
1
.9
]
Ye
a
r
o
f
b
ir
th
,
p
a
ri
ty
,
m
a
te
rn
a
l
a
g
e
,
sm
o
k
in
g
a
n
d
a
lc
o
h
o
l
co
n
su
m
p
ti
o
n
U
S
A
(1
9
7
6
–
1
9
8
7
)
N
e
w
Yo
rk
st
a
te
S
o
ra
h
a
n
e
t
a
l.
,
1
9
9
4
C
a
n
ce
r
R
e
g
is
tr
y
9
3
B
ir
th
R
e
g
is
tr
y
9
3
-
1
.0
[0
.8
–
1
.3
]
-
-
D
a
te
o
f
b
ir
th
,
se
x
U
K
(1
9
7
7
–
1
9
8
1
)
[1
0
]
S
ch
w
a
rt
zb
a
u
m
e
t
a
l.
,
1
9
9
2
[1
1
]
H
o
sp
it
a
l
C
a
n
ce
r
R
e
g
is
tr
y
1
0
1
H
o
sp
it
a
l
C
a
n
ce
r
R
e
g
is
tr
y
6
9
0
-
1
.9
[1
.1
–
3
.2
]
-
0
.7
[0
.4
–
1
.1
]
A
g
e
,
ra
ce
,
m
a
te
rn
a
l
a
g
e
,
so
ci
a
l
cl
a
ss
,
e
xp
o
su
re
to
x-
ra
y,
m
is
ca
rr
ia
g
e
,
o
th
e
rs
(n
o
t
sp
e
ci
fi
e
d
)
U
S
A
(1
9
7
9
–
1
9
8
6
)
S
ch
u
z
e
t
a
l.
,
2
0
0
1
[1
4
]
C
a
n
ce
r
R
e
g
is
tr
y
1
8
3
R
e
si
d
e
n
ts
d
a
ta
b
a
se
1
,7
8
5
1
.4
[1
.0
–
1
.9
]
-
0
.9
[0
.6
–
1
.3
]
-
a
g
e
,
se
x,
ye
a
r
o
f
b
ir
th
/S
E
S
,
d
e
g
re
e
o
f
u
rb
a
n
is
a
ti
o
n
G
e
rm
a
n
y
(1
9
8
8
–
1
9
9
3
)
P
a
n
g
e
t
a
l.
,
2
0
0
3
[1
5
]
C
a
n
ce
r
R
e
g
is
tr
y
1
8
8
Fa
m
il
y
H
e
a
lt
h
S
e
rv
ic
e
s
d
a
ta
b
a
se
6
,9
8
7
-
0
.9
[0
.6
–
1
.3
]
-
-
a
g
e
,
se
x,
p
a
re
n
ta
l
a
g
e
,
d
e
p
ri
va
ti
o
n
sc
o
re
U
K
(1
9
9
2
–
1
9
9
4
)
(C
o
n
ti
n
u
e
s)
6 Parental smoking, alcohol consumption and risk of neuroblastoma
Int. J. Cancer: 00, 00–00 (2019) © 2019 UICC
C
an
ce
r
E
p
id
em
io
lo
g
y
with an OR of 1.3 [95% CI 0.9–1.7] (Table 2). There was no
trend with the average number of cigarettes smoked per day
(OR for 5 CPD increase was 1.1 [95% CI 1.0–1.3]). The prev-
alence of smoking among mothers was similar between the
ESCALE and ESTELLE studies. In the ESTELLE study, most
of the mothers that reported having smoked during preg-
nancy started before conception and smoked during the whole
pregnancy. Maternal smoking before and during pregnancy
were highly correlated which precluded specific analysis by
time window (Spearman’s rho =0.69).
Paternal tobacco consumption during pregnancy was not
associated with the risk of NB as an independent exposure
(OR 1.1 [95% CI 0.9–1.4], but having both parents reported
as having smoked during pregnancy was associated with NB
(OR 1.5 [95% CI 1.1–2.1]) (Table 2). The maternal average
daily consumption of cigarettes did not differ significantly
according to whether only the mother or both parents were
reported smokers (mean 5.7 CPD vs. 6.1 CPD, respectively).
However, the percentage of mothers who smoked was higher
when the fathers also smoked (34.4 vs. 10%, results not tabu-
lated). The associations seemed to be only present among
children younger than 18 months (OR 1.4 [95% CI 0.9–2.2])
vs. (OR 1.1 [95% CI 0.7–1.7]) among older children, but
interaction with age was not significant (p-value for interac-
tion 0.4). Although based on small numbers, the analyses did
not reveal differences by MYCN status (Table 2).
Maternal alcohol consumption
Maternal alcohol consumption during pregnancy was not
associated with the risk of NB (OR 1.0 [95% CI 0.8–1.4]
(Table 3). There was not interaction between maternal smok-
ing and alcohol consumption (p-value = 0.4). The results were
similar with regards to different types of beverages and there
was no increasing risk with increasing alcohol consumption
or differences by age at diagnosis or MYCN status.
Compared to the ESCALE study, fewer controls mothers
reported alcohol intake during pregnancy in the ESTELLE
study (34 vs. 20%; p-value <0.01).
Sensitivity analyses
Results remain unchanged in sensitivity analysis performed
for the ESTELLE study excluding case children with no land-
line phone (see Supporting Information Table S1).
Meta-analysis
We identified 13 studies that provided data on maternal
smoking during pregnancy and seven of then also presented
data on maternal alcohol consumption. Their details and
main findings are summarised in Table 4.
The summary OR for maternal smoking during pregnancy
was 1.1 [95% CI 1.0–1.3] (Fig. 1). Between-study heterogene-
ity was low (I2 = 17.3%). The funnel plot did not provide any
evidence of publication bias and Egger test was not significant
(p-value = 0.2).Ta
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Figure 1. Forest plot of studies related to maternal smoking and neuroblastoma. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2. Forest plot of studies related to maternal alcohol consumption and neuroblastoma. [Color figure can be viewed at
wileyonlinelibrary.com]
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The analyses did not suggest any association between mater-
nal alcohol consumption during pregnancy and neuroblastoma,
with a summary OR of 1.0 [95% CI 0.9–1.2] (Fig. 2).
Discussion
The main finding of the ESCALE and ESTELLE studies was
the slight positive association between maternal smoking during
pregnancy and the risk of NB. By contrast, no association with
maternal alcohol consumption or paternal smoking around
pregnancy was observed. Findings are consistent between the
ESCALE and ESTELLE studies with regards to overall analysis
and also subgroup analysis by MYCN status and age at
diagnosis.
Our meta-analysis also suggested a slight but significant asso-
ciation between NB and maternal smoking during pregnancy.
This is consistent with the two previous meta-analyses by Chu
et al.21 (OR = 1.3 [95% CI 1.0–1.6]) and Müller-Schulte et al.20
(OR = 1.2 [95% CI 1.0–1.4]), which included almost the same
studies. Our meta-analysis adds nearly 500 cases from a recent
Australian study17 and the ESCALE and ESTELLE studies.
Given the rarity of NB, case–control is the most feasible
design. While there is potential risk of measurement error
with self-report, this may not be a major problem in the pre-
sent context where the delay between exposure and interview
is short. A Swedish validation study performed by Mattson
et al.25 found high level of agreement between mothers’ self-
reported smoking habits during pregnancy and their levels of
serum cotinine.
Our study is the first to report stratified analysis by age at
diagnosis and that the association with maternal smoking dur-
ing pregnancy seemed to be stronger among younger children.
These findings should be interpreted with caution given the
small numbers and overlapping on the confident intervals.
However, further investigation on these differences is needed
given the clinical heterogeneity of NB at different ages, which
could indicate differences in the aetiology. MYCN status was
also accounted for by Yang et al.16, whose findings were consis-
tent with ours, which does not support the potential for mater-
nal smoking to act through different pathways in the two
subtypes.
Paternal tobacco smoking has been shown to be associated
with increases in DNA damage, aneuploidies, and mutations
in sperm and may act as a human germ cell mutagen.26
Despite this, our study did not support the link between
paternal smoking around pregnancy and the risk of NB as did
two previous studies.15,16 In our study, paternal smoking was
assessed through the maternal report of the father’s tobacco
consumption and we cannot exclude misclassification bias.
However, the extent of the bias is limited since in the subset
used for validation, agreement between maternal and paternal
responses was high with regards to both ever smoking and
number of cigarettes smoked per day.24,27
The meaning of the apparent stronger association between
maternal smoking and NB when both parents smoked is still
unclear. We first hypothesised that when both parents smoked
the mothers may have been heavier smokers, but there was no
difference with regards to the quantity of cigarettes smoked
per day. However, the prevalence of tobacco consumption was
higher among mothers when the fathers also smoke. Yang
et al.16 also found stronger association when both parents
smoked (OR 1.3 [95% CI 0.9–2.0]) compared to only mothers
(OR 1.1 [95% CI 0.8–1.4].
Consistent with our findings, previous studies did not sup-
port the link between maternal alcohol intake during preg-
nancy and NB.8,9,11,16,17
Our study has several strengths. Since the ESCALE and
ESTELLE studies were designed to be pooled, with uniformly
defined exposures, this is one of the largest studies of NB at
present. Cases were ascertained by a nationwide cancer regis-
try, which has a high degree of completeness. The overall par-
ticipation rate of the controls was high (77% of eligible
controls) and we also adjusted our analysis for factors that
might be associated with control participation.
However, our study has the same limitations as all case–
control interview-based studies, with an inherent risk of selec-
tion and recall bias. Although there is potential for selection
bias, the prevalence of reported smoking among control par-
ents appears to be representative of the source population,
both in terms of the prevalence and time trends among
women and men of similar ages in the Perinatal National sur-
veys conducted during the same time periods.28
We attempted to reduce recall bias by the use of computer-
assisted standardised interviews conducted by trained inter-
viewers. This may not totally prevent mothers of cases thinking
more deeply and reporting the exposures more frequently than
control mothers. However, the opposite may also be possible.
Deleterious effects of smoking and alcohol consumption during
pregnancy are well known and case mothers may under-report
such behaviour. However, a recent validation study found high
level of agreement between self-reported data on smoking dur-
ing pregnancy and medical records.29
In conclusion, our findings provide some evidence of an
association between maternal smoking during pregnancy
and NB. These findings are consistent with literature and
add another reason to recommend that women refrain from
smoking during pregnancy.
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SUPPLEMENTARY MATERIAL 
Parental smoking, maternal alcohol consumption during pregnancy 
and the risk of neuroblastoma in children: Systematic Review and 
Meta-analyses 
 
METHODS 
This systematic review and meta-analysis was performed following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
(Table 1).  Please note that the Table and Figure numbering refers to material included 
in this document and does not refer to material presented in the main paper.    
 
Search Strategy 
The main author (PR) worked in study selection, data abstraction and assessment of 
study quality of the systematic review process. In case of doubts about study 
inclusions or estimates extraction, these were discussed with co-authors (JC and HB).  
The Medline and Embase database were searched from inception to October 2018 
using the following combination of appropriate key words in a search algorithm: 
(Maternal exposure OR prenatal exposure OR perinatal exposure OR perinatal 
characteristics OR perinatal risk factors OR prenatal risk factors OR risk factors OR 
exposure during pregnancy OR parental exposure OR smoking OR tobacco OR air 
toxics OR alcohol consumption OR maternal smoking OR parental smoking) AND 
(childhood cancer OR neuroblastoma OR risk of neuroblastoma) NOT neuroblastoma 
cells.  
Studies were included if they were published in English, French or Spanish. In 
addition, all references cited in original studies and reviews were manually searched.
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at it co
u
ld
 b
e 
rep
eated
.  
#
2
 S
M
 
S
tu
d
y
 selectio
n
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S
tate th
e p
ro
cess fo
r selectin
g
 stu
d
ies (i.e., screen
in
g
, elig
ib
ility
, in
clu
d
ed
 in
 sy
stem
atic rev
iew
, an
d
, if 
ap
p
licab
le, in
clu
d
ed
 in
 th
e m
eta
-an
aly
sis).  
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M
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n
 p
ro
cess  
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D
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o
d
 o
f d
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n
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o
rts (e.g
., p
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ted
 fo
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ep
en
d
en
tly
, in
 d
u
p
licate) an
d
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y
 
p
ro
cesses fo
r o
b
tain
in
g
 an
d
 co
n
firm
in
g
 d
ata fro
m
 in
v
estig
ato
rs.  
#
1
 #
6
 S
M
 
D
ata item
s  
1
1
 
L
ist an
d
 d
efin
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h
ich
 d
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u
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t (e.g
., P
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O
S
, fu
n
d
in
g
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u
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d
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y
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m
p
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n
s an
d
 
sim
p
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n
s m
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e.  
#
 5
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D
 
R
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f b
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2
 
D
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d
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g
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f b
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d
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u
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d
ies (in
clu
d
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g
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h
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w
as d
o
n
e at th
e stu
d
y
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u
tco
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d
 h
o
w
 th
is in
fo
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atio
n
 is to
 b
e u
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 an
y
 d
ata sy
n
th
esis.  
#
7
 S
M
 an
d
 T
ab
le 5
 
S
u
m
m
ary
 m
easu
res  
1
3
 
S
tate th
e p
rin
cip
al su
m
m
ary
 m
easu
res (e.g
., risk
 ratio
, d
ifferen
ce in
 m
ean
s).  
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1
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D
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 d
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d
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g
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d
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g
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f 
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n
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 (e.g
., I
2) fo
r each
 m
eta-an
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sis.  
#
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d
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8
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M
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f b
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1
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y
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f risk
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m
u
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e ev
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ce (e.g
., p
u
b
licatio
n
 b
ias, selectiv
e 
rep
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rtin
g
 w
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 stu
d
ies).  
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6
 
D
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d
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b
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u
p
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n
), if d
o
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g
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ere p
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.  
#
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G
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e n
u
m
b
ers o
f stu
d
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ed
, assessed
 fo
r elig
ib
ility
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d
 in
clu
d
ed
 in
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e rev
iew
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 reaso
n
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r ex
clu
sio
n
s 
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ith
 a flo
w
 d
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.  
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S
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y
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r each
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 d
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 p
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f b
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 d
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 m
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f b
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e m
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 m
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 m
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 b
ias).  
#
1
1
 M
D
 
C
o
n
clu
sio
n
s  
2
6
 
P
ro
v
id
e a g
en
eral in
terp
retatio
n
 o
f th
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t o
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f d
ata); ro
le o
f fu
n
d
ers fo
r 
th
e sy
stem
atic rev
iew
.  
 
M
D
=
 M
ain
 d
o
cu
m
en
t 
S
M
=
 S
u
p
p
lem
en
tary
 m
aterial stu
d
y
 p
ro
to
co
l
5	
	
 
Eligibility: 
Selection criteria are summarized in Table 2: 
 
Table 2: Selection criteria 
Item Description 
Patient  All children < 19 years old diagnosed with neuroblastoma 
Exposure  Maternal smoking or alcohol consumption during pregnancy 
Comparison Children without a diagnosis of  neuroblastoma 
Outcomes OR, RR estimates with 95% CI or provided data that allowed these to 
be calculated) 
OR= Odds ratio, RR= Relative risk, CI= Confidence interval 
 
To be included in the meta-analysis, each study was required to:	 
1. Be an original report.  
2. Be	a	cohort	or	case–control	study	that	presented	ORs	and	corresponding	
95%	 CIs	 for	 the	 association	 between	 maternal	 smoking	 or	 alcohol	
consumption	during	pregnancy	and	risk	of	childhood	neuroblastoma	(or	
provide	data	that	allowed	these	to	be	calculated).		
3. Include pediatric neuroblastoma cases (less than 19 years old) 
 
Exclusion criteria for studies were:  
 
1. Studies reporting “parental” consumption without specifying whether this was 
maternal or paternal exposure. 
 
2. Studies exclusively reporting maternal smoking or alcohol consumption but 
not related to around the pregnancy time window.  
 
3. Studies reporting estimates on “All childhood cancers” but not specifying 
numbers or estimates for neuroblastoma.  
 
Data extraction 
Extracted study characteristics encompassed: publication year, study time frame, 
study design, study size, recruitment source, and source of exposure information, age 
at diagnosis, matching variables, effect measures and confounders.  
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Quality assessment 
In the assessment of the quality of included studies, and as to evaluate comparability 
of cases and controls on the basis of design, age at diagnosis was set a priori as the 
most important matching or adjusting factor in the Newcastle-Ottawa Quality scale.  
 
Bias assessment 
In the assessment of the possibility of bias in study designs, conduct and analysis, we 
used the Joanna Briggs checklists for case-control studies.  
 
Statistical analyses 
A meta-analysis of the ESCALE and ESTELLE data on maternal smoking during 
pregnancy with published findings of relevant previous studies was conducted. We 
used random effects, precision-based weighting to calculate the summary OR with our 
results. 
Statistical heterogeneity between studies was assessed using the Cochrane Q test.  
The publication bias were assessed via inspection of the funnel plot and formal testing 
for funnel plot asymmetry using Egger’s test. 
Sensitivity analysis were performed by stratifying our analysis by study type (studies 
bases on record linkage/interview) were performed. Finally, studies with lower quality 
scores (Newcastle-Ottawa Quality scale <7) were excluded.  
 
RESULTS 
Results of Search Strategy 
7	
	
The results of the search strategy are summarized in Figure 1. Out of the 973 articles 
rendered from the algorithm-based search, 929 were deemed irrelevant according to 
their title or abstract. The full texts of the possibly eligible 41 remaining publications 
were obtained and assessed according to the eligibility criteria, leading to the 
exclusion of 28 studies for various reasons (Table 3).  
 
Data synthesis and assessment of quality of studies  
There were 13 eligible studies included in this meta-analysis (5 record linkage and 8 
case-control studies). All 13 studies assessed maternal smoking during pregnancy, and 
were jointly analyzed with our original data from the ESCALE and ESTELLE French 
studies. The same procedure was performed with seven studies (2 record linkage and 
5 case-control studies) that also reported information on maternal alcohol 
consumption.  
Ratings according to the Newcastle-Ottawa Quality scale spanned between 6 and 9 
(Table 4). Briefly, all the included studies ensured comparability of cases and controls 
on the basis of study design. Despite the variability of exposure ascertainment among 
included studies, the same data collection method was used for cases and controls 
within individual studies; no study, however, had validated alcohol consumption 
records or used structured interviews blinded as to case/control status. With regards to 
risk of bias assessment, five studies presented insufficient data regarding the 
comparability of cases and controls (Table 5). Evaluation of publication bias was 
analyzed using funnel plots, which did not provide any evidence of publication bias 
and Egger test was not significant (p-value= 0.2), but these findings should be 
interpreted with care because of small numbers of studies (Figure 3). 
The summary OR for maternal smoking during pregnancy was 1.1 [95% CI 1.0-1.3] 
(Figure 2a).  Between-study heterogeneity was low (I2= 17.3 %). The summary ORs 
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were similar for the analysis including studies reporting unadjusted and adjusted ORs 
(Figure 2 b and c).    
The analyses did not suggest any association between maternal alcohol consumption 
during pregnancy and neuroblastoma, with a summary OR of 1.0 [95% CI 0.9–1.2] 
(Figure 3 a) with similar findings among studies with unadjusted ORs only (Figure 3 
b).  
With regards to sensitivity analysis, slightly lower estimates were observed when only 
record linkage studies were included, compared with interview based studies (Figure 
6). However, results may be interpreted with caution because based in only five 
studies. Results did not change when studies with less than 7 in the Newcastle-Ottawa 
Quality scale were excluded.  
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Figure	1:	Flow	diagram	of	search	strategy	
Records	identified	through	
database	searching		
(n	=	973)	
S
cr
e
e
n
in
g
	
In
cl
u
d
e
d
	
E
li
g
ib
il
it
y
	
Id
e
n
ti
fi
ca
ti
o
n
	
Records	after	duplicates	removed		
(n	=	970)	
Records	screened		
(n	=	970)	
Records	excluded		
(n	=	929)	
Full-text	articles	
assessed	for	eligibility		
(n	=	41)	
Full-text	articles	
excluded,	with	reasons		
(n	=	28)	
Studies	included	in	
quantitative	synthesis	
(meta-analysis)	
(n	=	14)	
Out	of	which:	
-	18	did	not	report	on	tobacco	or	
alcohol	consumption	and	risk	of	
neuroblastoma	
-	9	reviews	of	literature	
-	1	duplicate	data	
Out	of	which		
-	7	studies	reported	data	on	maternal	
smoking	and	alcohol	consumption	
-	6	studies	reported	data	on	maternal	
smoking	only	
-	1	unpublished	study:	data	from	the	SCALE	
and	STELLE	studies	
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Table 3: excluded studies and reason for exclusion 
	
Reason for exclusion  Excluded study  
Did not report on tobacco or alcohol 
consumption during pregnancy and risk of 
neuroblastoma 
Lavigne É, 2017. PMID: 28108116 
De Paula Silva N, 2016. PMID: 27768709 
Momen NC, 2016. PMID: 26689564 
Bhattacharya S, 2014. PMID: 24394797 
Magnani C, 2014. PMID: 25539823 
Heck JE, 2013. PMID: 24139061 
Heck JE, 2013. PMID: 24021746 
Ghosh JK, 2013. PMID: 23989198 
Massamba D, 2012. PMID: 22891530 
Bluhm E, 2008. PMID: 18798548 
Bluhm EC, 2006.PMID: 16633913 
Kerr MA, 2000.PMID: 10977108 
Olshan AF, 1999.PMID: 10547138 
Klebanoff MA, 1996PMID: 8942433 
Neglia JP, 1988.PMID: 3365650 
Grufferman S, 1983.PMID: 6646007 
Ortega-García JA, 2010PMID: 20412413 
Review Müller-Schulte E, 2017.PMID: 29162685 
Chu P, 2016. PMID: 27461688 
Infante-Rivard C, 2007. PMID: 18074306 
Polańska K, 2006. PMID: 17219803 
Ferrís i Tortajada J, 2005PMID: 15989872 
Ross JA, 2000. PMID: 11122848 
Sasco AJ, 1999. PMID: 10333301 
Bolande RP, 1999.PMID: 10191343 
McBride ML, 1998.PMID: 9654794 
Duplicate data Michaelis J, 1996. PMID: 8776703 
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